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ABSTRACT 
Abdominal aortic aneurysm (AAA) disease causes dilation of the aorta that can lead 
to aortic rupture and death if not treated early. It is the 14th leading cause of death in the 
U.S. and is cited as the 10th leading cause of death in men over age 55, affecting thousands 
of patients and their families. To date, AAA patients have minimal access to safe and 
efficient imaging modalities for diagnosis as well as pharmacotherapies. AAA is usually 
detected and monitored with ultrasonography or contrast-enhanced computed tomography 
(C.T.), which doesn’t provide biomechanical information of the AAAs that are essential 
for predicting rupture risks. Furthermore, unfortunately, there is no currently known 
pharmaceutical treatment to cure the AAAs. 
Key pathological processes occurring within AAAs include inflammation, vascular 
smooth muscle cell apoptosis, and extracellular matrix (ECM) degradation. The 
deterioration of the elastic lamina in the aneurysmal wall is a consistent feature of AAAs 
and the fact that the adult elastic lamina does not remodel in aneurysm progression, making 
it an ideal target for delivering contrast agents and treatments. In this research, we have 
delivered gold nanoparticles (AuNPs), a commonly used C.T. contrast agent, and 
pentagalloyl glucose (PGG) loaded nanoparticles to the AAAs in an angiotensin II (AngII) 
infusion induced mouse model by conjugating the nanoparticles with antibodies that target 
degraded elastin.  
Here, owing to their degraded elastin targeting ability, we have observed a positive 
correlation between the quantities of the locally accumulated AuNPs in the aneurysmal 
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tissue in C.T. scans and the elastin damage levels of the AAAs. Furthermore, the AuNPs 
accumulations were found negatively correlated to the mechanical properties of the AAAs, 
which makes AuNPs a potential non-invasive surrogate marker of AAA rupture risk. 
Moreover, we have shown that targeted delivery of PGG could reverse the aortic dilation, 
ameliorate the inflammation, restore the elastin as well as the AAA mechanical properties 
of the aneurysmal tissue. Therefore, PGG loaded nanoparticles can be an effective 
treatment option for early to middle stage aneurysms to prevent disease progression. 
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1. INTRODUCTION 
An abdominal aortic aneurysm (AAA) is a cardiovascular disease featured by the 
abnormal dilation of the abdominal aorta. Male gender, genetic factors, aging, smoking, 
and other cardiovascular diseases such as atherosclerosis, diabetes, hypercholesterolaemia, 
and hypertension play as the risk factors of AAA onset [1]. Histologically, AAA is 
characterized by chronic transmural inflammation [2], resulting in the breakdown and 
elimination of essential proteins in the connective tissue of the aortic wall. Extensive 
research about AAAs has revealed that extracellular matrix (ECM) plays a vital role in its 
pathophysiology [3]. Mounting evidence has suggested that elastin, one of the critical 
components of ECM, drives this progression of this disease by virtue of its degradation. 
Among the enzymes that degrade ECM are matrix metalloproteinases (MMPs) and 
cathepsins, which can breakdown elastin laminae [4]. If not treated early, the weakening 
of the aorta can progressively worsen and led to aortic rupture and death [5]. In order to 
reduce the mortality of AAAs, the U.S. Preventive Services Task Force recommends that 
men aged 65–75 years who have ever smoked should get an ultrasound screening for 
abdominal aortic aneurysms, even if they have no symptoms [6]. 
The clinical standard for diagnosing AAA is whether the maximum aortic diameter 
reached 3cm or aortic dilation reached 1.5-fold [7]. Current imaging methods, such as 
ultrasound and computed tomography (CT), are excellent to look at the overall growth of 
aneurysms and can provide the geometrical information needed clinically to make the 
diagnosis and choose treatment strategies. However, focal aortic wall weakening caused 
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by ECM degradation and remodeling is generally not precisely detected. Such weak spots 
exhibit high-stress concentration and can increase the risk of rupture independent of the 
AAA size, thereby putting even small AAAs at high risk for rupture. In order to identify 
the AAAs that are in higher rupture risks and decrease mortality in AAA patients, it is 
desired to develop an imaging modality that could localize vulnerabilities at the aneurysmal 
site. 
Contrast-enhanced CT, an anatomical imaging technique, has been widely used in 
the diagnosis and long-term follow-up due to its ability to provide precise anatomical and 
morphological measurements of the AAAs [8, 9]. However, contrast-enhanced CT alone 
is unable to provide pathological information of the AAAs, such as the extent of ECM 
degradation and identify rupture-prone AAAs accurately. Moreover, a large dose of iodine- 
or gadolinium-based contrast agent is required for performing contrast-enhanced CT, the 
toxicity of which places it at a disadvantage compared to other imaging methods such as 
magnetic resonance imaging (MRI), nuclear imaging, and optical imaging [9, 10]. Gold 
nanoparticles (AuNPs) have been investigated for many years as an ideal radiopaque CT 
contrast agent for its excellent X-ray absorbing ability and low toxicity [10]. PEGylated 
AuNPs with prolonged blood circulation times were used for imaging of the cardiovascular 
system [11]. A targeted delivery of surface-modified AuNPs can reduce the dose of 
contrast agent applied, increase the imaging quality, and provide more information of the 
AAAs depending on the molecular probe attached to the AuNP surface. 
Besides an instructive imaging modality for diagnostic, an efficient treatment 
strategy can also achieve mortality benefit. To date, the most effective treatment for AAAs 
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is surgical intervention, and no pharmacological treatment is available on the market. 
Given the alarming mortality rate of 90% in the case of AAAs [12], and the fact surgical 
intervention is not possible in all the cases, it brings us to an imminent need for minimally 
invasive treatment options. Many drugs such as statins and doxycycline have been found 
to prevent AAA formation and progression in animal models when delivered systemically 
[13-15]. However, they were not successfully translated into clinical AAA treatment, 
possibly due to that systemic administration does not provide the necessary therapeutic 
drug concentration at the site of AAA [16]. A local delivery of the drugs using targeting 
nanocarriers could improve their therapeutic efficacy and prevent systemic side effects.  
Currently, most of the potential drugs focus on reducing the local inflammation in 
the aneurysmal tissue but not reversing already degraded ECM. An ideal therapeutic 
intervention would not only prevent further degradation of ECM but also restores the 
structural integrity, in turn leading to the restoration of aorta’s mechanical properties. On 
multiple occasions, our group has successfully demonstrated the beneficial effects of 
pentagalloyl glucose (PGG) in stabilizing and regenerating vascular tissue’s ECM both in-
vitro and in-vivo [17, 18]. Recently Nosoudi et al. have also demonstrated successful 
treatment of AAAs induced by a local injury model in rats [19].  
In this dissertation research, firstly, we have synthesized and conjugated AuNPs 
that possess the ability to target AAAs. It has been shown that the systemic delivery of 
surface-modified AuNPs that bind to degraded elastin in an angiotensin II (AngII) mouse 
model of AAA provides a unique way to visualize local areas of ECM degradation that are 
more prone to rupture. Secondly, we present the successful treatment of AAAs in the same 
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mouse model using targeted nanoparticle delivery. We tested our hypothesis that PGG 
loaded bovine serum albumin (BSA) nanoparticles can be targeted to damaged elastin in 
aneurysmal mouse aorta, thereby not only protecting elastin from MMPs but also 
regenerating elastic fibers. Apart from looking at the structural integrity of ECM, we have 
studied the ability of the nanoparticles to restore the mechanical properties of the aorta. We 
have also delved deeper to investigate if PGG treatment can trigger anti-inflammatory 
signals to understand its extended effects on ECM. Overall, our goal was to present targeted 
AuNPs delivery as an excellent imaging contrast agent for AAAs and PGG loaded BSA 
nanoparticles as an alternative therapeutic approach to reverse AAA clinically. 
This dissertation is organized as follows: 
§ In Chapter 2, we presented a comprehensive review of the cardiovascular 
system and diseases, physiology and histology of abdominal aorta, aortic 
elastin content, an introduction to AAAs including pathophysiology and 
biomechanics, the methods used for AAA rupture risk assessment, the 
animal models used for AAA studies, and the imaging modalities and 
treatment for AAAs. 
§ In chapter 3, we provided the specific aims designed for this project as well 
as a brief description of the approaches we took to achieve these aims. 
§ In chapter 4, we described the synthesis and characterization (including size, 
surface charge, cytotoxicity, cellular uptake, in-vitro targeting) of elastin 
antibody conjugated AuNPs. 
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§ In chapter 5, we presented the in-vivo targeting studies of the surface-
modified AuNPs in the AngII mice model and the correlation between the 
AuNPs accumulation and the AAA rupture risk. 
§ In chapter 6, we presented targeted therapy with nanoparticle loaded with 
PGG to protect the vascular elastic lamina and restore the aortic mechanical 
properties and showed that it could halt or even reverse the progression of 
AAAs in the AngII induced mice model. 
§ In chapter 7, we concluded the whole presented research and discussed 
future research attempts that needed to be taken to achieve clinical benefits 
for AAA patients further. 
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2. LITERATURE REVIEW 
2.1 The cardiovascular system and cardiovascular diseases 
The cardiovascular system, also known as the circulatory system for blood, is one 
of the most important organ systems that facilitates blood circulation and mass 
transportation [20]. The cardiovascular system consists of two subunits: the heart, which 
functions as an anatomical pump that pushes the blood through the whole body, and the 
blood vessels, including arteries, veins, and capillaries that are the conduits carrying the 
blood [21]. It plays a vital role in maintaining homeostasis by continuously regulating the 
blood flowing throughout the system, transporting nutrients, electrolytes, gases, and other 
essential materials into the environment where cells reside in as waste products are 
removed [22].  
Cardiovascular diseases (CVDs) are diseases that involve the heart or blood vessels 
(Figure 2-1). The physiological disorders of the heart include arrhythmia, carditis and 
cardiomyopathy, heart valve problems, rheumatic heart disease, and congenital heart 
disease, and vascular diseases include coronary artery disease, peripheral arterial disease, 
stroke, aneurysms, arterial calcification and atherosclerosis, deep vein thrombosis, and 
pulmonary embolism. According to the world health organization, it is the leading cause 
of death worldwide [23]. CVD accounted for approximately 17.8 million deaths in 2017 
globally and this number is expected to grow to more than 22.2 million by 2030, according 
to a 2014 study [24]. In the United States alone, CVDs have remained the number one 
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cause of death, responsible for as many as 859,125 deaths in 2017. The annual total cost of 
CVDs in the US has been estimated at $351.2 billion in 2014 to 15 [25].  
2.2 The arteries in the cardiovascular system 
An artery, which carries blood from the heart to various organs and tissues of the 
body, contains three tunics in the wall. The innermost layer, the tunica intima, is composed 
of epithelial and connective tissues that form the continuous endothelial lining of the entire 
vascular system. The middle layer, known as the tunica media, is a smooth muscular layer  
 
Figure 2-1. Human cardiovascular system with the associated various cardiovascular 
diseases [26]. 
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supported by connective tissue that is primarily made up of elastic fibers and some collagen 
fibers [27]. It is the essential part of the arteries to regulate blood flow and blood pressure. 
The tunica externa, also known as the tunica adventitial, is the outermost layer of the 
vascular wall composed primarily of connective tissue with fibroblasts, helping to hold the 
vessel in a relative position [28]. 
According to the various sizes, arteries can be categorized into arterioles (with a 
diameter below 0.5mm), muscular or distributing arteries (medium-sized), and elastic or 
conduit arteries (typically with a diameter larger than 10 mm). Although all types of arteries 
are composed of the three tunics, there are some structural differences between different 
types of arteries due to their variety of functionalities (Figure 2-2). The arterioles are the 
primary resistance vessels that distribute blood flow into capillary beds in the organs, 
featured with only one or two layers of the smooth muscle in the tunica media [29]. The 
muscular arteries, on the other hand, present a much thicker smooth muscle layer in the 
tunica media in corresponding to their leading role in vasoconstriction [30]. The elastic 
arteries such as aorta have the thickest tunica media that contains a high percentage of 
elastic fibers to withstand the high blood pressure causing by the heart blood ejection [31].  
2.3 Physiology and histology of abdominal aorta 
The abdominal aorta is a part of the aorta that passes through the abdominal cavity, 
beginning at the level of the diaphragm and ending at the common iliac bifurcation [32]. It 
supplies all of the abdominal organs such as the liver, stomach, spleen, duodenum with 
oxygenated blood to maintain their functionality. As a transitional elastic artery, the  
 9 
 
Figure 2-2. Types of Arteries and Arterioles. Comparison of the walls of an elastic artery, 
a muscular artery, and an arteriole is shown. In terms of scale, the diameter of an arteriole 
is measured in micrometers compared to millimeters for elastic and muscular arteries [30]. 
abdominal aorta has a monolayer of endothelium and a scant pad of sub-endothelial fibrous 
connective tissue upon an intact internal elastic lamina, a relatively thick media consists of 
smooth muscle cells (SMCs) embedded in structural proteins, and an adventitial that 
contains a network of vasa vasorum [33, 34]. Since the media normally accounts for up 
80% of the abdominal aortic wall, the thickness of the abdominal aortic wall nearly linearly 
relates to the number of the medial lamellar units [34]. For an adult human, the normal 
abdominal aorta has a media consists of 28 to 30 concentric fibromuscular layers with an 
average thickness of 0.8 to 1mm [35].  
In large arteries like aorta, the network of vasa vasorum plays an important role in 
the delivery of nutrients and oxygen to and the removal of waste products from the aortic 
walls. However, it has been demonstrated that the infrarenal abdominal aortic media is 
vastly avascular because the vasa vasorum has been shown to only penetrate the media of 
vessels with greater than 29 medial lamellar units [34]. Thus, it is likely that the relatively 
fewer lamellar units and lower collagen to elastin ratio in the abdominal aortic media 
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comparing to the theoretic aorta, and the fact that the survival of SMCs in the abdominal 
aortic media mainly depends on trans-intimal diffusion of nutrients make the abdominal 
aorta more prone to aneurysmal degeneration [36]. 
2.4 Elastin in the aortic wall 
Elastic fiber is the main component that makes up roughly 50% of the arterial 
extracellular matrix (ECM), and provide the necessary load-bearing ability in low-pressure 
regions and elasticity for proper cardiovascular function in vertebrate animals [37, 38]. It 
has two major components: an elastin core that comprises 90% of the fiber, and a scaffold 
of microfibrils, which are composed mostly of fibrillin-1 and -2 [39]. The synthesis of the 
elastin fibers can be divided into three stages, known as (a) secretion of the tropoelastin (a 
~60 -70 kDa protein) by elastogenic cells, including SMCs, endothelial cells, fibroblasts, 
and chondroblasts, into the ECM, (b) coacervation that forms self-aggregated tropoelastin 
spherules, and (c) cross-linking that generates the networks of elastic fibers by depositing 
the spherules onto microfibrils and forming intramolecular and intermolecular crosslinks 
with the participation of lysyl oxidase (LOX) enzymes (Figure 2-3) [40].  
ELN is the only tropoelastin gene in humans. Most of the elastin synthesis in human 
bodies happens very early in life. As we age, ELN expression decreases dramatically, 
resulting in a decrease of elastin product and causing difficulties for elastin damage repair 
[41]. The elasticity of the elastin fibers is a result of its massive cross-linking network that 
maintains the mechanical stability when elastic fiber undergoes deformation (Figure 2-4). 
The reversible elasticity of the aortic elastic fibers plays an important role in maintaining 
the  
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Figure 2-3. Elastogenesis: from tropoelastin to elastic fibers; Tropoelastin synthesis, 
binding with elastin-binding protein (EBP), transport, release of EBP, assembly with 
fibulins, binding to microfibrils, LOX-mediated cross-linking, and final formation of an 
elastic fiber [42]. 
Windkessel effect of the cardiovascular system to allow sufficient blood supply in the distal 
micro-vasculatures [43].  
The amount and organization of the elastic fibers, as well as the collagen fibers in 
the aortic ECM, dominate the passive mechanical behavior of the large elastic arteries. The 
arteries underwent elastase treatment in animal models were shown to have a significant 
increase of the side lengths in both longitudinal and circumferential directions, indicating  
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Figure 2-4. Crosslinking of elastin and mechanism of elastin stretch and recoil [44]. 
the weakening of the arterial wall [45, 46]. Experiments on the aorta from mice lacking 
elastin gene (ELN-/-) have demonstrated a reduction in the circumferential material 
stiffness at low pressure [47]. Thus, insufficient elastin, improper assembly, 
disorganization, fragmentation, and remodeling of the elastic fibers change the passive 
mechanical behavior of the elastic arteries. 
Aside from the influence it has in aortic mechanical properties, elastin and its 
degradation products, resulted from matrix aging and/or cardiovascular diseases, have 
signaling effects that can lead to pathological changes to the cardiovascular system. In a 
study on rat aorta, Sauvage M. et al. reported the colocalization of transforming growth 
factor (TGF) -β1 immunoreactivity and tropoelastin expression in the developing rat aorta 
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[48]. The accumulation of elastin has been suspected to change the availability of TGF-b 
indirectly by modulating latent TGF-b binding to microfibrils [49]. And soluble 
tropoelastin has been demonstrated to regulate the proliferation of VSMCs, as well as to 
change the stiffness in an in-vitro cell culture model [50, 51].  
Signaling effects of the elastin degradation products, such as elastin‐derived 
peptides (EDP), a bioactive product of elastic fiber degradation, and fragmentation that 
retain the VGCAPG peptide sequence, mostly depends on their interaction with elastin 
receptor complex (ERC) [52, 53]. ECR is a heterotrimeric cellular surface receptor for 
elastin composed of a peripheral elastin‐binding protein (EBP, 67 kDa), a protective 
protein/cathepsin A (PPCA, 55 kDa) and a membrane‐bound neuraminidase, Neu‐1 (61 
kDa) [54]. The EBP subunit presents two functional‐binding sites, including the EDP 
binding site that induces signaling pathways, and the galactosugars attaching site, which is 
associated with EDP release and dissociation of the complex [42].  
The binding between EDP to EBP is capable of activating several intracellular 
signaling pathways depending on the cell type (Figure 2-5). EDP can modulate the vascular 
tone through its ability to influence the vascular endothelial relaxation and the vascular 
smooth muscle cells (VSMCs) contraction [55, 56]. Moreover, the EDP has been implied 
to play a crucial role as a chemotaxin in the recruitment of monocytes, neutrophils, 
macrophages, and fibroblasts, as well as a regulator of VSMCs migration [57-61]. It has 
also been reported that EDP can modulate the macrophage polarization and the 
proliferation of fibroblasts and VSMCs [62-64]. The structural and mechanical change in  
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Figure 2-5. EDP affect various cell functions through its cognate receptor ERC, playing a 
crucial role in the development of cardiovascular diseases such as hypertension, 
atherosclerosis, and aneurysm [53]. 
the large elastic arteries such as aorta can result in a malfunctional circulatory system that 
is responsible for many acquired cardiovascular diseases.  
Arterial stiffness is one of the structural mechanical properties that depend on the 
mechanics of elastic fibers in the arterial wall. The assessment of arterial stiffness is usually 
achieved by measuring the pulse wave velocity (PWV), distensibility characterized by 
circumferential strain, and Peterson’s elastic modulus [47, 65-67]. Due to the limited 
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synthesis timeframe and low turnover rate, the damage of elastin fibers with aging or 
disease generally remains unrepaired. Insufficient or destruction of the elastin network 
initially leads to decreased stiffness in arteries and is characteristic of the first shift in 
mechanical behavior called the initial-softening phase [46, 68]. Meanwhile, the EDPs 
induce the local proliferation of VSMCs and fibroblasts and recruit the leukocytes to the 
remodeling sites, creating a proinflammatory remodeling environment. The remodeling of 
the ECM after the elastin damage, which is characterized as a deposition of non-organized 
collagen fibers and proteoglycans, in combination with a change of VSMC plasticity, 
stiffen the arterial wall and cause a loss in arterial mechanical properties [69, 70].  
2.5 Abdominal aortic aneurysm (AAA) 
An abdominal aortic aneurysm (AAA) is an abnormally widened or bulged area of 
the abdominal aorta. Depending on the location where the enlargement happens, AAAs 
can be divided into four main categories, suprarenal AAAs, pararenal AAAs, juxtarenal 
AAAs, and infrarenal AAAs (Figure 2-6). It is characterized by an impaired vessel wall 
integrity, which is featured as a progressive disruption and weakening of the ECM, leading 
to dilation of the aorta that can be fatal if not treated [35].  
A human AAA is diagnosed when the aortic diameter is higher than 3.0cm or more 
than 50% larger than the average diameter [5]. AAA is a common disease that has a 
prevalence of approximately 4.8% (6.0% for males and 1.6% for females) in the general 
population [71]. Including patients who die before reaching the hospital, the mortality rate 
due to abdominal aortic aneurysm rupture is 90%, and the number of deaths attributable to 
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the AAAs is more than 15,000 per year [72]. It is the 14th leading death cause in the US 
and is cited as one of the top 10 causes of death among older men [73]. 
2.6 Pathophysiology of AAA 
Several biological processes and risk factors, including genetic factors, lifestyle-associated 
risk factors, and other cardiovascular diseases have been identified to contribute to AAA 
pathogenesis. AAA is typically associated with aging and atherosclerosis, with attendant 
risk factors such as hypercholesterolemia, hypertension, and diabetes [74]. Smoking is also 
a significant risk factor for AAA development. As in a small aneurysm trial, which 
randomized 1090 patients with AAA with diameters of 4–5.5 cm between immediate repair 
and surveillance, 91.8% of the patients were former or current smokers [75]. 
 
Figure 2-6. Crawford’s classification of AAAs [76]. 
The pathophysiology of AAA has been studied on different levels (Figure 2-7) [5]. 
On the histological level, AAA onset is associated with chronic adventitial and media 
inflammatory cell infiltration, apoptosis of VSMCs, and ECM degradation, primarily 
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elastic lamina degradation by proteolytic enzymes such as matrix metalloproteinases 
(MMPs) and cathepsins[35, 77, 78]. Many inflammatory cells have been detected in the 
aneurysmal tissue, including macrophages, T lymphocytes subset, B lymphocytes, 
neutrophils, and mast cells. These cells elevate the inflammation in the aneurysmal tissue 
and accelerate the degradation of the ECM by influencing the production of multiple 
inflammatory factors and extracellular proteases [5, 79, 80]. Moreover, a recent study 
found that the abnormal presence of adipocytes in the aortic adventitial could recruit 
macrophages; therefore, increase the MMP-2 and MMP-9 levels and degrade collagen 
fibers surrounding them [81]. Aortic VSMCs in the aneurysmal tissue have been shown to 
have phenotype changes from a contractile type to synthetic one in consistence with the 
cytoskeletal rearrangement, which also preceded elastolysis and gross media remodeling 
[74]. Adventitial fibroblasts are presumed to promote structural repair when the damage is 
done to the aortic wall. However, the interstitial collagen becomes disorganized and 
compromises the mechanical properties of the aortic wall.  
On the molecular level, many chemokines, cytokines, proteases, microRNAs 
(miRs) and the renin-angiotensin system (RAS) have been implicated in the formation and 
progression of AAAs. Some upregulated pro-inflammatory cytokines such as interleukin 
(IL)-1b, IL-6, IL-17, IL-23 and tumor necrosis factor (TNF)-a, monocyte chemoattractant 
protein (MCP)-1 have been demonstrated to contribute to the recruitment and 
differentiation of macrophages at the aneurysmal site [5, 74]. TGF-b, on the other hand, is 
a critical down-regulated cytokine that plays a protective role in human AAA pathogenesis 
despite its ability to promote thoracic aortic aneurysm (TAA) formation [82].  
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Figure 2-7. Pathophysiology of AAA with the table legend that illustrates major cell types, 
cytokines, protease, miRs. and RAS involved in AAA pathogenesis [5].  
Lysyl oxidase (LOX), an oxidase the activity of which also has been found suppressed in 
the AAA, can stabilize the ECM by crosslinking the collagen and elastin and inhibiting 
MCP-1 secretion and the subsequent inflammatory responses, and slow down the 
progression of the AAA [83]. 
Some proteases and their inhibitors, including MMP, serine proteases, and cysteine 
proteases, have been involved in the AAA formation and progression by causing structural 
damage of elastin and collagen in the aortic ECM, which leads to weakening and dilation 
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of the abdominal aorta [84]. The complementary role of macrophage-derived MMP-9, and 
MMP-2, an MMP that has a unique ability to degrade both elastin and fibrillar collagen, 
has been proved critical in the development of AAAs [85]. Cysteine and serine proteases, 
on the other hand, can activate neutrophil elastase and some other proteases in AAAs, 
which cause further degradation of the ECM and AAA progression [86]. 
MiRs are a class of short, well-conserved, non-coding RNAs that play their 
biological role by influencing the stability and translation of mRNAs [87]. Several miRs 
have been identified as crucial regulators during the AAA development recently. A 
decrease of miR-29b has been detected in human AAA tissues due to the aortic damage 
[86]. However, several studies in mouse models indicated that when the expression of the 
miR-29b was further suppressed to levels lower than typical pathological decreases, several 
ECM proteins expression was upregulated and the progression of the AAA was slowed 
down [88]. The upregulation of murine specific miR-712 and its human/murine homolog 
miR-205 has been demonstrated to downregulate two key upstream inhibitors of MMPs, 
tissue inhibitor of metalloproteinases (TIMP)3 and reversion-inducing cysteine-rich 
protein with kazal motifs (RECK), which leads to ECM degradation and AAA progression 
[89]. Moreover, it has been pointed out that the overexpression of miR-181b could 
negatively regulate TIMP3 expression and activity [90]. On the contrary, overexpression 
of miR-21, a miR that has been identified as a critical mediator for proliferation and 
apoptosis of VSMCs, can prevent AAA formation [91]. 
The relationship between RAS and AAA development has been studied in many 
animal studies. The infusion of angiotensin II (AngII) in mice deficient for apolipoprotein 
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E (ApoE-/-) or low-density lipoprotein receptor (LDLr-/-) in combine with a high-fat diet 
can induce aneurysms and dissections at the suprarenal abdominal aorta [92]. AngII 
infusion in mice was shown to associate with the adventitial accumulation of C-C 
chemokine receptor type 2 (CCR2)+ macrophages specifically at the sites of aneurysm 
formation and the most prominently at the sites of dissection [93]. AngII also stimulates 
the angiotensin type 1a (AT1a) receptors to regulate the mitogen-activated protein kinase 
(MAPK) signaling cascade and enhance the TGF-b signaling, which eventually leads to 
the production of pro-inflammatory factors [74].  
2.7 Biomechanics of AAAs 
The biomechanics of the aneurysmal aortic wall has been extensively studied to 
develop a method to predict the rupture risk of the AAAs. The rupture of the AAAs happens 
when the strength of the wall cannot withhold the blood pressure. Thus, studying the effect 
of blood pressure on the aortic wall is essential. The aortic wall is a tubular structure that 
repeatedly deforms under pulsatile blood pressure, which generates forces that can be 
normalized and translated into radical, circumferential, axial, and wall shear stresses 
(Figure 2-8) [94].  
The formation of the AAAs can significantly change the aortic mechanical 
properties due to the degradation of the structural proteins such as elastin and collagen 
fibers [95]. Destructive AAA tissue characterization tests such as uniaxial extension test 
until failure, biaxial extension tests, and peeling tests were performed for material property 
data collection. Anisotropic responses with stiffer behavior have been demonstrated in the 
circumferential direction of AAAs in ex-vivo AAA studies [96, 97]. The geometrical  
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Figure 2-8. Mechanical loading state of aortic tissue shows circumferential, axial, radial, 
and wall shear stresses in the aortic wall. 
change of the abdominal aorta and other related pathological changes, including the 
formation of an intraluminal thrombus (ILT) and the apoptosis of VSMCs, can result in a 
change in the local fluid dynamics [94]. The combination of a weakened aortic wall and 
the abnormal fluid dynamics may elevate the mechanical stresses on the aneurysmal aortic 
wall and lead to rupture.  
2.8 Rupture risk assessment of AAA 
The potential risk of an aneurysm rupture is determined by factors such as evolving 
geometry, mechanical properties, and hemodynamic loads/perivascular conditions [98]. 
Nowadays, three major categories of assessment methods have been applied to predict 
AAA rupture risk: AAA geometrical analysis, local biomechanics analysis, and biomarker 
analysis.  
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AAA geometrical analysis 
Geometrical information such as maximum aortic diameter has been used as the 
standard clinical criteria for assessing the AAA rupture risk and deciding treatment strategy 
[99]. Advances in medical imaging, particularly computed tomography angiography 
(CTA) and magnetic resonance imaging (MRI), provide exquisite data on overall patient-
specific geometries. While using the geometric modeling to predict the rupture risk AAAs, 
at least 40 image-based geometric parameters are correlated with AAA rupture and 15 of 
the correlates are statistically significant for the predictive model [100]. However, the 
recommendation of intervention should not only base on the size of the AAA, as many 
small AAAs ruptured while large AAAs remained stable in clinical cases [101].  
AAA geometry is complex and, in most cases, cannot be approximated by a thin-
walled cylinder. For example, almost all clinically relevant AAAs contain ILTs composed 
of fibrin, inflammatory cells, platelets, and red blood cells [99]. The formation of ILT 
influences the structural and mechanical properties of the AAA. Thus, to predict the 
patient-specific rupture risk more precisely, fine element analysis (FEA) is used to 
reconstruct a more accurate 3-dimensional (3D) AAA morphology and to calculate the 
biomechanical parameters. 
AAA biomechanical analysis 
To understand the biomechanical properties of the aneurysms, computational 
models have been developed base on the AAA rupture factors (Figure 2-9). These models 
can be used to find the mechanical weak point of the aneurysm and predict its rupture 
possibility. FEA for AAA usually incorporates risk factors such as AAA geometry, gender, 
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Figure 2-9. Process of creation of appropriate 3D reconstruction for stress analysis: A. 
Initial surface shaded 3D reconstruction; B. Elimination of anatomic elements not pertinent 
to stress analysis; C. Merged 3D reconstruction to obtain outer boundaries of the aortic 
wall; D. Initial 3D mesh; E. Refined mesh ready for input into FEA program; and F. Stress 
analysis with stress mapped onto the surface of 3D reconstruction with color gradients to 
represent stress gradients [102].  
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blood pressure, smoking history, and the amount of ILT [103]. Two commonly used 
biomechanical dices, peak wall stress (PWS) and peak wall rupture index (PWRI), can be 
calculated using FEA to estimate the future AAA rupture risk. As we mentioned 
previously, the rupture of AAA happens when the aortic wall stress exceeds the mechanical 
strength of the wall. Thus, it is feasible to use PWS, the highest von Mises wall stress 
within an AAA, to predict the potential rupture. PWS calculations are based on blood 
pressure, aortic wall properties, and the geometry of the 3D AAA model reconstructed 
from the CTA images [104]. PWRI is a relatively more sophisticated mechanical parameter 
than PWS. While PWS considers only the stress, PWRI is estimated base on the 
relationship between the local wall stress and local wall strength, using the following 
equation: 
𝑃𝑊𝑅𝐼 = max	(
𝑊𝑎𝑙𝑙	𝑠𝑡𝑟𝑒𝑠𝑠
𝑊𝑎𝑙𝑙	𝑠𝑡𝑟𝑒𝑛𝑔𝑡ℎ) 
However, the classic FEA is usually performed base on a fixed AAA geometry. 
The progression of the AAA with time could greatly change the stress and the strength of 
the aneurysmal tissue, thus, make the previous rupture risk evaluation less accurate. 
Computational modeling of vascular growth and remodeling (G&R) provides a tool to 
model the time evolution of vascular diseases based on the assumption that mechanical 
hemostasis exists [102]. On the foundation of the FE analysis for stress, G&R modeling 
adapts the growth stimulation to the configuration by introducing the influence of 
constituents such as elastin, collagen, and SMCs, to mimic the AAA progression in-vivo 
(Figure 2-10) [105]. Zeinali-Davarani, S. et al developed a computational G&R model by  
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Figure 2-10. In-vivo configurations for fluid-solid growth simulations, iterative loop, and 
information transfer in the coupling between the hemodynamics and G&R simulations 
[106]. 
applying estimated material parameters as well as the distributions of wall thickness and 
anisotropy gained from an inverse optimization method to develop the vessel wall model 
and then introducing spatial elastin degradation as the stimulation to the model [107]. 
Sheidaei, A. et al. reported a G&R model based on the effect of wall shear stress to 
understand the progression and rupture mechanism of AAAs [106]. These models provided 
theoretical frameworks for further developing patient-specific AAA models for clinical 
use. 
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Both PWR and PWRI have been reported to be higher in symptomatic or ruptured 
than in intact AAAs in many independent studies, indicating their potential to be used as 
AAA rupture risk assessment tools [103, 108, 109]. Moreover, the development of the 
G&R model provided a tool for studying the rupture risk of AAA in a progression 
dependent manner. However, the calculations for PWR and PWRI, as well as the 
establishment of the G&R models are based on some predefined AAA parameters such as 
the aneurysmal wall thickness, due to the limitation in spatial resolution of imaging. The 
variety of these parameters between patients can cause inaccuracy of the rupture-predicting 
capability of the existing computational models. 
AAA biomarkers analysis 
In addition to the biomechanical features, some AAA related biomarkers, including 
serum EDP concentration, 18F-fluorodeoxyglucose (18F-FDG) uptake, and ILT size can be 
used to predict the expansion and rupture of AAAs [110]. As the AAA progress, the 
degradation and fragmentation of elastin in the aneurysmal tissue release EDP into the 
circulation and can be detected using ELISA method. It has been demonstrated in a five-
year human small AAA study that serum EDP level is significantly correlated with AAA 
expansion in ~90% of the tested cases [111]. The level of the inflammation in the 
aneurysmal tissue also varies during the progression of the AAAs. The high metabolic 
activity associated with a severe local inflammation precedes a phase of AAA rapid growth 
and is then followed by a period of stasis with low metabolic activity [112]. 18F-FDG 
uptake increase, featuring an increased metabolic activity in the aneurysmal tissue, can be 
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detected and quantified using positron emission tomography (PET) and can be used as a 
reliable marker for AAA expansion [113-115].  
Furthermore, the ILT size is also a promising prognostic growth marker for AAAs. 
A thin ILT layer can function as a protection for the aortic wall because it can buffer the 
stress and lower the rupture risk for the aneurysm [116]. However, when growing too thick, 
the ILT layer can cause the aortic wall to weaken, for example, due to hypoxia. ILT is also 
the source of many pro-proteolytic processes that stimulate aortic wall degradation [117]. 
A clinical study performed by Haller S.J. et al. pointed out that the protective 
biomechanical advantage that ILT provided by lowering wall stress seems to be 
outweighed by the weakening of the AAA wall, particularly in patients with small ruptured 
AAAs [118]. 
2.9 Animal models for AAA 
Animal models of AAA can provide insight into the mechanisms of progression of 
the human disease based on the assumption that the biochemical, biomechanical, and 
cellular properties in the animals are comparable to those in humans. However, due to the 
species-specific variety, there is no perfect animal model for AAAs. Each different 
experimental model of AAA only presents partially the pathological features that have been 
discovered in human AAAs. AAA animal models have been developed using genetic 
manipulation, physical and chemical induction, as well as the combinations of these 
technics. Different animal species have been used to create in-vivo AAA models, including 
mouse, rat, hamster/guinea pig, rabbit, turkey, dog, sheep, and porcine to study the 
mechanisms of AAA. 
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Rodent AAA models 
Rodents are most wildly used to develop animal models for reasons including the 
small size, relative cheapness, great accessibility, and the ability to be genetically 
manipulated. Several different techniques, including elastase treatment, calcium chloride 
(CaCl2) treatment, AngII infusion, and xenograft transplantation, has successfully induced 
the formation of AAAs with different characteristics in rodents.  
The elastase model in rodents is performed by intraluminal or periarterial 
application of elastase, usually porcine pancreatic elastase (PPE), via a midline abdominal 
incision (Figure2-11). Traditionally, to perform intraluminal perfusion of the PPE, the 
infrarenal abdominal aorta is dissected from the surrounding connective tissue and isolated 
from the circulation by applying atraumatic clamps. PPE is then injected into the isolated 
part of the aorta through a catheter. When the perfusion is finished, the catheter and the 
clamps are removed to restore the blood flow, and the incision is sutured close. This method 
can be challenging to perform due to the small size of the rodent aorta.  
A more straightforward elastase treatment that involves an application of a 
periadventitial PPE soaked gauze has been developed to introduce elastin damage to the 
rodent aorta [119]. Moreover, the combined use of 3-aminopropionitrile fumarate salt 
(BAPN) and periadventitial PPE treatment results in an advanced staged AAA that forms 
thrombus and can spontaneously rupture [120]. The AAAs developed using the rodent 
elastase model have multiple pathological features that are similar to human AAAs 
including the infiltration of the macrophages in the adventitial,  degradation of media 
elastin, apoptosis of VSMCs, and formation of intraluminal thrombus [119, 121].  
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Figure 2-11. Intraluminal and periarterial application of elastase on rodent aorta. 
Periadventitial administration of calcium chloride at the infrarenal aorta can also 
induce AAAs in rodents. The surgical protocol for this model is similar to the periarterial 
PPE treatment model, but a gauze soaked with calcium chloride solution is applied instead 
of PPE. The expansion of the aorta was mostly reported immediately after the CaCl2 
exposure. Increased endothelial permeability and VSMC apoptosis have been documented 
in CaCl2 treated vasculature, as well as vascular calcification and the infiltration of 
inflammatory cells in the adventitia and media [122]. This model is developed to closely 
mimic human AAA pathology in terms of upregulated inflammation, degradation of ECM, 
neovascularization, increased oxidative stress, VSMC apoptosis, and heavy aortic 
calcification which has been reported in 80% of human AAAs [123]. The main problem 
with the CaCl2 AAA model is that there is no evidence of intraluminal thrombus formation 
and rupture, as is seen in human AAAs. 
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Ang II infusion via a subcutaneously implanted osmotic pump for 28 days, can 
induce AAA in wild type C57BL/6 mice or transgenic mice (ApoE-/- or LDLr-/-) (Figure 
2-12). Aneurysms in this model are usually observed at the suprarenal abdominal aorta as 
well as the ascending aorta, making it a proper model for studying both AAAs and TAAs. 
AngII has been known as a peptide hormone that can increase blood pressure by 
constricting the blood vessels. Although the infusion of AngII in hyperlipidemic mice can 
increase mean arterial pressure, it has been demonstrated that the arterial dilation and AAA 
formation in these models was not related to the increased blood pressure [92, 124]. The 
upregulation of mRNA expressions of MMP, PPAR-γ, MCP-1, and uPAR in AngII 
induced AAAs increases the inflammation in the aortic wall in a blood pressure-
independent way [125]. AngII promotes the enlargement of the suprarenal aorta 
accompanied by atherosclerosis, medial hypertrophy, accumulation of macrophages in the 
external elastic lamina, and thrombosis in ApoE-/- mice, which mimics human AAA 
development [126]. 
 
Figure 2-12. Development of AngII infused AAA model. 
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Transplantation of a decellularized xenograft to replace a part of the healthy rodent 
aorta can also induce aneurysms. Usually, a donor aorta, for example, an aorta from guinea 
pig, is harvested and decellularized with sodium dodecyl sulfate (SDS) and then transplant 
into the rodent via major abdominal surgery. The donor aortic ECM induces a chronic 
interspecies immunological response that causes the destruction and dilation of the 
xenograft [127]. The infiltration of monocytes and T-lymphocytes has been reported in the 
intimal of the transplanted graft [128]. The pre-immunization of rodents with donor aortic 
ECM accelerates xenograft destruction and triggers AAA rupture [129]. This model is not 
as frequently studied in small animals but can be used to specifically study the roles of the 
immune system, aortic ECM, and VSMCs in AAA development. 
Non-rodent AAA animal models 
The development of new surgical techniques and new devices for AAAs created a 
need for animal models that can create AAA with anatomical similarities to humans. 
Medical devices, such as stents and grafts, need to be tested before incorporation to the 
clinic, and rodent models failed to translate the experimental findings due to their small 
size. Thus, increasing efforts have been made to create AAAs in larger species. Chemical 
induction is one way that has been wildly used in creating AAAs in large animals such as 
rabbits, dogs, and swine. The application of elastase, collagenase, or CaCl2 alone can 
induce AAAs in rabbit with a more than 50% dilation [130, 131]. However, for larger 
animals like dogs and porcine, a combined treatment (elastase, collagenase, and 
angioplasty) must be applied to generate AAAs that are big enough for further study [132]. 
A large animal model can also be developed using grafts or patches. In the graft model, a 
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manufactured graft or a xenograft is interposed into the infrarenal abdominal aorta to 
induce aneurysms. And in the patch model, instead of a graft, an elliptical patch or a pouch, 
made out of the vein, prothesis vascular graft, and rectus fascia, is applied through a 
longitudinal aortotomy [133, 134]. These models which apply biological materials such as 
abdominal rectus fascia and veins have rupture characteristics that are similar to humans 
[127]. 
2.10 AAA diagnosis strategies and imaging modalities 
When the enlargement of the aorta is greater than 1.5-fold of its normal size, it is 
considered an aneurysm [73]. Clinical diagnosis of AAAs is most common by ultrasound 
quantification of aortic diameter. It has been wildly used in the screening program for 
AAAs in many countries because it is inexpensive, non-invasive, and effective. Men and 
women, aged 65 years or older with a smoking or family AAA history, are recommended 
to receive onetime ultrasonography of the infrarenal abdominal aorta even if they have no 
symptoms [6]. Ultrasound is also used as a monitoring tool for patients with small AAAs 
to track AAA progression. Although it has been demonstrated to be a relatively accurate 
imaging modality for AAA screening, obese body habitus, bowel gas, and the observer’s 
skill set can compromise the ultrasound accuracy [135]. Moreover, the imaging accuracy 
of ultrasound decreases as the size of the aorta increases [136].  
When ultrasound images are suboptimal, computed tomography (CT) is used as an 
alternative imaging method. It is a superior diagnostic modality compared with 
ultrasonography because it can provide valuable information with high reproducibility, 
including a more accurate AAA morphology as well as the surrounding anatomy, the 
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presence of intraluminal thrombus, and calcifications. More advanced CT-based 
modalities, such as Helical CT and CTA are wildly used as the imaging modalities for the 
pre-operative AAA evaluation because they can generate a 3D road map of nearby vessels 
as well for planning surgical repair [137]. Moreover, some findings from the CT imaging 
render CTA the ability to provide information for assessing the inflammation level and 
rupture risk of the aneurysms. For example, CT-detected delayed enhancement in the aortic 
wall represents an increased density of inflammatory cells and neovessels in the aortic 
adventitial, and the intraluminal crescent sign represents the bleeding in the intraluminal 
thrombus [138]. However, the ionizing radiation and the contrast agents that are used in 
CTA can cause adverse effects in cases involving repeated imaging or renal insufficiency. 
Magnetic resonance imaging (MRI) is another advanced imaging modality for 
AAAs with high sensitivity and reproducibility. MRI can provide high resolution 3D 
anatomical imaging of AAAs, as well as the information about aortic calcification, 
inflammation, and biomechanics [139, 140]. The advantage of performing magnetic 
resonance angiography (MRA), comparing to CTA, is that no ionizing radiation and 
contrast agent exposure is required. Instead of gadolinium contrast agent injection, a longer 
acquisition time in MRA can also enhance the AAAs [138]. But the use of MRI is limited 
because of its relatively high cost, patient-related motion artifact, and patient 
claustrophobia during longer scanning times. 
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2.11 Contrast agent for computed tomography (CT) scan 
The X-ray absorption profile of different materials varies with the density and 
atomic number according to the formula that has been used to estimate the X-ray absorption 
coefficient under limited conditions: 
𝜇 ≈
𝜌𝑍!
𝐴𝐸" 
where 𝜌 is the material density, Z is the atomic number, A is the atomic mass and E is the 
X-ray energy. Different X-ray absorptions of different materials generate contrast in a CT 
scan. Many bodily tissues including bones and lungs are easily recognized in a CT scan 
due to their distinct X-ray absorption profile comparing to the soft tissues. However, it 
remains challenging to identify the interface between two adjacent soft tissues or between 
soft tissue and physiological fluids such as blood [141]. Contrast imaging agents are often 
applied to better visualize and differentiate the tissue of interest such as AAA from the 
surrounding connective tissue, improve the imaging quality, and increase the CT 
sensitivity. Various contrast media with a sufficient in-vivo retention-time has been 
developed to fulfill the requirement to highlight the tissue of interest in a CT scan.  
Iodine-based contrast agent 
Covalently bound iodine has historically been a popular choice for designing CT 
contrast agent due to the high atomic number of iodine (Z = 53) (Figure 2-13). The 
iodinated contrast agent can be divided into ionic and non-ionic categories. Ionic contrast 
agents dissociate into negative and positive ions when dissolved in water while non-ionic 
contrast agents do not dissociate and contain polar hydroxide groups that confer them their 
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water solubility [142]. Non-ionic contrast agents comparably present more advantages to 
be used clinically including lower intrinsic osmolality and lower incidence of adverse 
health effects [143]. Over the past few decades, efforts have been made to optimize the 
iodinated contrast agent design by manipulating the functional groups present on the 
aromatic ring. The purpose of the optimization is to increase the water solubility and bio-
tolerability while decreasing the binding to biological receptors and the toxicity of the 
iodinated contrast agent. Moreover, iodine can be encapsulated into nanoparticles to 
achieve some additional benefits, including increased blood circulation time, reduced renal 
clearance rate, and capillary leakage [144]. It is a better choice to enhance CT imaging for 
the cardiovascular system. 
 
Figure 2-13. Different designs of iodinated contrast media [145]. 
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Lanthanide-based contrast agents 
Given their high atomic numbers, Lanthanide-based contrast agents, which are 
commonly used in MRI imaging, can also be used as a CT contrast agent for cardiovascular 
and pulmonary imaging [146, 147]. Although free lanthanide ions are extremely toxic, 
gadolinium (Z = 64), dysprosium (Z = 66), and ytterbium (Z = 70) form highly 
thermodynamically stable polyaminocarboxylic acid chelate complexes that make them 
clinically safe to be used as contrast agent [148, 149]. Since the lanthanide atoms have 
higher atomic numbers than iodine, they can offer higher X-ray attenuation and CT 
sensitivity than the equal mole amount of iodine atoms. However, some clinical studies 
show that gadolinium imaging media can be a cause of pancreatitis and nephrotoxicity that 
results in nephrogenic systemic fibrosis (NSF) and encephalopathy in certain at-risk 
patients [150-152]. Lanthanide based contrast agents can be nanoparticulated as well to 
increase the stability of the contrast agent, minimize the free lanthanide ion release and 
prolong their circulation time in blood [153].  
The gold nanoparticles-based contrast agent 
Gold nanoparticles (AuNPs) are an ideal radiopaque contrast media because of the 
following reasons: (a) gold has high density and high atomic number (Z=79), which renders 
it a high X-ray attenuation; (b) AuNPs have been demonstrated to have good 
biocompatibility in-vivo; (c) physical, chemical and biological properties of the AuNPs can 
be manipulated by the well-established synthesis and modification chemistry [154]. It has 
been reported that when the size of the AuNPs falls in a certain range, usually small sizes, 
AuNPs have a wild biodistribution and exhibit toxicity [155]. This problem can be solved 
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by controlling the size and shape of the AuNPs during synthesis, and by modifying the 
surface of the AuNPs with biocompatible molecules such as polyethylene glycol (PEG) 
and albumin [156, 157].  
Surface coated AuNPs have long blood circulating time and can be used as the 
contrast agent for blood pool imaging. Moreover, the surface-modified AuNPs can be used 
to image targeted organs. The application of heparin polysaccharides conjugated AuNPs 
can produce a highly liver-specific contrast in mice [158]. Lisinopril coated AuNPs can be 
used to target the angiotensin-converting enzyme (ACE) overexpression in lung tissue in-
vitro [159]. AuNPs coated with antibodies that can target the pathological biomarkers in 
cancer, for example, UM-A9 antibodies and Herceptin, have been studied as specific tumor 
targeting contrast agents for CT imaging [160, 161]. Although AuNPs based contrast agent 
has been demonstrated to be a great compromise between contrasting properties, 
physicochemical properties, and biocompatibility, the high cost of gold has been limiting 
its application in clinical CT imaging [154]. 
Other metallic contrast agents 
Other metallic contrast agents such as water-soluble tantalum oxide (Ta2O5) and 
bismuth (Z=83) based contrast agents have been studied as inexpensive alternatives for 
AuNPs. Ta2O5 nanoparticle is an inexpensive, biocompatible contrast agent that has been 
used in tracheobronchial and gastrointestinal imaging [162] The sizes of these particles are 
easily controllable and surfaces of Ta2O5 nanoparticles can be modified with zwitterionic 
coatings. It possesses better CT attenuation properties than an iodinated agent on a per-
mole basis [141]. Bismuth-based nanoparticles with good X-ray attenuating properties that 
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exhibit long vascular half-life have been developed and tested in mice as a potential 
contrast agent [163]. However, the clinical application of bismuth-based contrast agents is 
confined due to the difficulties in controlling the nanoparticle size and modifying the 
surfaces, and the lack of toxicity evaluation. As the synthesis and modification of these 
nanomaterials get optimized, they hold promise in the field of cardiovascular, lymphatic 
system, and tumor tissue CT imaging. 
2.12 AAA Treatment Strategies  
Current treatments for AAAs 
Currently, AAA patients can be clinically treated with either conservative methods 
or surgical interventions depending on the absolute/relative size or the growth rate of the 
aneurysm. Conservative management via regularly repeated ultrasonography for smaller 
AAAs with diameters vary from 3.0 to 5.4 cm greatly reduced the observed AAA-related 
mortality [6]. It is also a common treatment strategy for patients whose assessment of 
surgical risk overweighs the benefits. The medical aim for conservative management is to 
slow down the growth of AAAs and reduce the rupture risk pharmacologically by treating 
AAA related cardiovascular disease such as hypertension [164]. In the meantime, patients 
are recommended to quit the AAA promoting lifestyles such as smoking and unhealthy 
diets. By limiting the risk factors associated with AAA progression, patients with 
nonprogressive small aneurysms can get a better benefit from a conservative approach than 
a surgical treatment that usually has high risks of complications.  
However, for patients with (a) AAAs that reach a diameter threshold of 5.5 cm, (b) smaller 
AAAs of which the diameters grow 1.0 cm per year, or (c) ruptured AAAs, a surgical repair 
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is usually recommended to diminish the risk of fatal rupture [165]. The two most common 
and effective interventions for AAAs are traditional open surgery (OR) and abdominal 
endovascular aneurysm repair (EVAR). OR fix the AAA with a major operation by 
excluding the aneurysm with a synthetic tube or bifurcated graft while EVAR only requires 
a small groin incision that allows the placement of a stent-graft in the aneurysm (Figure 2-
14) [166]. Although surgical repair can effectively reduce the overall AAA mortality, 
perioperative mortality remains high because of the risk of operation process including 
long surgical time and a large surgical incision during an OR surgery, and post-operation 
complications such as infection, ischemia, thromboembolism, pulmonary insufficiency, 
and myocadiac dysfunction for both OR and EVAR treatment [167]. 
 
Figure 2-14. Open repair and endovascular repair of an infrarenal AAA [166]. 
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Potential pharmacotherapy for AAAs 
A lot of recent studies focused on developing pharmacotherapy for AAA to stop the 
expansion of AAAs at an early stage or reduce post-operation complications, so the patients 
can avoid surgical risks. Most of the prospective pharmacotherapies aim to reduce the local 
inflammatory response in the aneurysmal tissue and stabilize and regenerate the damaged 
aortic wall. One of the main targets for the AAA pharmacotherapies is the class of MMPs. 
MMPs are a group of calcium-dependent zinc-containing endopeptidases that play an 
important role in ECM degradation and tissue remodeling [168]. There are 23 known 
human MMPs currently (Table 2-1), among which upregulated activities of MMP-2 and 
MMP-9 in the aneurysmal tissue have been wildly studied in the pathogenesis of AAAs.  
MMP inhibitors, including doxycycline and batimastat (BB-94) (Figure 2-15), are 
the most extensively tested pharmacotherapy for AAA treatment in both animal models 
and clinical trials. The administration of MMP inhibitors can reduce the production and the 
activity of MMPs, thus, prevent the destruction of elastic lamellae without decreasing 
inflammatory cell infiltration [169]. Doxycycline is a synthetic antibiotic derived from 
tetracycline that has been clinically used to treat many different types of infections. It also 
has some non-antibiotic properties, including inhiation of inflammation, proteolysis, 
angiogenesis, and apoptosis [15]. Doxycycline inhibits MMPs via diminishing the 
activation of pro-MMPs, accelerating the MMP degradation, and loss of enzymatic activity 
[170].  
The inhibition of MMP activity can be also achieved by altering the enzyme 
structure by chelating the zinc (II) ion of the active site, binding to the backbone of the  
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Table 2-1. Human matrix metalloproteinase 
No. Class MMP No. Trivial name 
1 Collagenases MMP-1 Interstitial collagenase 
2  MMP-8 Neutrophil collagenase 
3  MMP-13 Collagenase 3 
4 Gelatinases MMP-2 72 kDa gelatinase A 
5  MMP-9 92 kDa gelatinase B 
6 Stromelysins MMP-3 stromelysin-1 
7  MMP-10 stromelysin-2 
8  MMP-11 stromelysin-3 
9 Matrilysins MMP-7 Matrilysin 1 
10  MMP-26 Matrilysin 2 
11 MT-MMPs MMP-14 MT-1 MMP 
12 (Transmembrane) MMP-15 MT-2 MMP 
13  MMP-16 MT-3 MMP 
14  MMP-24 MT-5 MMP 
15 (GPI anchored) MMP-17 MT-4 MMP 
16  MMP-25 MT-6 MMP 
17 Other enzymes MMP-12 Macrophage elastase 
18  MMP-19 RASI-1 
19  MMP-20 Enamelysin 
20  MMP-21 - 
21  MMP-23 CA-MMP 
22  MMP-27 - 
23  MMP-28 Epilysin 
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enzyme, or interacting with subsites of the enzyme [171]. BB-94 is one of the board 
spectrum MMP inhibitors that has a hydroxamate group which can bind to the active zinc 
in MMPs [172]. Treatment with a low dose of BB-49 with an aneurysm targeting 
nanoparticle system has been reported to suppress MMP activity and AAA progression in 
a CaCl2 induced rat AAA model [169]. 
 
Figure 2-15. Structure of doxycycline and batimastat. 
Several drugs, such as pyrrolidine dithiocarbamate (PDTC) and statins, were 
studied for their ability to reduce the inflammatory response in aneurysmal tissue by 
interacting with pro-inflammatory signaling pathways. Nuclear factor-kappa B (NF-κB) is 
a transcription factor implicated in the processes of inflammatory responses and oxidative 
stress. The activation of NF-κB signaling pathway can result in mRNA expressions of the 
genes for numerous cytokines, growth factors, and adhesion molecules [173]. NF-κB 
activation is a major early event in the pathogenesis of inflammation-related vascular 
diseases, making the blockade of endothelial NF-κB signaling a promising strategy for 
preventing vascular inflammation and dysfunction, especially aneurysm formation [174]. 
PDTC, an antioxidant, and inhibitor for NF-κB signaling pathway, has been reported to 
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successfully relieve cancer cachexia and attenuate lipopolysaccharide (LPS) induced injury 
[175-178]. PDTC can induce the expression of the regulator of calcineurin activity 1 
(RCAN1), thus, prevent the activation of NF-κB signaling pathway (Figure 2-16) [179]. 
Considering the important role NF-κB plays in the AAA pathogenesis, PDTC has also been 
tested in animal AAA models, and has effectively inhibited AAA progression by 
modulating the expression of MMPs and proinflammatory cytokines [180-182].  
 
Figure 2-16. PDTC inhibits NF-κB signaling via inducing RCAN1 expression [179]. 
Statins, the inhibitors of 3-3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, are a class of well-established drugs for lowering the cholesterol level in 
vascular diseases [183-185]. It has been shown that statins can reduce the secretion of pro-
inflammatory proteins such as MMPs and MCPs in ex-vivo studies with cultured human 
AAAs by preferentially inhibit the Rac1/ NF-κB signaling pathway [186, 187]. Further 
studies on simvastatin and pravastatin (Figure 2-17), two kinds of statins that had the fewest 
side effects in this class of medications, have demonstrated their ability to increase TIMP-
1 production in rodent models [13, 14]. Statin treatment not only attenuates the AAA 
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progression in animal models but also in clinical studies. In a study of 130 patients with 
AAAs not treated surgically, the group of patients who were received statins treatment 
showed significantly smaller AAA sizes and lowered mortality comparing to the group of 
patients not treated with statins [188].  
 
Figure 2-17. Structures of simvastatin and pravastatin. 
The development of AAA is associated with increased oxidative stress in the aortic 
wall. Overproduction of reactive oxygen species (ROS) as a result of the change in aortic 
mechanical stress and expression of cytokines can subsequently induce vascular 
inflammation, increased MMP activity, SMCs apoptosis, and change in collagen properties 
[189]. α-tocopherol, known as vitamin E, is a dietary antioxidant that has been 
demonstrated to reduce macrophage infiltration, osteopontin (OPN) expression and ROS 
activity in an AngII induced ApoE-/- mouse AAA model [190]. The size and weight of 
these AAAs were both decreased, indicating that vitamin E has the potential to slow down 
AAA progression. β-carotene is another antioxidant that has been reported to attenuate the 
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AAA formation. β-carotene may activate RAR/RXR pathway and dimerize with 
peroxisome proliferator-activated receptors (PPARs) to repress the target genes, regulate 
inflammatory reactions, alleviate macrophage recruitment and resolve atheromatous 
plaques in the ApoE-/- mice model [125]. 
 
Figure 2-18. Structures of α-tocopherol and β-carotene. 
Given the fact that RAS participates in several pro-AAA mechanisms, ACE 
inhibitors, and angiotensin receptor blockers (ARB) have been studied as pharmacological 
treatments for AAAs [191]. It has been well established that the clinical application of ACE 
inhibitors and ARBs can regulate the blood pressure in patients with hypertension [192]. 
The decrease in blood pressure lowers the aortic wall stress, thus decrease the rupture risk 
of AAAs. Moreover, ACE inhibitors and ARBs have anti-inflammatory effects on the 
aneurysm wall by suppressing the NF- κB pathway and TGF-b/SMAD signaling [193]. 
ACE inhibitors such as captopril, lisinopril, and enalapril prevented the development of 
AAA and attenuated the degradation of media elastin in an elastase infusion model [194]. 
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ARBs such as telmisartan and valsartan limit the progression of AAAs by inhibiting the 
angiotensin II type I receptor (AT1R) cascade [195-197].  
Table 2-2. Potential pharmacotherapy for abdominal aortic aneurysms 
Drugs Known mechanisms Effects 
Doxycycline Pro-MMPs activation ↓ MMP-9 ↓, MMP-2 ↓, preserved elastin 
BB-94 Zinc (II) ion chelation MMP-9 ↓, MMP-2 ↓, preserved elastin 
PDTC 
NF-κB pathway ↓, 
Notch pathway ↓ 
Cellular infiltration ↓, MMP-9 ↓, IL-1b ↓, 
IL-6 ↓, preserved elastin 
statins 
(simvastatin and 
atorvastatin) 
Rac1/NF-κB pathway ↓ 
Macrophage infiltration ↓, MMP-9 ↓, MCP-1 
↓, MCP-2 ↓, epithelial neutrophil-activating 
peptide (CXCL5) ↓, TIMP-1 ↑, preserved 
elastin 
α-tocopherol Oxidative stress ↓ Macrophage infiltration ↓, ROS ↓, OPN ↓ 
β-carotene 
Oxidative stress ↓, 
RAR/RXR pathway ↑ 
Macrophage infiltration ↓, ROS ↓, 
Atheromatous plaques ↓ 
ACE inhibitors 
AT1R ↓, AT2R ↓, NF-
κB pathway ↓, TGF-
b/SMAD ↓ 
Blood pressure ↓, MMP-9 ↓, preserved 
elastin 
ARBs 
AT1R ↓, ERK ↓, NF-κB 
pathway ↓ 
Blood pressure ↓, MMP-9 ↓, Bcl-2/Bax ↑, 
preserved elastin 
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All the drugs that can be used as a pharmacotherapy for AAA mentioned above are 
summarized in Table 2-2. 
Polyphenols are a large and varied family of natural compounds that consist of a 
hydrophobic core surrounded by phenolic (-OH) groups on the exterior. Pentagalloyl 
glucose (β-1,2,3,4,6-Pentagalloyl-O-D-Glucopyranose, PGG) is one of the tannic acid 
derivatives that contain five identical gallic acid ester linkages involving the aliphatic 
hydroxyl groups in the sugar core (Figure 2-19) [198]. It has gained a lot of scientific 
attention recently because of its potential use as an antimicrobial, anti-inflammatory, 
anticarcinogenic, antidiabetic, and antioxidant agent [199].  
Studies indicated that PGG could be used as an ECM stabilizer due to its capability 
to bind to structural fibers in the ECM and, in doing so, render them resistant to enzymatic 
degradation. Periarterial treatment with PGG preserved elastin fiber integrity and hindered 
aneurysmal dilatation of the abdominal aorta in clinically relevant calcium chloride and 
elastase-induced animal injury model of AAA [200, 201]. More interestingly, enhancement 
of ECM biosynthetic enzymes such as LOX can not only stabilize the ECM but also 
reduced inflammatory responses, including MCP-1 secretion, macrophage infiltration, and 
c-Jun N-terminal kinase (JNK) pathway activation, thereby preventing AAA progression 
in mice [83]. 
Most of the pharmacotherapies mentioned above were tested in animal models. To 
translate the research findings into clinical practice, further studies need to focus on how 
these drugs interact with human AAA in-vivo. In the established human AAA treatment 
 48 
clinical trials, drugs were usually administrated systemically. Although systemic 
pharmacologic treatments have shown effectiveness in animal models, they did not bring 
many benefits to the AAA patients due to either low local drug concentration or severe  
 
Figure 2-19. Gallic acid and PGG structure [202]. 
systemic side-effects. For instance, systemic delivery can cause off-target inhibition of the 
MMP activities that are essential for normal homeostasis [203]. Since AAA is 
predominately localized to a limited area on the aorta, targeted delivery of pharmacologic 
agents is a tempting approach to increase therapeutic efficacy and reduce systemic side 
effects. Local drug delivery can be achieved by establishing a nanoparticle system that 
targets pathological biomarkers located in the aneurysmal tissue or combining the drugs 
with medical devices such as grafts or endovascular stents via surface coating.  
 49 
2.13 Targeting nanoparticles (NP) systems 
Nanotechnology is a powerful tool that has been wildly used in developing and 
optimizing novel diagnostic strategies and pharmacotherapies in many fields. The 
physiological and chemical properties of the materials change drastically in nanoscale. It 
provides a possibility to make the synthesized materials less toxic and more biocompatible 
for in-vivo use by making them into size-controlled and surface-modified NPs. NPs are 
relatively stable in biological systems, characterized by a long blood half-life and their 
ability to evade elimination by the reticuloendothelial system [204]. The surface 
modification also can render NPs certain unique features that enable them to target specific 
tissues or organs to maximize the beneficial effects of the loaded chemicals by improving 
local availability and lower off-target complications. 
Many types of nanosystems, including dendrimers, quantum dots, micelles, 
liposomes, polymeric nanoparticles, carbon nanotubes, albumin, and metallic nanoparticles 
such as gold and iron oxide, have been studied in a range of diseases. The nanosystem is 
usually selected base on the applications. For example, self-assembling peptide amphiphile 
nanofibers are being investigated as treatments to modify stem cell proliferation and 
differentiation in regenerative medicine [205]. Gold nanoparticles, magnetic iron oxide 
nanoparticles, and quantum dots can be used directly for targeted bioimaging [206-208]. 
Moreover, drugs can be loaded to the surface of these nanosystems via surface 
modifications to achieve both diagnostic and treatment capabilities at the same time [209-
211]. Dendrimers, polymeric, liposomal, and albumin nanoparticles have been extensively 
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studied as in-vivo drug delivery nanocarriers because of their high biocompatibility, 
biodegradability, and high dug payload [212-214]. 
To date, the targeting of AAAs for therapeutic and imaging purposes remains 
significantly challenging because of the limited number of viable targets and a relatively  
 
Figure 2-20. Schematic diagram of nanocarriers, potential targets, and potential 
applications in medicine [215].  
low hemodynamic residence time in the diseased aorta. As NPs have to be administered 
intravenously into circulation to target vascular disease, an immune response, known as 
opsonization, to the blood proteins that are absorbed onto the particle surface will occur 
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[216]. Opsonization will result in the particles being quickly eliminated from circulation 
by the mononuclear phagocyte system (MPS), and the desired imaging and therapeutic 
effect would not be achieved [217]. Yet, despite the difficulties in designing targeting 
systems for vascular diseases, some surface-modified nanosystems have been developed 
to successfully target AAAs. 
Metallic nanoparticles 
Ultra-small SPIO (USPIO) nanoparticles are a novel category of MRI contrast 
agents that play a crucial role in the imaging of AAAs. USPIO nanoparticles include 
ferumoxtran-10 and ferumoxytol with a diameter of <50 nm. They can be used as a blood 
pool contrast agent but also can be taken up by tissue-resident macrophages and can be 
used to identify cellular inflammation within tissues [218]. In several rodent animal 
models, marked accumulation of USPIO-labeled macrophages was found within the 
aneurysmal aorta that could be identified by MRI and was confirmed by 
immunohistochemistry [219-221]. Preliminary evidence of USPIO uptake in human 
abdominal aortic aneurysms (AAA) has been described by Sadat U. et al in a 14 patient 
study [222]. Thus, USPIO enhanced MRI can be potentially effective in the quantification 
of the AAA associated inflammatory processes. 
Cross-linked iron oxide nanoparticles (CLIO) also have been reported to possess 
the ability to target the monocytes/ macrophages in the aneurysmal tissue. A recent study 
performed in ApoE-/- mice indicated that dextran-coated iron oxide nanoparticles could be 
labeled with fluorine-18 (18F) and could provide a specific signal intensity enhancement in 
the aneurysmal wall in PET -CT scans [223]. In this reported AAA targeting NP system, 
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CLIO was avidly internalized by phagocytic cells in the aneurysmal tissue to achieve 
targeting and 18F functioned as the PET scan tracer to visualize the inflammatory level of 
the AAAs. 
Polymeric nanoparticles 
Biodegradable polymeric NPs have shown significant therapeutic potential for 
controlled drug delivery. Nanoparticles made of polymers, such as poly (lactic acid) (PLA), 
poly-lactic-co-glycolic acid (PLGA), polyethylene glycol (PEG), and their copolymers, 
present themselves as lucrative options for drug delivery owing to the possibility to tailor 
their physical, surface, and degradation characteristics. Drugs that are enclosed within the 
polymeric NPs would be protected from potential degradation by enzymes or hydrolysis, 
and the encapsulation would allow for developing more flexible and patient-friendly 
delivery techniques [224]. Most of the drug-loaded polymeric NPs can be obtained using 
an emulsification-solvent evaporation technique [225, 226]. 
PLA is biocompatible, biodegradable by hydrolysis and enzymatic activity. It has 
low immunogenicity, as well as a broad range of mechanical and physical properties that 
can be engineered appropriately to suit different applications [227]. The matrix of PLA-
NP allows the control of drug release kinetics, offering PLA-NP based drug carriers the 
benefit of sustainable therapeutic drug release over prolonged periods [228]. The United 
States Food and Drug Administration (FDA) has approved the use of PLA-NPs in humans, 
which makes PLA-NPs suitable for expedited clinical translation. Previous studies from 
our lab have demonstrated the ability of the antibody conjugated PLA-NPs to target 
aneurysmal tissue and slowly release therapeutic drugs [169, 229].  
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PLGA is a co-polymer with physicochemical characteristics that vary with the 
lactic to glycolic ratio. Its application in humans has also been approved by the FDA [230]. 
Surface modified PLGA NPs have been used for AAA therapeutic and imaging purposes. 
Surface functionalization of PLGA NPs with a cationic amphiphile, such as 
didodecyldimethylammonium bromide (DMAB), endows the NPs with the ability to bind 
fibrin clots [231]. When loaded with fibrinolytic drugs, the NPs have been shown to slowly 
cause clot lysis and attenuate the proteolytic loss of vascular elastic matrix. Moreover, 
hyaluronan oligomers loaded PLGA NPs have been reported to have a controlled and 
sustained drug delivery profile and elastogenic induction property when added into 
cultured aneurysmal rat aortic SMCs [232]. PLGA NPs have also been used to encapsulate 
contrast agents such as iron oxide and gadolinium, and modified to target thrombosis to 
enhance the AAA MRI signal intensity [233, 234]. 
Albumin based nanoparticles 
Albumin, a major transport protein component in blood plasma, has been 
commonly used for drug delivery because it is known to be non-toxic, non-immunogenic, 
biocompatible, and biodegradable. Albumin in its monomeric formula and albumin-based 
nanoparticles have emerged as attractive drug carriers, owing to its promising intrinsic 
binding capability of a significant amount of drug molecules [235]. According to the 
sources, albumin can be divided into three major types: ovalbumin (OVA) from egg white, 
bovine serum albumin (BSA), and human serum albumin (HSA). BSA is a type of albumin 
that is wildly accepted in the pharmaceutical industry because of its medical importance, 
low cost, and ease of purification. HSA could be used to substitute BSA in in-vivo 
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applications to avoid a possible immunologic response [236]. Registered HSA-based 
particles such as Albunex™ and Abraxane™ presented high in-vivo tolerance and great 
drug delivery profile in clinical studies [237, 238]. 
NPs that are made out of albumin have been studied for targeting several vascular 
diseases. Apatinib-loaded HSA NPs have been used to inhibit vascular endothelial growth 
factor (VEGF) induced retinal vascular leakage both in vitro and in vivo in a study 
performed by Jeong J. H. et al. [239]. Piceatannol-loaded BSA NPs have been studied to 
prevent vascular inflammation by blocking β2 integrin signaling in leukocytes and 
detaching the adherent neutrophils on vascular endothelial cells [240]. Ji, J. et al have 
reported a method to crosslink albumin NPs crosslinked into albumin ultrasound 
microbubbles. A highly expressive tissue-type plasminogen activator gene (t-PA) plasmid 
was packaged inside to prevent the formation of thrombosis in a dog model of coronary 
bypass [241]. More importantly, according to the previous research from our lab, an 
antibody conjugated BSA-NPs drug delivery system loaded with PGG has been shown to 
be capable of targeting AAA in a CaCl2 induced rat model and an elastase-induced mouse 
model [169, 201]. And ethylenediaminetetraacetic acid (EDTA)-loaded BSA NPs 
conjugated with the same antibodies have been reported to successfully target chronic 
kidney disease-induced arterial calcification in a rat model and achieve therapeutic 
purposes [242] 
Albumin nanoparticles can be prepared using techniques including coacervation, 
emulsification, thermal gelation, and nanospray drying. Different techniques result in 
albumin NPs with different sizes. The coacervation method can be used to produce NPs 
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with mean diameters between 150 and 280nm [243]. In the process of simple coacervation, 
albumin is phase-separated by adding a desolvating agent such as ethanol to diminish the 
solubility of albumin in the aqueous phase. In order to obtain stable albumin nanoparticles, 
crosslinker such as glutaraldehyde, polyethyleneimine (PEI), methyl polyethylene glycol 
modified oxidized dextran (Dextranox-MPEG), formaldehyde, and 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) is then used as a to harden the coacervates 
[244, 245]. 
Biomarkers for AAA targeting 
Targeting of NPs can be achieved either passively or actively. Passive targeting 
mainly relies on inflammation/hypoxia-induced increase of vascular endothelium 
permeability. It is the concept that was commonly used for targeting tumors because of 
their enhanced permeability and retention (EPR) effect [246, 247]. The leaky vessels and 
the absence of normal lymphatic drainage in tumors contribute to the local accumulation 
of macromolecules larger than 40kDa and NPs [248]. The circulation time of the NPs in 
the blood pool plays an important role in passive targeting. The prolongation of the 
circulation time can be achieved by NPs surface coating, for example, PEGylation [249].  
Active targeting, on the other hand, depends on molecular recognition such as 
ligand/receptor and antigen/antibody interactions. Surface modification with molecules 
that target disease-related biomarkers is essential for NPs active targeting. Comparing to 
free drug delivery or passive targeting, active targeting can significantly increase the 
quantity of drug delivered to the tissue of interest [250, 251]. Moreover, the active targeting 
of AAAs can be achieved by a combination usage of NPs and external medical device. 
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Magnetic NPs can be guided to the location of the AAA under the influence of an applied 
external magnetic field. Superparamagnetic iron oxide (SPIO) nanoparticles, along with 
doxycycline were encapsulated in poly(lactic-co-glycolic acid) (PLGA) NPs and were 
successfully delivered to the aneurysmal tissue owing to the magnetic properties of SPIO 
[252].  
The physiological abnormalities in aneurysmal tissues can generate local 
biomarkers for AAA targeting imaging and drug delivery. Overproduced ROS in the AAA 
wall provides targeting possibility for NPs made out of ROS responsive materials. An 
oxidation-responsive β-cyclodextrin (OxbCD) material based nanocarriers have been 
reported to successfully release loaded rapamycin upon triggering by a high level of ROS 
in a CaCl2 induced rat AAA model [253]. The inflammatory response can also produce 
biomarkers for targeting, such as macrophage infiltration and upregulation of inflammatory 
molecules. The macrophage infiltration has been labeled by USPIO and was enhanced in 
MRI imaging for inflammation assessment in an ApoE -/- mice AAA study carried out by 
Turner, G.H. et al. [220]. The αvβ3 integrin, a cell surface glycoprotein receptor, has been 
shown to be upregulated in neovessel endothelial cells and atherosclerotic macrophages 
and has been used as a AAA target [254]. By using Arg-Gly-Asp (RGD), an extensively 
studied short amino acid sequence binder of the αvβ3 integrin, both macrophages and 
angiogenesis within AAA lesions in ApoE -/- mice can be targeted [255]. Cathepsin K, a 
lysosomal protease that is highly overexpressed within AAA tissue, was targeted with 
antibody conjugated cationic amphiphile (DMAB)-modified submicron particles [256]. 
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The pathological structural changes in the aneurysmal tissue result from ECM 
degradation can be also used as targets for localized delivery. The microstructural defects 
in the aneurysmal wall have been successfully targeted in an elastase-induced rat AAA 
model using rapamycin loaded poly (γ-benzyl L-glutamate) (PBLG) NPs [257]. Degraded 
elastin fibers have been targeted using elastin antibody-conjugated PLA NPs loaded with 
BB-94 in a CaCl2 induced rat AAA model [169]. The remodeling of the ECM causes 
abnormal deposition of collagen in the aneurysmal wall, which can also be used as a target. 
CNA-35 functionalized paramagnetic/fluorescent micellar nanoparticles target type I 
collagen in the AAA and result in a significantly higher magnetic resonance signal 
enhancement in the aneurysmal wall that can be used to predict the rupture risk [258]. The 
formation of AAAs and ILTs is associated with endothelial dysfunction and injury as 
animal models of endothelial dysfunction and endothelial nitric oxide synthase (eNOS) 
uncoupling had a very high rate of AAA formation [259]. The damaged endothelial cells 
on the surface of the AAA wall can be targeted with microbubbles conjugated with 
molecules that have affinities to specific endothelial determinants such as P-selectin [260].  
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3. PROJECT RATIONALE AND SPECIFIC AIMS 
As described in the previous chapter, AAA patients can be currently treated with either 
conservative methods or surgical interventions depending on the extent of disease 
progression. Up to 90% of detected AAAs are small enough that they do not require 
surgery. However, for patients who do not meet the surgical criteria, their AAAs can still 
rupture unpredictably. Patients diagnosed with smaller AAAs are under a life-threatening 
situation since about 13% of AAAs cause death in patients before they are recommended 
for surgery [96]. This could be a result of the limitations of current imaging modality and 
the lack of pharmacotherapies. On the one hand, current imaging methods are excellent to 
look at the overall growth of aneurysms, while focal aortic wall weakening is generally not 
precisely detected. Such weak spots are usually the repercussions of severe elastin 
degradation in the aneurysmal tissue and can increase the risk of rupture. On the other hand, 
the small AAAs or AAAs that cannot be surgically replaced are also not treated effectively 
because there are no current pharmacological treatments to prevent AAA expansion 
approved by the FDA.  
An imaging modality that can provide progression information other than diameter 
change of the AAAs is necessary to identify the patients with higher rupture risks, even if 
the sizes of their aneurysms were still small. To date, there is no satisfying imaging method 
that could be used to predict the rupture risk of AAAs. Current clinical diagnostic imaging 
modalities such as abdominal ultrasound imaging or contrast-enhanced CT provides mostly 
geometrical information of the AAAs but little insight on these factors that precede rupture 
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in AAAs. Moreover, in order to visualize the vascular system, a large dose of contrast agent 
is required for performing contrast-enhanced CT, the toxicity of which may raise concerns 
among the patients and place it at a disadvantage [141, 261]. Thus, it is desired to develop 
a more biocompatible and efficient contrast agent for CT imaging that can reveal the 
mechanical properties of the AAAs.  
AAA treatment strategies are usually chosen based on the criteria that the treatment 
should bring more benefits than risks to the patient. With a well-established imaging 
modality that provides information about AAA rupture risks, clinical decisions will no 
longer be made simply contingent on the AAA sizes. For the patients with small AAAs 
who are left to wait until their AAA grows large enough to require surgery, or the patients 
whose peri and post-operatory risks are too high to receive surgical intervention, 
pharmacological management of aneurysms would be an attractive option. During the last 
decade, several pharmacological therapies to stop ECM degradation showed promising 
results in animal studies, as mentioned in the previous chapter. However, the high required 
dose and related off-target systemic side effects of these drugs limited the translating of 
these drugs into clinical application.  
Among all the drugs that have been studied to reduce the inflammatory response, 
halt ECM degradation and suppress the ARS activities, PGG is highly promising for 
clinical use because of its relatively low cytotoxicity and ability to bind to stabilize the 
ECM to prevent AAA progression and improve the mechanical properties of the damaged 
aortic wall [262]. Although PGG is usually considered safe or even beneficial at low levels, 
few studies report on the acute toxicity of the use of a high dose of PGG in animals such 
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as a precipitous and lethal drop of blood pressure and a significant reduction in blood urea 
nitrogen level [263]. It is important to lower the required PGG dose for treating AAAs in 
vivo to achieve long-term treatment safety. A local drug delivery system with a controlled 
drug releasing profile can greatly increase the efficiency of the drug. Surface modified 
nanocarriers are great candidates for developing a target-oriented and controlled delivery 
system for precise medicines owing to their customizable characteristics. It can achieve the 
same therapeutic effect as systemic drug delivery while administrating drugs at a much 
lower total dosage.  
The innovation strategy of this research is to develop a targeted CT imaging 
contrast agent using surface modified AuNPs, as well as a therapeutic local drug delivery 
system that delivers PGG to the degraded matrix in the aneurysmal tissue. We hypothesize 
that elastic lamina degradation can be measured by site-specific targeting of AuNPs to the 
degraded elastic laminae and that the spatial distribution of AuNP binding will correlate 
with wall weakness. Thus, these AuNPs could prove useful as a non-invasive surrogate 
marker of AAA rupture potential. We further hypothesize that the targeted delivery of 
pharmacological agents will prevent expansion and the ultimate rupture of AAA. The 
potential of targeting PGG loaded albumin NPs to be used as a novel local pharmacological 
treatment to stop and reverse the progression of AAAs by preserving and regenerating 
elastin in the aneurysmal aorta without severe systemic side effects would be studied in 
this research. 
Specific aim 1: To synthesize and characterize AuNPs that can target degraded elastin 
and create distinguishable CT contrast in the vascular wall. 
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Sub aim 1: To synthesize, characterize and functionalize AuNPs.  
Approach: We will firstly synthesize citrate-capped AuNPs with a size of ~150nm 
using a kinetically controlled seeded growth method [264]. Then after we replace the citrate 
cap on the surface of the AuNPs with PEG, the AuNPs will be conjugated with custom 
made elastin antibodies that can target the degraded elastin. The size and zeta-potential of 
both bare and antibody-conjugated AuNPs (EL-AuNPs) will be measured for 
characterization. 
Sub aim 2: To investigate the toxicity and in-vitro targeting of EL-AuNPs.  
Approach: We will use human smooth muscle cells (hSMCs) to evaluate the 
cytotoxicity of the EL-AuNPs. EL-AuNP uptake will be evaluated in both hSMCs and 
mouse macrophages. We will optimize the targeting performance of EL-AuNPs by trying 
out different combinations of PEG to AuNP ratios and incubating conditions. PPE treated 
porcine carotids will be used to study the in-vitro targeting and imaging capability of EL-
AuNPs. 
Specific aim 2: To investigate whether EL-AuNPs can be targeted to AAAs in-vivo 
and to build a correlation between the micro-CT signal intensity of the targeted EL-
AuNPs and the mechanical properties of the aneurysm in a clinically relevant AAA 
animal model.  
Sub aim 1: To build an ex-vivo correlation between the micro-CT signal intensity 
of targeted EL-AuNPs and mechanical properties of the aneurysmal tissue.  
Approach: We will use the AngII infused mice model of AAA for these studies. 
We will inject EL-AuNPs intravenously to target the AAA in-vivo. Then the entire mouse 
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aorta will be explanted and imaged using micro-CT. We will quantify the micro-CT signal 
intensities of EL-AuNPs accumulated within the aneurysms from the ex-vivo scans and 
correlate them with the corresponding burst pressures. We will perform histological 
analysis on the targeted aneurysms to reveal the targeting site of the EL-AuNPs. 
Sub aim 2: To visualize AAAs in-vivo with micro-CT using EL-AuNPs as a 
contrast agent and build a correlation between the targeted micro-CT signal intensity and 
mechanical properties of the aneurysmal tissue.  
Approach: We will still use the AngII infused mice model of AAA for these studies. 
We will first, inject EL-AuNPs intravenously to visualize the AAAs distinctively in-vivo 
with micro-CT. Secondly, we will quantify the in-vivo micro-CT signal intensity of EL-
AuNPs accumulated in the suprarenal aortic region since it is where the aneurysm usually 
develops in this animal model. And we will correlate the obtained signal intensity with the 
corresponding aortic burst pressure which represents AAA rupture risk, to investigate the 
potential of EL-AuNPs in predicting the progression of AAAs. We will perform 
histological analysis on the targeted aneurysms to reveal the targeting site of the EL-
AuNPs. 
Specific aim 3: To investigate whether PGG loaded albumin NPs that are conjugated 
with antibodies can be targeted to AAAs in an AngII model and whether they stop 
the disease progression and restore the healthy function of the aortic wall by repairing 
elastin matrix. 
Approach: PGG loaded NPs will be synthesized and conjugated to anti-elastin 
antibodies. In AngII infused mice, we will investigate whether systemic injection with 
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PGG loaded NPs can target and reverse already developed AAA by monitoring the 
diameter changes of the aneurysms with an ultrasound system. We will also study the 
change in biomechanical properties of the aneurysmal tissue, such as biaxial mechanical 
properties, circumferential strain, and PWV. We will study the effect PGG has on the 
systemic and local status of inflammation, the local genetic expression, and the structure 
of ECM in the aneurysmal tissue. 
Each specific aim research is described in separate chapters below. 
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4. SPECIFIC AIM 1: TO SYNTHESIZE AND CHARACTERIZE AuNPS THAT CAN 
TARGET DEGRADED ELASTIN AND CREATE DISTINGUISHABLE CT 
CONTRAST IN THE VASCULAR WALL 
4.1 Introduction 
Gold in nanoscale has been studied as an ideal radiopaque CT contrast agent for its 
high density, high atomic number, high X-ray absorption coefficient, and low toxicity 
[141]. The shape and size of the nanosized gold can be easily controlled during the 
synthesis. And the availability of different kinds of surface modification methods for AuNP 
renders it the potential to be a safe and effective contrast agent that can be applied both 
systemically and locally. PEGylated AuNPs with prolonged blood circulation times have 
the potential to be used to create contrast for the imaging of the cardiovascular system with 
aneurysms [265]. Moreover, surface modified AuNPs with a size of about 15nm have been 
targeted delivered to enhance the contrast of tumors, lymph nodes, and micro-calcifications 
in-vivo [266-268].  
However, AuNPs with small sizes are not suitable for targeting vascular wall 
because of a large amount of unspecific cellular uptake and clearance by the host immune 
system. Moreover, a few studies have shown in-vivo toxicity of small AuNPs including 
acute inflammation and apoptosis in the liver, loss of structural integrity in the lungs, and 
diffusion of white pulp in the spleen, accompanied by gene expression changes [269-271]. 
AuNPs with a particle size of ~150nm show better biocompatibility and increased 
circulation time owing to their ability to escape the endothelium uptake and phagocytosis 
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by macrophages, thus, have a better potential to be used as a AAA targeting contrast agent 
for CT scan. 
AuNPs are usually synthesized by a standard single phased water-based reduction 
of a gold salt with citrate as the initiator as described by Turkevich, J. et al and refined by 
Frens, G. [272, 273]. Briefly, HAuCl4 solution was brought to boil and then the sodium 
citrate solution was added. An immediate color change of the solution was observed 
indicating the nucleation and formation of monodispersed spherical particles. The mixture 
was then kept boiling till the reduction of gold chloride was complete. However, this 
method was usually used to produce AuNPs with a size smaller than 100nm. In order to 
get monodisperse citrate-stabilized AuNPs with sizes larger than 150nm and uniform 
quasi-spherical shapes that are preferable in AAA targeted imaging, we adapted an 
improved seed growing AuNP synthesizing method reported by Bastus, N. G. et al for this 
research [264]. 
Surface modification for AuNPs also plays an essential role in AAA targeting. In-
vivo targeting of AuNPs is achieved through either passive or active targeting. Passive 
targeting depends on the homing of the vectors in unhealthy tissues due to extravasation 
through the leaky blood vessel, while active targeting presents ligands on the AuNP surface 
for specific recognition [274]. In this study, the elastin antibodies that only bind to 
degraded elastin will be conjugated to the AuNP surface to actively targeting degraded 
elastin fibers presented in aneurysmal aortic walls. The quality of the conjugation will 
affect the number of antibodies attached to the AuNPs surface, thus, influence the targeting 
efficiency of EL-AuNPs. The accumulated EL-AuNPs at the aneurysmal site will 
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eventually be visualized in the CT scan by generating contrast against surrounding soft 
tissues. When the targeting efficiency is high, the dose of systemically administrated EL-
AuNPs to generate enough contrast in AAAs would be lower. Thus, the conjugation 
process should be optimized to reduce the required EL-AuNPs dose while still allow the 
production of acquiring high-quality CT images that provide accurate information about 
the rupture risks of AAAs.  
4.2 Materials and Methods 
Synthesis of ~150nm AuNPs 
Citrate-stabilized AuNPs with a size of ~150nm were synthesized using a 
kinetically controlled seeded growth method (Figure 4-1) [264]. Briefly, the reduction of a 
gold hydrochloride solution was initiated by injecting 1 mL of 25mM HAuCl4• 3H2O  
(Sigma Aldrich, St. Louis, MO) into 150 mL of 2.2 mM sodium citrate (Sigma Aldrich, St. 
Louis, MO) in a three-necked round-bottomed flask at boiling temperature for 10 min 
under vigorous stirring to form Au seeds with a diameter of ~10nm. Immediately after the 
synthesis of the Au seeds, the reaction was cooled to 90 °C in the same reaction vessel to 
avoid the secondary nucleation.  
Then, 1 mL of 25 mM HAuCl4 solution was injected into the reaction vessel and 
allowed to react for 30 mins. This process was repeated twice before the sample was diluted 
by extracting 55 mL of sample and adding 55 mL of 2.2mM sodium citrate. This diluted 
solution was then used as a seed solution, and the growing process was repeated. In order 
to control the growing speed and maintain the homogeneous growth of the AuNPs, the gold 
precursor to seed particle concentration was carefully controlled. The sizes of the AuNPs 
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were monitored after each growth step and the growth step was repeated until the AuNPs 
reaches the desired size. AuNPs solution was allowed to cool down and stored at 4°C for 
further usage. The sizes of three different batches of AuNPs were measured to evaluate the 
reproductivity of this method. 
Preparation of EL-AuNPs under different conjugation conditions 
The citrate-capped AuNPs were then conjugated with degraded elastin targeted 
antibodies using a three-step method (Fig 4-2). Three different batches of EL-AuNPs were 
produced under different conjugating conditions (Table 4-1). For the first batch of EL-
AuNPs, a heterobifunctional thiol-PEG-acid (SH-PEG-COOH, 2000MW, Nanocs, NY) 
was firstly added to the AuNPs at a weight ratio of 1:4 (PEG: AuNPs) to replace the citrate 
cap of the AuNPs. The SH-PEG-COOH can not only stabilize the AuNPs but also provided 
carboxylic groups for further modifying reaction. The PEGylation process was finished at 
25ºC for 4 hours. Secondly, a commonly used EDC (N-(3-Dimethylaminopropyl)-N-ethyl 
carbodiimide)/NHS (N-hydroxysulfosuccinimide) chemistry was applied to provide 
binding sites for antibodies on PEGylated AuNPs. EDC (Oakwood Chemical, Estill, SC) 
and NHS (Sigma Aldrich, St. Louis, MO) were added to the PEGylated AuNPs at a weight 
ratio of 1:2:1 (EDC: NHS: PEG) and incubated at 25ºC for 2 hours. Finally, the anti-elastin 
antibody (custom-made at Clemson University) was incubated with the surface modified 
AuNPs overnight to achieve the final conjugation. 
For the second batch of EL-AuNPs, SH-PEG-COOH was added to the AuNPs at a 
weight ratio of 5:2 (PEG: AuNPs) and incubated at 25ºC for 8 hours. Then, EDC and NHS 
were added to the PEGylated AuNPs at a weight ratio of 1:2:1 (EDC: NHS: PEG) at 25ºC  
 68 
 
Figure 4-1. A schematic overview of the synthesis of AuNPs. 
for 4 hours before antibodies were added and incubated overnight at 4ºC. And for the third 
batch of EL-AuNPs, AuNPs were incubated with the SH-PEG-COOH at a weight ratio of 
4:1 (PEG: AuNPs) at 4ºC for 48 hours. Then, EDC and NHS were added to the PEGylated 
AuNPs at a weight ratio of 1:2:1 (EDC: NHS: PEG) and incubated at 25ºC for 6 hours 
before conjugating to the antibodies overnight at 4ºC. 
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Figure 4-2. A schematic overview of the conjugation of elastin antibody to AuNPs. 
Table 4-1. Different conjugation conditions for AuNPs 
 PEG: AuNP PEGylation EDC/NHS incubation 
Batch 1 1:4 4 hours, 25°C 2 hours, 25°C 
Batch 2 5:2 8 hours, 25°C 4 hours, 25°C 
Batch 3 4:1 48 hours, 4°C 6 hours, 25°C 
Characterization of AuNPs and EL-AuNPs 
The hydrodynamic sizes of the AuNPs were measured after each diluting step and 
were also measured before and after the conjugation using a dynamic light scattering (DLS) 
system (Zetasizer Nano ZS, Malvern, Westborough, MA). Briefly, 40µL of each sample 
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was diluted in 1mL DI water and was then measured in disposable acrylic cuvettes under 
room temperature. Three measurements with at least twelve runs per measurement were 
performed for each sample with an absorption (k) of 3.32 and a refractive index (n) of 0.02. 
The zeta-potentials of AuNPs before and after the conjugation were measured using the 
same DLS system. Briefly, 40µL of each sample was diluted in 1mL DI water and was 
injected into the disposable folded capillary cells. Zeta potentials were measured under 
room temperature and three measurements with 100 runs per measurement were performed 
for each sample using the Smoluchowski model with an F(ĸa) value of 1.50. 
To determine the concentration of the prepared AuNPs and EL-AuNPs, 1mL of 
each sample was firstly digested with 1mL of aqua regia in glass test tubes under room 
temperature for 1 hour. Then, the digested samples were dried under constant nitrogen flow 
until all the liquid was vaporized. The remaining solids were re-dissolved in 6mL of 0.1M 
hydrochloride acid and were sent to Agricultural Service Laboratory, Clemson University, 
for gold element quantification. 
Cytotoxicity of EL-AuNPs 
A standard live/dead assay was performed to evaluate the cytotoxicity of EL-
AuNPs in hSMCs. Cells were seeded at a density of 10,000 cells/well in a 24-well tissue 
culture plate and incubated at 37ºC, 5% CO2 overnight. 10µL of EL-AuNPs (to achieve a 
final concentration of 1.0, 2.0, and 5.0mg/mL) were then added into the seeded cells in 
triplicates and were incubated at 37ºC, 5% CO2 for 1 hour. Then the cells were stained with 
Live/Dead cell staining kit II (PromoCell, Heidelberg, Germany) for 40 mins at room 
temperature and then imaged with a fluorescent microscope (Keyence, Itasca, IL). Live 
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cells were stained with the polyanionic dye calcein that produced an intense uniform green 
fluorescence with excitation of 495 nm and emission of 515 nm while dead cells were 
stained with EthD-III that produced a bright red fluorescence which was observed with 
excitation of 530 nm and emission of 635 nm. 
The lactate dehydrogenase (LDH) assay (Thermo Scientific, Rockford, IL) is used 
to evaluate the cytotoxicity of EL-AuNPs in hSMCs in a quantified manner. Briefly, after 
determining the optimum cell number for LDH cytotoxicity assay, 10,000 cells/well were 
seeded in 100µL of media in a 96-well tissue culture plate, and the plate was incubated at 
37ºC, 5% CO2 overnight for the cells to attach. 10µL of EL-AuNPs (to achieve a final 
concentration of 1.0, 2.0 and 5.0mg/mL) were then added into the seeded cells in triplicates 
and were incubated at 37ºC, 5% CO2 for 45 mins alone with a complete medium control 
without cells, and triplicates of both spontaneous LDH activity controls and maximum 
LDH activity controls. 50µL of each sample medium was transferred to another flat bottom 
96 well-plate followed by adding 50µL of the reaction mixture to each sample well and 
incubating at room temperature for 30 mins protected from light. The reaction was stopped 
by applying 50µL of stop solution to each sample well and the absorbance of each sample 
at 490nm and 680nm was measured using a spectrophotometer (Epoch, BioTek, Winooski, 
VT). %Cytotoxicity was then calculated using the following two equations: 
𝐿𝐷𝐻	𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 = (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒	𝑎𝑡	490𝑛𝑚) − (𝐴𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒	𝑎𝑡	680𝑛𝑚) (1) 
%𝐶𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦 =
𝑇𝑟𝑒𝑎𝑡𝑒𝑑	𝐿𝐷𝐻	𝑎𝑐𝑡𝑖𝑐𝑖𝑡𝑦 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠	𝐿𝐷𝐻	𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦
𝑀𝑎𝑥𝑖𝑚𝑢𝑚	𝐿𝐷𝐻	𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 − 𝑆𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠	𝐿𝐷𝐻	𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 × 100		(2) 
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Cellular uptake of EL-AuNPs 
Mouse macrophages were used as the cell line for in-vitro cellular uptake 
evaluation. Mouse macrophages were seeded in a 12-well plate with a density of 40,000 
cells/well. Cells were then cultured in RPMI-1640 growth media that contains 10% fetal 
bovine serum at 37 °C with 5% CO2 overnight for complete attachment. Macrophages were 
treated with 2mg/mL of EL-AuNPs for different periods (4 and 24 hours) in triplicates, 
after which the supernatant was removed, and cells were washed 3 times with PBS. 
Macrophages were gently scraped off the plate using cell scrapers, resuspended in 1mL of 
PBS, and collected by centrifugation at 1000 g for 4 minutes. Collected macrophages were 
further washed 3 more times with PBS and were lysed in an acid solution (2% HCl + 2% 
HNO3) for 5 days for the quantification of gold by inductively coupled plasma mass 
spectrometry (ICP-MS). 
The hSMCs were used for further in-vitro cellular uptake evaluation. hSMCs were 
plated at a density of 200,000 cells/well in a 12-well plate and cultured in complete growth 
media at 37 °C with 5% CO2 overnight for complete attachment. hSMCs were treated with 
2mg/mL of EL-AuNPs in triplicates for 4 and 24 hours, respectively. Trypsin/EDTA was 
used to release the hSMCs from the plate and the cell suspensions were centrifuged at 1000 
g for 5 min. hSMCs were collected and washed for 3 more times with PBS then treated 
with an acid solution (2% HCl + 2% HNO3) for 5 days to prepare lysates for the 
quantification of gold by ICP-MS. 
In-vitro targeting of EL-AuNPs 
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The targeting and imaging property of EL-AuNPs were tested using an in-vitro 
elastase treated porcine carotid model. Porcine carotids were bent into a U-shape and the 
middle part of each porcine carotid was immersed in 1mL of 20U/mL PPE (Tris buffered, 
pH= 7.8) for 90mins to induce limited elastin damage (Fig 4-3). After the PPE treatment, 
entire segments were immersed at 4 ºC overnight in three batches of 2mL of 3mg/mL EL-
AuNPs that were conjugated differently. Samples were washed in phosphate-buffered 
saline (PBS) three times for 5 mins per time to remove the non-specifically bound EL-
AuNPs and were scanned with micro-CT (0.2mm Al filter, 90kV, 250mA, 300ms) (Bruker, 
Billerica, MA) in corn oil. Reconstructions were carried out using the Skyscan NRecon 
software based on the Feldkamp algorithm. The distribution of the EL-AuNPs within the 
whole porcine carotids were visualized by building a 3D model using the maximum 
intensity projection (MIP) mode in the CT-Vox software. 
 
Figure 4-3. Schematic representation of the in-vitro PPE treatment of the middle part of 
porcine carotids that were used to test the targeting properties of EL-AuNPs. 
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Moreover, a quantitative in-vitro study has been performed on rat aortas to decide 
if there was a correlation between the EL-AuNPs accumulated in the tissue and the elastin 
damage level. The rat aorta segments with different elastin degradation levels were 
obtained by immersing the rat aorta segments in PPE for a different amount of time. 
Briefly, the rat abdominal aorta was firstly separated into suprarenal and infrarenal 
segments to minimize the influence of the intrinsic aortic elastin content difference. Then, 
the segments were immersed in 2 mL of 5U/mL PPE (Tris buffered, pH= 7.8) for 30, 60, 
and 90mins respectively to induce different levels of elastin damage. After PPE treatment, 
the segments were washed in PBS and immersed in 2 mL of 2mg/mL optimized EL-AuNPs 
overnight at 4 ºC under slow rocking. Samples were washed PBS three times for 5 mins 
per time to remove the non-specifically bound EL-AuNPs and were scanned with micro-
CT (40kV, 600mAs, 300ms, no filter). The EL-AuNPs were separated from the aortic 
tissue and quantified using CT-An software and normalized to the volume of the sample. 
And 3D models of the aortic segments and the EL-AuNPs attached to the tissue were built 
using the same software and the models were visualized using the CT-Vol software. 
Histological analysis  
After being washed in deionized (DI) water, porcine carotid, and rat aorta segments 
from the treated middle and two untreated ends were embedded in optimal cutting 
temperature (OCT) compound (Sakura Finetek, Torrance, CA) and froze in -80ºC to form 
blocks. The blocks were then sectioned per standard procedures. Five-micrometer sections 
were mounted on positively charged glass slides. And slides were placed in 100% pre-
cooled acetone (Fisher Science Education, Nazerath, PA) for 10 minutes to fix the sections. 
 75 
Subsequently, the slides were rinsed with tap water for 5 minutes to remove the OCT 
compound and stained with Verhoeff-van Gieson (VVG) for elastic fibers. 
Desmosine quantification 
Desmosine is a component of elastin that cross links with its isomer, isodesmosine, 
giving elasticity to the tissue [275]. Desmosine in the PPE treated aortic tissue was 
measured to be a marker for healthy elastin preserved in the tissue, representing the elastin 
damage level. Firstly, a small piece of tissue was cut off from each aortic sample and was 
lyophilized and the dry weights of which were weighed and recorded. The small aortic 
pieces were then homogenized to release the desmosine. The desmosine was measured 
using a mouse desmosine enzyme-linked immunosorbent assay (ELISA) kit 
(MyBiosource, San Diego, CA) and normalized using the dry weight of each tissue piece. 
Statistical analysis 
All in vitro experiments including cell culture studies and tissue studies were done 
in triplicates. The data are reported as the mean ± standard deviation. Data from different 
groups were analyzed by one-way analysis of variance (ANOVA) followed by Tukey’s 
HSD as a post-hoc test. Results were reported at three different significant levels: *** p≤
0.01, ** p≤0.05, and * p≤0.1. 
4.3 Results 
Characterization of AuNPs and EL-AuNPs 
The sizes of the AuNPs increased gradually after each growth step and after 18 
growth steps, the dynamic diameter of the AuNPs reached ~150 nm (Figure 4-4A and Table 
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4-1). The Z-average hydrodynamic size of the obtained AuNPs after 18 growth steps was 
146 nm with a polydispersity index (PdI) of 0.060. According to the size distribution by 
volume, the peak of the diameters appeared at 169 nm with a standard deviation of 48 nm. 
These results indicated that we successfully synthesized monodispersed AuNPs most of 
which had a size of around 150 nm. The final Z-average sizes of the other two different 
batches of AuNPs were 143 nm (PdI: 0.050) and 154 nm (PdI:0.047)  
Table 4-2. The Z-average diameters and volume distribution of AuNPs from each growth  
Growth 
step 
Z-Average 
diameter (nm) 
Volume distribution 
peak (nm) 
St Dev 
(nm) 
1 24 13 5 
2 26 16 6 
3 26 19 7 
4 28 23 7 
5 31 26 9 
6 34 30 10 
7 36 32 11 
8 41 39 12 
9 44 43 14 
10 51 48 16 
11 60 54 22 
12 62 58 24 
13 73 63 30 
14 99 93 52 
15 100 97 50 
16 113 127 39 
17 131 150 49 
18 146 169 48 
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respectively, with volume distributions of 168 ± 51 nm and 177 ± 47 nm respectively. The 
batch to batch variation of the AuNP size distribution was very small. 
 
Figure 4-4. Size distribution by intensity measured using the DLS system. (A) Sizes of 
AuNPs from growth step 13 to 18. (B) Sizes of three different batches of AuNPs.  
 
Figure 4-5. Size and zeta-potential characterization of AuNPs and EL-AuNPs. (A) Size 
distribution of AuNPs before and after conjugation; (B) Zeta-potential distribution of 
AuNPs before and after conjugation. 
After the conjugation step, the intensity weighed hydrodynamic diameter of the 
AuNPs increased from 145 ± 46 nm to 157 ± 44 nm, and the volume weighed 
hydrodynamic diameter of the AuNPs increased from 156 ± 57 nm to 173 ± 53 nm, 
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indicating the formation of a PEG-EDC-NHS-Antibody shell surrounding the AuNPs in 
place of the original citrate cap (Figure 4-5A). The average zeta-potential of the AuNPs 
also increased from -17.6 ±9.4 mV to -10.4 ±4.2 mV after the conjugation, which also 
confirmed that the completion of the surface modification (Figure 4-5B). 
Cytotoxicity of EL-AuNPs in hSMCs 
The cytotoxicity of EL-AuNPs was tested at a concentration of 1, 2, and 5mg/mL. 
EL-AuNPs tested at all three concentrations were not found toxic to hSMCs in cell cultures  
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Figure 4-6. Live/dead assay for deciding cytotoxicity of EL-AuNPs with concentration of 
1mg/mL, 2mg/mL and 5mg/mL. 
according to both live/dead assay and LDH assay. Live/dead assay of hSMCs showed no 
abnormalities in morphology and a limited number of dead cells (Figure 4-6). The live and 
dead cells were identified and counted for each group from the images and the percentages 
of the dead cells were calculated. The cell viabilities for all three treated groups were 
similar to the control group (Table 4-3). 
Table 4-3. Live/dead cell count and the percentage of dead cells 
  Total count Live count Dead count Dead (%) 
CTRL 45 36 9 20.0% 
1mg/mL 53 44 9 17.0% 
2mg/mL 100 81 19 19.0% 
5mg/mL 51 40 11 21.6% 
According to the LDH cytotoxicity assay, the average LDH activity of the 
spontaneous control is 0.232 and the average LDH activity of maximum control is 2.766. 
The average LDH activities for 1, 2 and 5mg/mL group are 0.229, 0.230, and 0.229, 
respectively. The LDH activities in EL-AuNPs treated group is not significantly different 
from the spontaneous control group and none of the calculated average percentages of 
cytotoxicity of the three treated groups were positive (Figure 4-7). It provided further 
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evidence to indicate that the treatment with EL-AuNPs at a concentration of 1, 2, and 
5mg/mL shown no cytotoxicity to cultured hSMCs. 
 
Figure 4-7. Cytotoxicity (%) calculated from LDH assay, the cytotoxicity percentage of 
individual sample was represented with a circle and the average result was represented with 
a bar. 
Cellular uptake of EL-AuNPs  
For mouse macrophages, the mass of the intracellular gold after incubation for four 
and twenty-four hours with the AuNPs were both below the detection limit of ICP-MS. For 
hSMCs, the average mass of the AuNPs taken by the cells after incubation for 4 h was 
13.17µg. The percentage uptake from the total added gold was 0.687%. After incubation 
for 24 h, the average mass of gold in the cells incubated with AuNPs was 16.69µg and the 
percentage uptake from the total added gold was 0.834%. Thus, AuNPs as prepared for in-
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vivo studies showed no significant uptake by hSMCs and mouse macrophages in cell 
cultures due to their size and negative surface charge. 
In-vitro targeting study for optimizing the conjugation condition 
After PPE treatment of the porcine carotids, the elastin fibers in the middle segment 
of the porcine carotids were fragmented and degraded while the elastin fibers in the two 
ends remain intact, as shown in the VVG staining (Figure 4-8). It suggested that we 
successfully established a partially damaged in-vitro elastase model for studying the ability 
of the EL-AuNPs to target the degraded elastin in the vascular wall. 
 
Figure 4-8. VVG stain for untreated and elastase treated porcine carotid sections. 
In the 3D models that were reconstructed from the micro-CT scans, the EL-AuNPs 
showed a much higher contrast than the soft tissue because of its higher x-ray adsorption 
rate (Figure 4-9). EL-AuNPs accumulated exclusively at the PPE treated section while 
sparing the untreated healthy two ends of the carotids, indicating the targeting ability of 
the EL-AuNPs to degraded elastin. Also, different combinations of conjugation conditions 
resulted in different targeting efficiency of EL-AuNPs. For the porcine carotids treated 
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with batch one EL-AuNPs, the CT scan had not shown the accumulation of EL-AuNPs in 
the damaged tissue. Batch two EL-AuNPs showed some targeting signal at the damaged 
site in the CT scans, but the signal was still very weak. The third batch of EL-AuNPs 
provided strong and specific signals in the reconstructed micro-CT model in the PPE 
treated porcine carotid tissue. The third conjugation condition which showed the highest 
signal intensity of the EL-AuNPs at the damaged section was used for further studies. 
 
Figure 4-9. Signals for differently conjugated EL-AuNPs in the reconstructed porcine 
carotid MIP models. B1, B2, and B3 were the porcine carotids that were targeted with EL-
AuNPs conjugated under the first, second, and third conditions mentioned in Table 4-1 
respectively. 
After PPE treatment of the rat aortic segments for 30, 60, and 90 mins respectively, 
different levels of elastin fiber fragmentation and degradation were observed in VVG 
staining (Figure 4-10). In the control group, the elastin fibers in the aortic wall were intact 
and well-aligned. As the PPE treatment time increased, the elastin laminae became more 
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disorganized and fragmented. The quantification of desmosine in the PPE treated tissues 
further confirmed different damage levels of the elastin content. All three treated groups 
 
Figure 4-10. VVG staining of healthy control and rat aortic tissue after 30, 60, and 90 
minutes of PPE treatment. The aortic lumen was indicated with *.  
 
Figure 4-11. Quantification of desmosine extracted from damaged aortic tissue using 
ELISA assay, ***p<0.01, **p<0.05, *p<0.1. 
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had significantly lower desmosine concentration comparing to the control group. 
Moreover, the quantities of desmosine in the tissues decreased as the PPE treatment time 
increased (Figure 4-11). These results suggested that a longer PPE treatment time can 
induce a more severe elastin degradation in the rat aortic tissue. It provided us a model for 
studying the correlation between the quantity of targeted EL-AuNPs and the aortic elastin 
damage level in-vitro.  
3D reconstructed Micro-CT model showed the distribution of the EL-AuNPs within  
 
Figure 4-12. 3D models of the aortic tissue samples and the accumulated EL-AuNPs 
(highlighted in yellow) reconstructed from micro CT imaging. 
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the rat aortic tissues (Figure 4-12). The signal from EL-AuNPs was differentiated from the 
aortic tissue and highlighted yellow. More EL-AuNPs were found accumulating in the 90-
minute PPE treated group comparing to the 30- and 60-minute group. And the 30- minute 
group showed the least EL-AuNP attachment to the tissue. Moreover, for quantitative 
analysis, the amount of the EL-AuNP signal was calculated and normalized to the total 
volume of the tissue. A negative correlation between the EL-AuNP to tissue ratio and the 
concentration of desmosine in the tissue has been built (Figure 4-13). As the desmosine 
level in the tissue decreased and the signal percentage of EL-AuNPs increased. Since a 
lower tissue desmosine concentration indicated more elastin degradation, the accumulation 
of the EL-AuNPs within the tissue could positively correlate to the degree of tissue elastin 
damage. 
 
Figure 4-13. The correlation of the EL-AuNPs to tissue ratio with tissue desmosine 
concentration. 
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4.4 Discussion  
Colloidal gold is wildly used in nanotechnology research as model particles. They 
can be synthesized in different shapes, such as spheres, rods, and stars, with various size 
ranges. And AuNPs with different shapes and sizes have different pharmacokinetic and 
biodistribution parameters [276]. In order to increase the efficacy of using AuNPs for 
biomedical purposes, the combination of shape and size has to be chosen carefully 
according to specific applications. For drug-delivery or imaging applications, spherical 
AuNPs suit the best since they can be easily synthesized with high monodispersity using 
highly labile stabilizing ligands that allow for facile, efficient, and high-density ligand 
exchange [277].  
Besides, the size has been demonstrated to influence the blood half-time and the 
biodistribution of the AuNP, two parameters that play important roles in achieving desired 
biomedical effects when injected intravenously. A study of the size-dependent 
biodistribution of the AuNPs in rats performed by De Jong, W.H. et al. has demonstrated 
that small AuNPs had more widespread organ distribution while larger particles were only 
detected in blood, liver, and spleen [278]. In this study, in order to target AAAs, we 
synthesized spherical AuNPs with a hydrodynamic size of ~150 nm. The spherical shape 
was beneficial for attaching antibodies to the surface of AuNPs to achieve targeting. And 
the relatively large size could prevent the AuNPs from staying in organs like the brain and 
lungs while still allow them to circulate for enough time to ensure vascular targeting. 
The cytotoxicity of the AuNPs was also reported to be size and shape dependent. 
Generally, the cytotoxicity of the AuNPs decrease as the size increase. Pan, Y. et al. have 
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demonstrated that AuNPs 1–2 nm in size have a much higher cytotoxicity and wilder 
distribution comparing to larger 15-nm gold colloids [279]. Mateo, D. et al. have reported 
that stronger cytotoxic effects were observed in 30 nm AuNPs treated human dermal 
fibroblasts than those obtained with the 50 and 90 nm NPs-treated cells [280]. Meanwhile, 
different shapes of AuNPs have different cytotoxic profiles. Lee, Y.J. et al. have reported 
that among chitosan capped nanorods, stars and spheres, nanorods showed the highest 
toxicity against AGS, HeLa, HepG2, and HT29, followed by nanostars and finally by 
nanospheres [281]. Furthermore, surface modification has been proved to help reduce the 
AuNPs cytotoxicity. Niidome, T. et al. suggested that surface modification of gold 
nanorods with PEG could reduce their in-vitro toxicity [282].  
For our EL-AuNPs with a size of ~170 nm, Live/dead assay showed no difference 
in cell viabilities between EL-AuNPs treated group and untreated control. LDH leakage 
due to cell membrane damage was measured as another indicator of EL-AuNP-induced 
cytotoxicity. Cells that were treated with EL-AuNPs showed no higher LDH leakage in the 
short term comparing to the untreated control. These results suggested the low cytotoxicity 
of EL-AuNPs on hSMCs in-vitro. The good biocompatibility of the EL-AuNPs could be a 
result of the combination of their spherical shape, relatively large particle size, and 
PEG/antibodies coated surface. Thus, it is considered safe to use the AuNPs at the 
concentration designed for in-vivo studies. 
Surface functionalized AuNPs have been regarded as an ideal contrast agent for 
diagnostic purposes because of their great imaging properties and biocompatibility. Not 
only their surface can be modified with PEG to achieve prolonged circulation time for 
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blood pool imaging, but also, the conjugation with molecules that target specifically to 
pathological biomarkers renders AuNPs the ability to selectively and effectively enhance 
the contrast of the tissue of interest. Passive targeting, active targeting, or a combination of 
both strategies can be used to achieve aneurysm-specific particle accumulation for 
imaging. For example, Kim, D. et al. reported that they have gained more than 4-fold 
greater CT intensity when imaging prostate cancer by using AuNPs that has been surface 
functionalized with a prostate-specific membrane antigen (PSMA) RNA aptamer that 
actively targeted prostate cancer cells that express the PSMA protein [283]. 
The amount of contrast that could be generated in CT scans depends on the 
mass/concentration of the contrast agent accumulated in the desired tissue. For blood pool 
imaging, a large dose of contrast agent is usually applied to visualize the vasculatures, 
which could result in side effects such as hepatoxicity and nephrotoxicity [284]. Thus, 
targeting efficiency of the EL-AuNPs could drastically influence the imaging quality and 
should be optimized to reduce the systemic dosage required. For a given size of 
nanoparticles, how NP surface modification was achieved would influence their surface 
charge and the number of conjugated surface antibodies. Thus, it would result in variable 
clearance rate in-vivo and different chances for the antibodies to interact with the desired 
ligands. In our study, we conjugated EL-AuNPs using different combinations of PEG to 
AuNPs ratio, PEGylation duration and temperature, and the incubation time for the 
EDC/NHS reaction. Moreover, the combination that showed a higher contrast at the 
elastase damaged area in an in-vitro porcine carotid model was considered to have a better 
targeting efficiency. The combination that has presented the highest targeted signal in the 
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CT scan has been chosen as the protocol to prepare the EL-AuNPs that were used in 
targeting studies. 
However, surface coatings can change the charge of the nanoparticle and alter 
protein adsorption and cellular uptake during circulation [285]. Nanoparticles that are 
positively charged have higher rates of phagocytosis and shorter blood circulation half-life 
than neutral and negatively charged particles [286]. We successfully conjugated the AuNPs 
to be negatively charged according to the results of the zeta-potential measurement. It 
would help the NPs avoid being phagocytosed by macrophages and also uptake by any 
other cells like SMCs and make them applicable for effective vascular targeting. According 
to the cellular uptake study performed in hSMCs and mouse macrophages, an infinitesimal 
amount of the AuNPs was detected that entered the cells. The fact that most of the AuNPs 
stayed outside of both SMCs and macrophages rendered them the ability to achieve 
targeting to the aortic lesions. Moreover, our AuNPs were surface modified with antibodies 
that could specifically bind to the degraded elastin. It has been shown in our in-vitro study 
that these EL-AuNPs s could target to the tissues that presented elastin damage and 
specifically increased the local contrast in CT-scans. Since the degradation of elastin 
laminae is one of the key pathological features of AAAs, it is possible to use EL-AuNPs to 
target AAAs in-vivo for imaging purposes.  
Based on the elastin targeting property of the EL-AuNPs, we investigated the 
correlation between the EL-AuNPs accumulation and the elastin damage using an in-vitro 
elastase model. Different elastin damage level could be induced by treating the aortic tissue 
for a different amount of time and the degradation of the elastin in this model were not 
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reversible. Since elastin is an important mechanical component in the aortic wall that 
provides strength and elasticity to endure the stress given by the blood flow [287], the 
decrease in elastin content could result in a weaker aortic wall with a higher rupture risk. 
Moreover, as more elastin in the aortic wall degraded, it provided more binding sites for 
the elastin antibodies anchored on the surface of the EL-AuNPs. We have observed a 
positive correlation between the gold to tissue volume ratio and the duration of elastase 
treatment, which indicated that more EL-AuNPs have accumulated in the samples with 
more degraded elastin. This observation suggested that our EL-AuNPs had the potential to 
be used as an indicator of elastin damage and a novel tool for evaluating the rupture risk of 
the AAAs. 
4.5 Conclusion 
In this aim, we successfully produced degraded elastin antibodies conjugated 
AuNPs that had an average size of ~170 nm and were negatively charged. We have shown 
that these NPs are biocompatible with minimal cytotoxicity to SMCs and low cellular 
uptake by both SMCs and macrophages. After being tested in an elastase treated porcine 
carotid model, the EL-AuNPs presented the ability to actively target the tissue with elastin 
damage and can increase the contrast of the targeted area in CT scans. Moreover, the 
accumulated gold to tissue ratio decided by the CT analysis was positively correlated to 
the damage level of the elastase treated tissue. Thus, the EL-AuNPs could be used as a safe 
and efficient targeting CT contrast reagent for vascular diseases with the potential to reveal 
the local elastin damage.  
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5. SPECIFIC AIM 2: TO INVESTIGATE WHETHER EL-AuNPS CAN BE 
TARGETED TO AAAS IN-VIVO AND BUILD A CORRELATION BETWEEN THE 
MICRO-CT SIGNAL INTENSITY OF EL-AuNPS AND MECHANICAL 
PROOERTIES OF THE ANEURYSM IN AN ANGII INFUSION INDUCED MOUSE 
MODEL 
5.1 Introduction 
Ultrasonography is the gold standard tool for AAA screening and diagnostic due to 
its simplicity, safety, validity, cost-effectiveness, reproducibility, and public acceptance 
[288]. It can provide relatively precise AAA geometrical information such as the diameter 
and the growth rate of the aneurysm, which are commonly used as clinical interventional 
criteria. However, the potential risk of an aneurysm rupture is determined by its mechanical 
condition more than just AAA geometry. The intrinsic biomechanical properties and the 
environmental stress conditions of the aneurysm change all the time during the disease 
progression and decide the rupture risk of the AAAs. 
 Although large AAAs are statistically more prone to rupture, small AAAs can fail 
prior to meeting the surgical criteria. Patients with smaller AAAs can still be under a life-
threatening situation since about 13% of AAAs cause death in patients before they are 
recommended for surgery [96]. Thus, geometrical information alone is insufficient as a 
universal predictor for AAA failure. Identification of localized vulnerabilities (i.e., weak 
points within the wall) would provide crucial diagnostic information to aid clinical 
strategies and decrease mortality in patients suffering from AAAs. A targeted nanoparticle 
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system can be ideal to serve the purpose of providing pathological information for AAAs 
when being used as an imaging contrast agent. 
As described previously, key pathological processes occurring within AAAs such 
as increased ROS activity, inflammation, VSMCs apoptosis, and ECM remodeling have 
emerged as potential targets for nanoparticle-based diagnostics. Imaging agents and drugs 
have been successfully delivered to the AAAs by applying surface modified NPs that target 
these biomarkers as carriers. However, levels of inflammation and collagen remodeling 
that happen in the AAA vary with time and patients, and therefore cannot be used as a 
reliable surrogate for chronic aneurysmal rupture risk assessment. On the other hand, since 
there is rarely elastin synthesis in adults, the elastic lamina in the aortic wall does not 
remodel substantially within the timeline of aortic disease progression. The degradation of 
the aneurysmal wall is a consistent feature of AAAs making it an ideal target for delivering 
NPs. 
Animal models are well established for studying AAAs in-vivo. Considering the 
complicated in-vivo environment, it is important to test imaging agents and treatments with 
AAAs that were developed in animal models to provide some insights about how they 
might interact with human bodies. Many models of AAAs have been developed that use a 
diverse array of methods for producing the disease, including but not limited to genetic 
manipulation and chemical induction [289]. The genetic approaches are spontaneous and 
engineered mutations and the chemical approaches include the intraluminal infusion of 
elastase, peri-aortic incubations of calcium chloride, and subcutaneous implantation of 
AngII osmotic pump.  
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Even though these models recapitulate some facets of the human disease including 
medial degeneration, inflammation, thrombus formation, and rupture, each animal model 
can only mimic some pathogenesis of the real disease. The AngII infusion induced AAA 
model in the LDLr −/− mice is ideal to be used in the studies that aim to understand the 
AAA mechanical properties because of the formation of the ILTs in this model. Moreover, 
the formation of AAAs in the systemic AngII infusion induced model resembles human 
disease in the setting of mild hypertension with an enhanced incidence in the presence of 
hyperlipidemia [290]. 
5.2 Materials and methods 
The animal study of EL-AuNPs was performed in an established AngII infusion 
induced mouse AAA model. The EL-AuNPs that were accumulated in the AAA sack via 
active targeting were visualized using both ex-vivo and in-vivo micro CT imaging (Figure 
5-1). Briefly, the animal study can be divided into three parts: development of AAAs in-
vivo, micro CT imaging, and tissue analysis. The AAAs were firstly induced in mice by 
the application of high cholesterol diet and AngII from subcutaneously implanted osmotic 
pumps. And the pumps were explanted from the mice before imaging to eliminate the high 
imaging noise given by the metal core of the pump. EL-AuNPs were injected intravenously 
to achieve targeting and create contrast. In the imaging step, the aortas were explanted and 
cleaned after the euthanasia for ex-vivo imaging study and were imaged with the micro-CT 
when immersed in corn oil to prevent it from drying out, while a live abdominal micro CT 
scan was performed before euthanasia and organ harvesting for the in-vivo imaging study. 
The harvested aortas were then analyzed mechanically and histologically.  
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Figure 5-1. Schematic representation of the study design. 
Preparation of EL-AuNPs  
For the ex-vivo imaging study, citrate capped AuNPs were purchased from 
Meliorum Technologies (Rochester, NY) with an average size of 150.0 ± 25.0 nm. And for 
the in-vivo imaging study, citrate capped AuNPs with an average size of 156.0 ± 57.4 nm 
were synthesized as described in the previous chapter. The conjugation process for both 
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types of AuNPs was the same. Briefly, a heterobifunctional thiol-PEG-acid (2000MW, 
Nanocs, New York, NY) was added to the AuNPs at a weight ratio of 4:1 and the mixture 
was incubated at 4°C for 48 hrs with gentle rocking to achieve PEGylation. PEGylated 
AuNPs were collected after centrifuging at 10,000 rpm for 20 minutes at room temperature 
and resuspended in 0.1M 2-(N-morpholino) ethanesulfonic acid buffer (MES, pH:5.5).  
EDC/NHS chemistry was followed to conjugate the PEGylated AuNPs with the 
anti-elastin antibody. Briefly, EDC (Oakwood Chemical, Estill, SC) and Sulfo-NHS 
(Sigma Aldrich, St. Louis, MO) were added at a weight ratio of 2:1 and 4:1 to PEGylated 
AuNPs respectively. The mixture was incubated at room temperature for 6 hours with 
gentle vortexing. Resulting AuNPs were collected after centrifuging at 10,000 rpm for 20 
minutes at room temperature and resuspended in 1mL of PBS (pH 7.8). 4µg anti-elastin 
antibody (custom-made at Clemson University) per mg AuNPs was added, and the mixture 
was incubated overnight at 4 °C under slow rocking. The excess antibodies were removed 
by centrifuging the resulting solution at 10,000 rpm for 20 minutes. EL-AuNPs were 
resuspended in saline to a concentration of 3mg/mL for ex-vivo imaging study injection 
and 20mg/mL for the in-vivo imaging study. 
Development of aneurysms with AngII in a mouse model 
For the ex-vivo imaging study, fifteen male LDLr (-/-) mice (2 months of age, on a 
C57BL/6 background) were obtained from the Jackson Laboratory (Bar Harbor, ME). 
Eleven mice were used for aneurysm studies while four other mice were used as healthy 
age-matched controls. Aneurysms were induced by systemic infusion of angiotensin II 
(AngII, Bachem Americas, Torrance, CA) in combination with a diet with saturated fat 
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(21% wt/wt) and cholesterol (0.2% wt/wt; catalog no. TD88137; Harlan Teklad) [92]. 
Briefly, mice were fed with a high-fat diet for one week before, and six weeks during AngII 
infusion. Osmotic pumps (model 2004; Alzet, Cupertino, CA) filled with AngII were 
implanted subcutaneously through an incision at the right back shoulder of the mice. 2% 
to 3% isoflurane was inhaled by the mice as anesthesia throughout the surgical process. 
The pumping rate for AngII was set to 1000ng/kg/min. Pumps were explanted four weeks 
after the implantation and mice were allowed to recover for two weeks. Disease 
progression was monitored with a high-frequency ultrasound machine, Fujifilm 
VisualSonics Vevo 2100 (Fujifilm VisualSonics, Toronto, ON, Canada), by utilizing a 
linear array probe (MS-550D, broadband frequency 22 MHz -55 MHz).  
For the in-vivo imaging study, twenty male LDLr (-/-) mice (2 months of age, on a 
C57BL/6 background) were obtained from the Jackson Laboratory (Bar Harbor, ME). 
Seven mice were used for aneurysm studies among which one mouse was a healthy age-
matched control. Aneurysms were induced monitored in the same way as in the ex-vivo 
imaging study. All animal use protocols for the study were approved by the Clemson 
University Animal Research Committee. 
Ultrasound analysis of AAAs 
The ultrasound system, Fujifilm VisualSonics Vevo 2100 (Fujifilm VisualSonics, 
Toronto, ON, Canada), was used for monitoring percent dilation and to assess the 
circumferential strain throughout the cardiac cycle and PWV of the aneurysm. The animals 
were placed in a supine position on the imaging table and were maintained under anesthesia 
by inhaling 2% to 3% isoflurane during imaging. Heart rate and body temperature of the 
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mice were carefully monitored during the imaging process. Suprarenal aortic inner 
diameters were measured using the built-in ultrasound software on the basic-mode 
ultrasound images.  
Sagittal and transverse images for both healthy and aneurysmal aortas were 
obtained in motion mode. Systolic and diastolic diameters were measured and recorded at 
three different regions on each aneurysm or parent vessel using the built-in ultrasound 
software. The diastolic-to-systolic circumferential Green-LaGrange strains were calculated 
assuming axial symmetry using the two equations given below, 
𝐶𝑖𝑟𝑐𝑢𝑚𝑓𝑒𝑟𝑒𝑛𝑡𝑖𝑎𝑙	𝑆𝑡𝑟𝑎𝑖𝑛	(%) =
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where 𝐷#$#  represents the inner systolic aortic diameter and 𝐷%&'  represents the inner 
diastolic aortic diameter. 
Ex-vivo Micro-CT imaging study 
EL-AuNPs were given to the mice (n=15) as a contrast agent through a retro-orbital 
injection at a dosage of 10 mg/kg animal weight under 2%-3% isoflurane anesthesia. Mice 
were euthanized 24 hours after the injections, and intact aortas (from ascending aorta to 
iliac bifurcation) were explanted. Surrounding connective tissue was cleaned before micro-
CT scanning. Aortas were then immersed in corn oil and imaged (90kV, 250mAs, 300ms, 
0.2mm Al filter) with a high-performance micro-CT system (Skyscan 1176, Bruker, 
Billerica, MA). Reconstructions were carried out using the Skyscan Nrecon software based 
on the Feldkamp algorithm. The reconstructed images of the aortas were visualized, and 
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the dimensions of the aneurysms measured using DataViewer and CT-Vox software. 3D 
maximum intensity projection (MIP) images were obtained to determine the distribution 
of EL-AuNPs within the aortas while attenuation images were acquired to study the 
intensity of the signals given by both EL-AuNPs and tissue. Signal intensity was further 
quantified using CT-An software. 
In-vivo Micro-CT imaging study 
A baseline micro-CT scan (90kV, 250mAs, 200ms, 0.2mm Al filter) for each 
mouse was performed with a high-performance micro-CT system (Skyscan 1176, Bruker, 
Billerica, MA) to be used as control before the EL-AuNPs injection. EL-AuNPs were then 
administrated retro-orbitally to the mice (n=14) as a contrast agent at a dosage of 10 mg/kg 
animal weight under 2%-3% isoflurane anesthesia. The mice that received EL-AuNPs 
injection were fasted for 24 hours to clear out the feces and at the meantime EL-AuNPs 
were allowed to circulate for 24 hours to achieve targeting. Mice were scanned using the 
same micro-CT system and the same imaging settings as were used in baseline scan under 
1.5% isoflurane anesthesia. Reconstructions were carried out using the Skyscan Nrecon 
software based on the Feldkamp algorithm. The reconstructed images of the aortas were 
visualized using DataViewer and CT-Vox software. And signal intensity was further 
quantified using CT-An software. 
EL-AuNPs biodistribution analysis 
Ten mice were used for determining the biodistribution of EL-AuNPs in-vivo. EL-
AuNPs were given to the mice (n=9) via retro-orbital injections at a dosage of 10 mg/kg 
animal weight under 2%-3% isoflurane anesthesia. Mice were euthanized at day 1, day 5, 
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and day 9 after the injections, and the entire livers, spleens, lungs and kidneys were 
explanted. 1 mm thick of sample from each harvested organ was embedded in OCT and 
sectioned for further darkfield imaging use. The rest of the samples were homogenized and 
lysed in an acid (2%HCl +2% HNO3) overnight for gold extraction. The solution was then 
collected, and ICP-MS was performed for quantifying the concentration of the gold 
element in the samples. 
Aortic burst failure testing  
Burst pressure testing was performed on each suprarenal aortic segment within 24 hrs 
after explant to study the rupture potential and location of the failure. Aortas were shipped in 
EDTA-free-protease-inhibitor-cocktail on ice overnight to the University of South 
Carolina. Branches were ligated using 12/0 nylon suture and the aneurysm, including 1-2 mm 
distal and proximal to the necking region, were cannulated on shortened and roughed 26G 
needle tips with 7/0 silk suture and mounted to our custom-designed multi-axial murine artery 
mechanical testing device within an adventitial bath of PBS. The device enables temperature 
control, hydration, inflation, and extension capabilities while recording images at 45° intervals 
around the circumference of the tissue. All instruments are controlled via an integrated 
LabVIEW code. Samples reported here were first extended to an axial stretch ratio of 1.2 and 
then preconditioned through slow cyclic pressurization of luminal media using a syringe pump. 
Then the syringe pump was set to maintain an inflation rate of 1-3 mmHg/s until bursting was 
observed. PBS supplemented with phenol red was used as the luminal media to provide contrast 
capabilities to identify burst locations. During inflation, the vessels were closely monitored for 
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signs of failure, including dissection, and the pressure and location of failure were recorded. No 
tissue that failed at or around the mounting suture or hardware were included in the analysis. 
Aortic biaxial mechanical testing and data analysis1 
The mechanical properties of aortic aneurysmal tissues and controls were tested at 
the University of South Carolina (UofSC) within 24 hours of receiving tissues so that no 
more than 48 hours passed between animal sacrifice and mechanical testing. Aortas were 
mounted to a custom-designed biaxial testing rig. The details for this device and biaxial 
testing procedures can be found in Lane et al. 2020a and 2020b [291, 292]. Briefly, this 
test rig is equipped with a thin-beam loaded cell (LCL-113G; Omega Engineering), 
pressure transducer (PX409; Omega Engineering), RS-232 infuse/withdraw syringe pump 
(AL-1000; World Precision Instruments), motorized linear actuator (Z825B; Thorlabs), 
and K-Cube motor controller (KDC101; Thorlabs). All components had PC USB interface 
through a custom-written LabView code used to gather synchronous measurements while 
controlling pumps and actuators. The testing chamber was filled with warm PBS solution 
to maintain hydration throughout testing and PBS was flushed through the vessel lumen 
and device tubing to remove bubbles. The unloaded outer diameter ( ) and length ( ) 
were recorded using digital calipers. The artery then underwent five preconditioning cycles 
consisting of pressurization from 10 to 160 mmHg and axial stretching to a deformed 
length ( ) at, and 5% above and below, the pressurization force-invariant axial stretch 
ratio, deemed the in vivo axial stretch. 
 
1 Section prepared by John F. Eberth, PhD, Shahd Hasanain, BS and Liya Du, BS 
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For data acquisition, the artery was extended to the three axial stretch ratios 
described previously before undergoing pressurization cycles (0–120 mmHg) with 
simultaneous force and outer diameter measurements at 10 mmHg pressure increments. 
Data was recorded in triplicate and the average and standard deviations of these tests 
reported. Primary continuous data collection consisted of pressure ( ), deformed outer 
diameter at the peak bulge location ( ), axial force ( ), and axial stretch ratio ( ). Then 
vessels were pressure fixed by replacing luminal PBS with 4% paraformaldehyde solution 
and re-inflated to 100 mmHg in the axially extended state for 4 hours. In the deformed but 
fixed state, micro-Computed Tomography Imaging (Quantum GX Micro-CT Imaging 
System; PerkinElmer) was used to measure the deformed inner diameter. This step was 
necessary due to the lack of transparency of these calcified and heterogeneous tissues. 
Measurements consisted of an average of 4 locations along the circumference of the 
aneurysm bulge and were processed using Fiji-ImageJ.  
Assuming axial symmetry and incompressibility, the inner diameter is calculated 
from, 
  (1) 
where  is the volume measured using a combination of micro-CT and biaxial testing. 
From the primary data collection described above, the mid-wall circumferential and 
axial stretch ratios are calculated from 
   (2) 
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where  is the unloaded inner diameter. 
The mean circumferential and axial stresses are then calculated from  
   (3) 
and the lumen area compliance from 
 , (4) 
where  is the change from diastolic to systolic transmural pressures (80 to 120 
mmHg) and  the change in inner diameter at these pressures.  
In general, discrete data were analyzed at a common pressure and in vivo axial 
stretch ratio unless otherwise noted. 
Morphological analysis of the explanted suprarenal abdominal aorta  
Morphological analysis was performed in the suprarenal area of the abdominal 
aorta. For the ex-vivo study, outer aortic diameters were measured on the abdominal 
ultrasound basic-mode-images at three different time points during a cardiac circle within 
the parent vessel and the lesion. For the in-vivo study, inner suprarenal aortic diameters at 
six different regions were measured using the built-in ultrasound software on the basic-
mode ultrasound images. Mean values were then calculated for each. The dilation was 
calculated using the equation given below, 
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where 𝐷]* represents the mean diameter of the healthy aorta and 𝐷]) is the mean diameter 
of the pathological section. 
Histological analysis of the aneurysms 
Cryosections of both aneurysms and healthy aortas were used for histological 
analysis. Aortas were fixed in buffered formalin, embedded in optimal cutting temperature 
(OCT) compound (Sakura Finetek, Torrance, CA) after being washed in DI water and 
sectioned per standard procedures. Five-micrometer sections were obtained and mounted 
on positively charged glass slides. Slides were placed in 100% pre-chilled acetone (Fisher 
Science Education, Nazerath, PA) for 10 minutes to further fix the tissue sections. 
Subsequently, the slides were rinsed with tap water for 5 minutes to remove the OCT 
compound for further staining. Slides were then stained with Verhoeff-van Gieson (VVG) 
to visualize the elastin damage in different samples.  
Darkfield microscopy and hyperspectral mapping 
Cryosectioned histological samples (5µm) were examined with a CytoViva 
enhanced darkfield microscope optics system (CytoViva, Inc., Auburn, AL). The system 
(Olympus BX51) employs an immersion oil (Type A, nd> 1.515, Cargille Brand) ultra-
dark-field condenser and a 40× air Plan-FL objective with an adjustable numerical aperture 
from 1.2 to 1.4. Illumination was provided by a Fiber-lite DC 950 regulated illuminator. 
Enhanced darkfield microscopy images were obtained using Exponent7 software with a 
gain setting of 2.8 and an exposure time of 53 ms to visualize the EL-AuNPs. A 
hyperspectral imager (mounted on a microscope and controlled by Environment for 
Visualization software from Exelis Visual Information Solutions, Inc.) was used to extract 
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spectral information for mapping the EL-AuNPs in the samples at an exposure time of 
0.25ms with a full field of view (643 lines). Negative control samples (without AuNPs) 
were imaged and analyzed to create a spectral library as a reference. Gold mapping was 
achieved by applying a filtered spectral library by subtracting the negative control spectral 
library. 
Statistical analysis 
All the results, including graphs in the figures, are given as mean± standard 
deviation. Statistical analysis was performed using a one-way ANOVA and Tukey’s HSD 
as a post-hoc test. Results were considered significantly different when p-values ≤0.05. 
5.3 Results 
Characterization of EL-AuNPs 
EL-AuNPs used the ex-vivo study were prepared by conjugating the custom-made 
antibody that recognizes degraded elastin with commercial gold nanoparticles. They were 
characterized by a DLS system for size and surface charge before and after the conjugation 
process. Before antibody conjugation, bare AuNPs had an average size of 150.00 ± 
25.00nm and a zeta potential of -29.20 ± 3.91mV. EL-AuNPs had a final average size of 
184.20 ± 18.09nm. The zeta potential of the NPs was measured as -5.06 ± 1.25mV. The 
EL-AuNPs used in the in-vivo study were homemade and the characteristics were described 
in the previous chapter. Briefly, the size of the AuNPs increased from 156.00 ± 57.40 nm 
to 173.40 ± 53.08 nm and the zeta potential also increased from -17.6 ± 9.36 mV to -10.4 
± 4.16 mV. 
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Systemic AngII infusion-induced aneurysm mouse model 
After the infusion of the AngII, severe aortic dilation (> 1.5-fold) as well as 
moderate aortic dilation was observed at the suprarenal abdominal aorta in most of the mice 
(Figure 5-2a). 2D transverse ex-vivo micro-CT images revealed an increase of aortic outer  
 
Figure 5-2. Development of suprarenal aortic aneurysms with various properties, a. 
Representative pictures showing the morphology of the whole explanted aortas. Various 
levels of dilations (indicated by arrows) were found at the suprarenal abdominal aortic 
regions in most of the AngII pump-implanted mice; b. Ex-vivo micro CT image showing 
the cross-sections of aortas at the healthy region (c1) and the aneurysmal region (c2); c. 
VVG staining shows different levels of elastin degradation amongst aneurysmal tissues 
(4x, c2-c4, 40x, c6-c8) compared to the healthy aortic control with only intact elastin (4x, 
c1, 40x, c5).  
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diameters and thickening of the aortic wall in the lesions compared to the normal aorta 
(Figure 5-2b). The enlargement of the suprarenal aortic diameters resulting from the 
systemic infusion of AngII varied from 9.08%-193.25% of the normal size (Table 5-1). 
VVG staining of the aneurysmal aorta demonstrated the degradation of elastin laminae 
inside the aortic wall. Lesion development in mice corresponded with the extent of elastic 
lamina degradation (Figure 5-2c). In fact, samples did not meet the 1.5-fold threshold but 
still presented with elastin damage (Figure 5-3). 
Table 5-1. Diameter and dilation percentages of suprarenal abdominal aortas  
Sample Healthy (mm) 
Aneurysmal 
(mm) 
Diameter Measurements 
Dilation Percentages Fold Increase 
MS#1 1.18±0.01 2.27±0.04 92.67% 1.93 
MS#2 1.12±0.02 2.31±0.04 106.62% 2.07 
MS#3 1.03±0.05 2.35±0.01 127.97% 2.28 
MS#4 1.30±0.05 2.83±0.08 117.64% 2.18 
MS#5 1.17±0.01 2.25±0.01 92.20% 1.92 
MS#6 0.93±0.04 1.55±0.04 66.39% 1.66 
MS#7 0.88±0.06 2.15±0.08 144.83% 2.45 
MS#8 1.03±0.07 1.84±0.10 79.15% 1.79 
MS#9 1.02±0.05 1.40±0.08 38.23% 1.38 
MS#10 1.23±0.02 1.39±0.06 12.18% 1.12 
MS#11 1.30±0.03 2.51±0.03 92.45% 1.92 
MS#12 0.92±0.03 2.18±0.26 137.39% 2.37 
MS#13 1.15±0.05 1.69±0.06 47.00% 1.47 
MS#14 1.14±0.03 1.25±0.13 9.22% 1.09 
MS#15 1.03±0.12 2.04±0.09 97.87% 1.98 
MS#16 0.85±0.08 1.24±0.06 45.63% 1.46 
MS#17 1.06±0.14 2.30±0.10 117.92% 2.18 
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Figure 5-3. Elastin damage in aortic walls indicated by the red arrows for samples did not 
meet the 1.5-fold threshold. 
EL-AuNPs targeting to degraded elastin in the damaged aorta 
3D reconstructed micro-CT models from both ex-vivo (Figure 5-4a) and in-vivo 
scan (Figure 5-4b) presented stronger signals in the aneurysmal aortic segment than the 
healthy aortic segment. This suggested that a much higher concentration of EL-AuNPs 
accumulated at the aneurysmal area, which indicated their ability to target the aneurysms 
within 24 hours while sparing the healthy regions of the aorta. Enhanced darkfield 
microscopy (EDFM) in combination with VVG staining on the histological sections further 
confirmed the targeting sites of EL-AuNPs within the aneurysmal tissues. EL-AuNPs were 
found in darkfield microscopy images (Figure 5-4c) accumulating exclusively around the 
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degraded elastin as identified by VVG staining while sparing healthy and intact elastin 
fibers (Figure 5-4d). A stronger DFM signal was found in the section (Figure 5-4c1) which 
showed more elastin damage (Figure 5-4d1) than the control section (Figure 5-4c2) that 
contained only intact elastin fibers (Figure 5-4d2).  
 
Figure 5-4. Localization of EL-AuNPs within aneurysmal tissues. a. An ex-vivo 3D model 
that visualizes the morphology of an aneurysmal aorta (a1) and corresponding attenuation 
mode that showed the distribution of EL-AuNPs (a2). b. An in-vivo 3D model showing 
EL-AuNPs targeting in transverse, longitudinal, and sagittal sections; c. Darkfield 
microscopy (DFM) of and d. corresponding histological analysis of elastin with VVG 
staining. The signal given by EL-AuNPs was found at the positions where degraded elastin 
was present, indicated by red arrows, while healthy and intact elastin fibers were devoid of 
signals as indicated by yellow arrows. 
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EL-AuNP accumulation indicates elastin damage level 
Hyperspectral imaging (HSI), in conjunction with EDFM, provided spectral 
information for the aneurysmal tissue and the attached EL-AuNPs. Specific signatures of 
EL-AuNPs were mapped and separated from the noise given by the soft tissue according 
to their different spectral features. Bright field microscopy indicated different levels of 
elastin damage within different tissue samples by VVG staining (Figure 5-5a). EDFM and 
hyperspectral mapping of the counterparts demonstrated that the amount of EL-AuNPs that 
accumulated within the tissue samples varied with the elastin damage level (Figure 5-5b, 
c, d). The decreasing integrity of elastic fibers in the aortic wall increased local EL-AuNP 
accumulation. When extensive damage to elastin laminae was present in the bright field 
image (Figure 5-5a2), hyperspectral mapping identified a large quantity of EL-AuNPs in 
the tissue (Figure 5-5e2). Conversely, no EL-AuNP accumulation was mapped (Figure 5-
5d1) in a control sample that showed no signs of elastin degradation (Figure 5-5a1). 
Biodistribution of AAAs 
HSI and EDFM were further used to visualize the distribution of EL-AuNPs in different 
organs at different time points after the injection (Figure 5-6). One day after the injection, 
EL-AuNPs were found in liver, spleen, lungs and kidneys in large quantities. Four days 
later, there were still EL-AuNPs found in all four organs. The quantities of EL-AuNPs 
slightly decreased in the liver, lungs and kidneys but increased in the spleen. On day 9 after 
the injection, a small number of EL-AuNPs were still in the liver and spleens. However, 
there was a significant decrease of the EL-AuNPs in all four organs. The images of lungs 
and kidneys barely showed differences from the control that had no EL-AuNPs injection. 
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Figure 5-5. Hyperspectral mapping of suprarenal aorta tissue targeted by EL-AuNPs, rows 
from top to bottom correspond to suprarenal aortas with different levels of elastin damage 
within the aortic walls, from high to low, respectively. a. Different elastin degradation 
levels were found in the selected tissue samples; b. EDFM (40X) showed the existence of 
high contrast EL-AuNPs in the tissues denoted by the white arrows; c. HSI (40X) and d. 
Mapped images against their respective reference spectrum library generated with negative 
controls.  
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Figure 5-6. Hyperspectral mapping of liver, spleen, lungs, and kidneys visualizing the 
biodistribution of EL-AuNPs at day 1, 5 and 9 after the injection. 
The biodistributions of the EL-AuNPs at day 1, 5 and 9 after the injection have 
been further quantified using ICP-MS. On day one, 1.70% of the given EL-AuNPs dose 
accumulated in the liver while 1.10%, 0.55% and 0.07% of the EL-AuNPs were found in 
spleen, lungs and kidneys, respectively. On day five, the EL-AuNPs in the liver was 0.59% 
of the given dose. There were 1.39%, 0.53%, and 0.07% of the given EL-AuNPs remained 
in the spleen, lungs, and kidneys, respectively. After 8 days of clearance, the number of the 
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EL-AuNPs in the liver and spleen decreased to 0.32% and 0.03 % respectively. The amount 
of the gold component in the lungs and kidneys were both below the detective limit.  
Ultrasound analysis of AAAs 
Ultrasound images of abdominal aortas were obtained before euthanasia. Healthy 
controls exhibited a relatively uniform inner diameter (Figure 5-7a1) while dilation in the 
AngII infused mice was most commonly observed at the suprarenal location (Figure 5-7a2-
a4). Circumferential strains for all samples ranged from 3.44 to 12.82%. Circumferential 
strains of the healthy aortas were 16.08±2.40% (n=5) and were significantly decreased at 
the aneurysmal aortic regions of the AngII-infused mice. For aneurysms with a similar 
extent of dilation (MS#1, #5 and #11 with 92% dilation), the circumferential strains were 
4.28±1.17%, 5.95±1.08%, and 9.60±1.05% respectively, suggesting the acute distensibility 
of the aneurysmal aortic wall was not necessarily related to the extent of chronic dilation 
(Figure 5-7b).  
Correlation of ex-vivo CT signal and burst pressure of the aorta 
The burst pressures for the samples harvested for ex-vivo study varied from 141.0 
to 540.0 mmHg, while the burst pressure for healthy aortic controls was 566.5±30.4mmHg. 
The 3D micro-CT models of the aortas showed higher signal intensity at the suprarenal 
aortic regions of specimens having more server elastin damage and lower burst pressures, 
indicating that the accumulation of our EL-AuNPs was inversely correlated to the level of 
elastin damage and the load at failure (Figure 5-8a1-a3) while the age-matched control 
samples did not show any signs of EL-AuNPs accumulation (Figure 5-8a4). In order to 
establish a quantitative relationship between the signal and the ultimate burst pressure of  
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Figure 5-7. In-vivo ultrasound and circumferential strains. a. Representative B-mode in 
vivo ultrasound images of focalized aortic dilation indicated by red arrows; b. 
Circumferential Green-LaGrange strains throughout the cardiac cycle for three aneurysms 
with similar dilations (92%) but with different degrees of elastin damage. Ms#11 had minor 
aortic elastin damage and Ms#1 had severe aortic elastin damage. * p<0.05, solid line in 
each group represents the mean value. 
the suprarenal aortas, the signals of the healthy aortic regions were used as negative 
controls and were subtracted from the total. For the age-matched control groups, the signal 
strength for all samples in the suprarenal region was 0. As the burst pressures of the 
suprarenal aorta decreased, indicating a weakening of the aorta, higher signals for EL-
AuNPs were detected (Figure 5-8b). A power-law equation y = 20+08x-3.586 was 
established with R2=0.9415, where x represents the burst pressure and y represents the 
signal intensity, which demonstrated that the signal strengths given by EL-AuNPs had a 
strong negative correlation to the burst pressures of the aneurysmal tissues (Figure 5-8b) 
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whereas changes in aortic dilation (R2=0.1932) or circumferential strain (R2=0.3918) failed 
to show strong correlations to burst pressures (Figure 5-8c, 5-8d).  
 
Figure 5-8. Representative reconstructed aorta models in attenuation mode and correlation 
between signal intensity, diameter increase, and burst pressure. a. 3D attenuation models 
for aneurysmal and control aortas with different elastin damage levels showing different 
suprarenal aortic signal intensity; b. A strong negative nonlinear correlation between signal 
intensity and burst pressure was found while c. dilation vs. burst pressure and d. the CSs 
vs. burst pressure was only weakly correlated with each other using the power-law. 
EL-AuNP distribution and the initial burst site defined in ex-vivo CT scans 
The initial sites where suprarenal aortas started to rupture under pressurization were 
captured by a camera through visualization of the PBS supplemented with phenol red being 
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expelled at rupture site (Figure 5-9a arrows). 3D micro-CT data obtained from ex-vivo 
scans was displayed in the MIP mode, in which the lower-attenuation structures are not 
well visualized [293], in order to study the distribution of EL-AuNPs within the aneurysmal 
region (Figure 5-9b). Bright spots for EL-AuNPs in the reconstructed model could be 
correlated to where the first rupture occurred, suggesting that the weakest spots had the 
highest density of AuNP accumulation. 
 
Figure 5-9. Representative burst pressure tests pictures and corresponding reconstructed 
aorta models in MIP mode. a. Burst pressure test showing the location on the aneurysmal 
wall where rupture is initiated under pressurization; b. For corresponding mouse aorta, the 
EL-AuNP induced signals were non-uniformly distributed within the aneurysmal 
segments. High-intensity spots correlate to the rupture sites. 
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Correlation of in-vivo CT signal and biaxial mechanical properties of the aorta 
Two geometrical parameters, outer aortic diameter and aortic wall thickness, and 
two mechanical parameters, circumferential and axial stress, were measured and correlated 
to the AuNPs to tissue ratio using OLS regression (Figure 5-9). There was no correlation 
found between the outer aortic diameter and the AuNPs to tissue ratio while a slightly 
negative correlation was found between the aortic wall thickness and AuNPs to tissue ratio 
with R2=0.5602. Strong positive correlations with AuNPs to tissue ratio were found in both 
circumferential stress (R2=0.9375) and axial stress (R2=0.7469). 
 
Figure 5-9. Correlations between different parameters measured and calculated from the 
biaxial mechanical testing and the AuNPs to tissue ratio. 
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5.4 Discussion 
In this aim, we tried to develop a potential targeted contrast agent for CT imaging 
which will provide morphological information along with a better assessment of the rupture 
risk of AAAs. Nanoparticles have been used for the development of enhanced molecular 
imaging technologies targeting cancer cells [294]. AuNPs are commonly used due to their 
outstanding properties such as noncytotoxicity, excellent biocompatibility, ease of surface 
functionalization, strong light absorption, and scattering effects [294, 295]. Gehrmann, M. 
K. et al. reported using 50nm cmHsp70.1-conjugated AuNPs for imaging Hsp70 
membrane-positive mouse tumor cells in-vivo [296]. Here, we used spherical gold 
nanoparticles with a final diameter of around 180 nm to target the AAAs. The increase in 
gold particle size from ~150nm to ~180nm after the antibody conjugation process indicated 
that we successfully conjugated the elastin antibody to the surface of the gold nanoparticles 
for achieving targeted delivery.  
Suprarenal aortic aneurysms were then successfully initiated by systemically 
delivering AngII into LDLr (-/-) mice. AAAs were considered significant when the dilation 
of the aorta exceeded 1.5 times (i.e., 50% dilation) its normal external diameter [297]. 
Based on this criterion, some of the aortic dilations we found in the mice were not 
considered AAAs but at the initiating stage of AAAs. As reported by Trachet, B. et al., the 
incidence rate of AAAs in AngII infused mice was 56% [298]. Pathological features such 
as degradation of the elastic lamina and atherosclerosis were demonstrated by the 
histological study results. These features are consistent with what has been reported in the 
AngII infusion-induced AAA in the ApoE(-/-) mouse model [299], as well as in human 
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AAAs [300]. And our results showed that the diameter increase, elastin degradation level, 
and intraluminal atherosclerotic plaque formation in the suprarenal aortas vary among 
animals. Such variability was advantageous in this study because it enabled a wider 
spectrum fragmentation for correlation with AuNP accumulation.  
To date, the targeting of AAAs for therapeutic and imaging purposes remains 
significantly challenging because of the limited number of viable targets and a relatively 
low hemodynamic residence time in the diseased aorta. Key pathological processes 
occurring within AAAs such as inflammation, vascular smooth muscle cell apoptosis, and 
even ECM remodeling have emerged as potential targets for nanoparticle-based 
diagnostics [215]. Shirasu, T. et al. reported a passive AAA targeting system using 
rapamycin nanoparticles. It was hypothesized in their study that the accumulation of 
nanoparticles was a result of micro-defects caused by inflammatory cell infiltration and 
ECM fragmentation [257]. For active targeting, macrophage targeting was reported for an 
MRI imaging with ultra-small superparamagnetic iron oxide (USPIO) and fluorine 18-
labeled cross-linked iron oxide (18F-CLOF) in AngII-infused ApoE (-/-) mouse model 
[220, 221, 223]. Klink, A. et al. [258] described the targeting of aortic adventitial ECM 
remodeling-related collagen in AngII-infused and TGFb-neutralized C57BL/6 mice using 
paramagnetic/fluorescent micellar nanoparticles functionalized with a collagen-binding 
protein (CNA-35). All these previous targeting efforts focused on either inflammatory cells 
or collagen. Levels of inflammation and collagen remodeling vary with time and therefore 
cannot be used as a reliable surrogate for chronic aneurysmal rupture risk assessment. 
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On the other hand, the metabolic turnover of elastin is slow, with a half-life 
comparable to the human lifespan. Thus, unlike collagen fibers, the function of elastic 
fibers is not thought to depend on constant remodeling and turnover [301]. The adult elastic 
lamina does not remodel substantially within the timeline of aortic disease progression and 
the degradation of in the aneurysmal wall is a consistent feature of AAAs making it an 
ideal target for delivering nanoparticles. In this study, we successfully targeted gold 
nanoparticles to the aneurysmal site in AngII-infused LDLr (-/-) mice by conjugating them 
with antibodies that target only degraded-elastin as described previously [229]. Our results 
suggested that the targeting of our EL-AuNPs was both elastin-specific and damage-
dependent as most of the EL-AuNPs were found attached to degraded elastin while sparing 
the healthy unimpaired aorta. Furthermore, the quantity of EL-AuNPs accumulated in the 
aneurysmal tissue was related to the extent of local elastin degradation which highlights 
altered biomechanical properties of the aortic wall leading to further disease progression 
and failure [45]. Thus, we tested if EL-AuNPs targeting could improve imaging and could 
be used as a potential non-invasive AAA rupture risk stratification tool. 
Non-invasive abdominal ultrasound is commonly used in the diagnosis and 
monitoring of AAAs, mainly providing morphological information to evaluate disease 
progression. Others reported that high-frequency ultrasound could be used to assess aortic 
wall strain as part of biomechanical analysis in murine models [302, 303]. Our in-vivo 
abdominal ultrasound results indicated a reduction of circumferential wall strain 
throughout the cardiac cycle in the aneurysmal suprarenal aorta compared to the healthy 
aorta and these findings are consistent with the results from previous studies. An increasing 
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trend of EL-AuNP accumulation was found while the wall strain decreased. Our results 
demonstrate that there could be a correlation between EL-AuNP accumulation and overall 
biomechanics of the aneurysmal tissue. 
Burst testing, a direct method of identifying rupture pressure and location, 
supported the correlation between the signal given by targeted EL-AuNP and the rupture 
potential of aneurysms [304]. We have used a well-established AngII model to assess 
AAAs. Aneurysms in this model, however, do not spontaneously rupture, so all burst 
pressure testing was performed on explanted aortas for correlation of rupture risk. Using a 
power model, a strong negative correlation was found between EL-AuNPs in the ex-vivo 
CT scans and the pressures at which a AAA will burst. Since the aortic diameter is the 
primary clinical criteria used for surgical intervention, it was interesting to note that no 
immediate pattern emerged correlating burst pressure to the extent of dilation in our AAAs. 
Although many large AAAs failed at lower pressures, others withstood much higher 
pressures. Incidentally, most AAAs in our study failed at or around the necking region and 
a few failed at the site of the branches. Likewise, aneurysms with similar dilation were 
shown to experience varying levels of circumferential strain throughout the cardiac cycle. 
Thus, the signal intensity of EL-AuNPs measured by ex-vivo CT shows a more meaningful 
relationship with the rupture risk of AAAs than does the increase in diameter or a decrease 
in circumferential strain. 
This finding was further confirmed in the in-vivo imaging study. Targeted in-vivo 
imaging is more challenging because the AAAs usually locate deeply in the body covered 
with connective tissues. Also, the unbonded EL-AuNPs in the blood pool can influence the 
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targeted signal quantification. In order to minimize the influence of the non-specific signal 
from the blood pool, we allowed the EL-AuNPs to circulate for 24 hours to achieve 
sufficient targeting while most of the untargeted nanoparticles would be cleared out from 
the blood. We found an increase of contrast at the suprarenal aortic area in the in-vivo CT 
scan which again confirmed the targeting of the EL-AuNPs to the aneurysmal site. 
Moreover, we found that the number of the AuNPs accumulated in the aneurysmal tissue 
is not correlated to size of the aneurysm but was slightly negatively correlated to the 
thickness of the aortic wall. AuNPs to tissue ratio was positively correlated to both 
circumferential and axial stress suggesting the accumulation of AuNPs could be used as an 
indicator of stresses in the aneurysmal tissue. Since the high stresses in the aneurysms make 
them more tend to rupture, the AuNPs have the potential to assess the rupture risk of AAAs 
from in-vivo CT imaging. 
The variability of the animal model used in the current work provides a tremendous 
strength in assessing our micro CT-based EL-AuNPs approach to AAA rupture potential. 
Variations in EL-AuNP distribution were found not only among different suprarenal aortic 
segments but also within the same aorta, suggesting variable degrees of elastin damage 
within the aneurysm and the possible existence of a ‘weak point’ where the rupture of the 
aneurysm initiates. Thus, our data suggest that an extent ECM degradation could be a more 
meaningful way to look at which patients are more prone to rupture and need immediate 
attention. 
Moreover, the biodistribution of the EL-AuNPs in the major organs was studied to 
assess their clearance rate. Contrast agents should be cleared out of the system within a 
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reasonable time to ensure the safe application for the patients. Sonavane, G. et al. have 
reported the biodistribution of AuNPs with different sizes in mice 24 hours after the 
injection [305]. For 200nm EL-AuNPs, they found the highest concentration of gold in the 
liver followed by spleen, lung, and kidneys. Similarly, according to our results, the EL-
AuNPs (~170nm) were mainly found in the livers and spleens, followed by kidneys and 
lungs on all three time points after the injection. In general, the total number of EL-AuNPs 
in the system decreased as the time goes by. And most of the EL-AuNPs were cleared out 
of the system eight days after a working dose injection for imaging. The results indicated 
that the EL-AuNPs were successfully cleared out of the system even in an animal model 
that presented compromised liver functions [306]. Thus, our EL-AuNPs are promising to 
be translated into a safe clinical use. 
5.5 Conclusion 
An AngII infusion LDLr (-/-) mouse model provided us with AAAs at different 
stages and having different biological and biomechanical properties. Degradation of elastin 
led to a decrease in aortic wall strain and a decrease in burst pressures in the aneurysmal 
aorta. EL-AuNPs enabled visualization of the degraded elastin in AAA sites so that the 
quantity of AuNPs could be used as a marker to predict the rupture risk and rupture sites 
for AAAs. This approach is highly advantageous because small and pre-aneurysmal tissues 
would likely demonstrate elastin damage prior to ultrasound diagnostics. Thus, such 
degraded elastin-targeting nanoparticles have the diagnostic potential as a sensitive 
noninvasive AAA targeting contrast agent for CT imaging.  
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6. SPECIFIC AIM 3: TO INVESTIGATE WHETHER ELASTIN ANTIBODY 
CONJUGATED PGG LOADED NANOPARTICLES CAN BE TARGETED TO AAAS 
IN AN ANGII MOUSE MODEL AND WHETHER THEY STOP THE AAA 
PROGRESSION AND RESTORE THE HEALTHY FUNCTION OF THE AORTIC 
WALL BY REPAIRING ELASTIN 
6.1 Introduction 
AAA patients can be currently treated with surgical interventions or conservative 
methods depending on the AAA status evaluated by its geometrical information and the 
patient's condition. Although surgical repair can effectively help patients who have big or 
ruptured AAA, the risk of the operation process and post-operation complications keep the 
perioperative mortality high. Pharmacotherapy is an ideal choice for AAA patients who are 
not recommended to be treated surgically. Even though to date, there is no 
pharmacotherapy available on the market, potential pharmacotherapy for AAA that 
focused on how to inhibit the degradation of ECM and maintain the integrity of the aortic 
vascular wall has been wildly studied.  
As described in chapter 2, many reported drugs are effective in preventing AAA 
progression by inhibiting the MMP activity, stabilizing and regenerating the damaged 
elastin lamina in the aneurysmal vascular wall in animal models. However, these drugs did 
not show effects on stopping nor reversing the human AAA progression [307-310]. In order 
to develop a pharmacotherapy that can effectively and safely work in AAA patients, it is 
important to understand human AAA pathology. Various inflammatory mediators that can 
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activate pro-inflammatory signaling pathways, such as TNF-α and MCP-1, are involved in 
the pathogenesis of AAA by causing and maintaining the inflammatory response. 
Proinflammatory signaling pathways, in turn, activate ECM degradation enzymes, such as 
MMP-9 and MMP-2, and simultaneously reduce the expression of ECM synthetic 
enzymes, such as LOX, thereby causing an overall loss of elastic fibers [180, 311]. It has 
been established that elastin degradation is a primary cause of AAA progression [312]. The 
regression of elastin fibers in the aortic wall and restoration of normal arterial architecture 
would be preferable for treating AAA patients regardless of the aneurysm size. 
PGG is a tannic acid derivative that has gained a lot of scientific attention recently 
because of its inherent ability to stabilize elastin by establishing a strong cohesive bond 
with the elastin in the ECM of the blood vessel. It can be used to provide an enhancement 
in vascular biomechanical properties and increased enzymatic degradation resistance 
[313]. Although tannic acid was also reported to have the same elastin binding ability as 
PGG, PGG was found to be more stable and had less cytotoxicity; thus, it was more 
favorable as an elastin-stabilizing agent [314].  
Medial lamellar degradation in AAAs due to a combined effect of VSMC apoptosis, 
increased inflammatory responses and oxidative stress, and disruption of tissue enzymatic 
homeostasis can result in a reduction in elastin content and crosslinking [315]. Therapeutic 
traits of PGG such as elastin stabilization, inhibition of MMPs, and antioxidant capacity 
make it an attractive pharmacological option for AAA patients. In-vivo stabilization of 
infrarenal aortic elastin by periadventitial PGG application or systemic PGG-NPs 
administration in CaCl2-mediated rat AAA model has shown to preserve the integrity of 
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the elastic lamellae, thus, prevent early AAA formation [200, 313]. Moreover, immediately 
after a localized elastase infusion in the porcine aorta, the intraluminal application of PGG 
in the elastase treated aortic segment was also reported to inhibit early AAA formation 
[316]. PGG-NPs that can successfully target to degraded ECM will achieve the controlled 
release of PGG to the AAAs and be a potential pharmacotherapy to stop and reverse the 
AAA progression. 
It is important to test the functionality of PGG in stabilizing the degraded ECM in 
an AngII infused mouse model. Comparing to the previously studied CaCl2-mediated rat 
AAA model and elastase-mediated mouse AAA model, which were developed based on 
localized surgical aortic damage, the aneurysms in AngII infused mouse model were 
induced using a systemic method, which resembles human aneurysm formation. It will 
offer a fresh perspective on the functionalities of PGG-NPs as a novel AAA treatment. 
6.2 Materials and methods 
Preparation of blank, DiR loaded and PGG loaded BSA NPs 
Blank BSA NPs (BLN-NPs) were prepared to be used as a control for the study by 
using a coacervation method described previously [19]. Briefly, 250 mg of BSA (Seracare, 
Milford, MA) was dissolved in 4 mL of DI water. 3mg glutaraldehyde (EM grade 70%, 
EMS, PA) was added into the BSA solution during stirring as a crosslinker. After an hour 
of stirring under room temperature, the mixture was added dropwise to 24 mL of ethanol 
under continuous sonication (Omni Ruptor 400 Ultrasonic Homogenizer, Omni 
International Inc, Kennesaw, GA) on ice for 30 minutes. The obtained BLN-NPs were 
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obtained by centrifugation at 6,000 rpm for 10 minutes and washed with water for three 
times by resuspension. 
1, 1-dioctadecyl-3, 3, 3, 3- tetramethylindotricarbocyanine iodide (DiR) dye 
(PromoCell GmbH, Heidelberg, Germany) loaded BSA NPs (DiR-NPs) were obtained for 
studying in-vivo targeting using the procedure described above with modifications. 250 mg 
of BSA was dissolved in 4ml of DI water. 2.5 mg of DiR dye was dissolved in acetone first 
and was then added to the BSA solution. 10.5 mg glutaraldehyde was added as a crosslinker 
during stirring. After an hour of stirring under room temperature, the mixture was added 
dropwise to 24 mL of ethanol under continuous sonication on ice for 30 minutes. The 
obtained DiR-NPs were obtained by centrifugation at 4,000 rpm for 10 minutes and washed 
with water for three times by resuspension. 
PGG-loaded NPs (PGG-NPs) were prepared for the treatment study using the 
modified version of the procedure described above. 250 mg of BSA was dissolved in 4 mL 
of DI water. 125mg PGG was dissolved in 400 µl of dimethyl sulfoxide and added slowly 
to the BSA solution under stirring. 3mg glutaraldehyde was then added as a crosslinker. 
After an hour of stirring at room temperature, the mixture was added dropwise to 24 mL 
of ethanol under continuous on ice for 30 minutes. PGG-NPs were obtained by 
centrifugation at 6,000 rpm for 10 minutes and washed with water by resuspension. 
Conjugation of NPs with degraded elastin antibodies 
All NPs were conjugated with homemade degraded elastin antibodies before being 
used in the animal study as described previously [19]. Briefly, 10 mg of NPs (blank, DiR 
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loaded, or PGG loaded) were PEGylated with 2.5 mg α-maleimide-ω-N-
hydroxysuccinimide ester poly (ethylene glycol) (mPEG-NHS, M.W. 2000, Nanocs, NY, 
U.S.A.) at room temperature for one hour under gentle vortexing. 68 μg of Traut’s reagent 
(G-Biosciences, Saint Louis, MO) was used for thiolation of 20 μg of a homemade elastin 
antibody, and the mixture was incubated in PBS for an hour at room temperature under 
gentle vortexing. Thiolated antibodies were added to the PEGylated NPs and incubated 
overnight at 4 ºC on a slow rocker for conjugation. 
In-vivo study in an AngII infusion induced mouse model 
Forty-two male LDLr -/- mice (2 months of age, on a C57BL/6 background) were 
obtained from the Jackson Laboratory (Bar Harbor, ME) for investigating the effects of the 
NP treatment on the aneurysms. Aneurysms were induced by systemic infusion of AngII 
(Bachem Americas, Torrance, CA) in combination with a diet with saturated fat (21% 
wt/wt) and cholesterol (0.2% wt/wt; catalog no. TD88137; Harlan Teklad) throughout the 
whole study. Osmotic pumps (model 2004; Alzet, Cupertino, CA) filled with AngII were 
implanted subcutaneously to the mice. 2% to 3% isoflurane inhalation was used as 
anesthesia during the surgery. The osmotic pump released AngII consistently for 4 weeks 
at a rate of 1500ng/kg/min. Disease progression was monitored with Fujifilm VisualSonics 
Vevo 2100 ultrasound machine (Fujifilm VisualSonics, Toronto, ON, Canada) by utilizing 
a linear array probe (MS-550D, broadband frequency 22 MHz -55 MHz).  
For the targeting study, 10mg/kg animal weight of anti-elastin antibody (EL) 
conjugated DiR-NPs were injected intravenously to three mice after the 4-week infusion 
of AngII. These mice were euthanized 24 hours later, and the aortas were harvested for 
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further analysis. For treatment study, twelve mice were treated with EL conjugated BLN-
NPs while another twelve mice received EL conjugated PGG-NPs, both at a dose of 
10mg/kg animal weight, biweekly on week 4 and week 6 via the tail vein. Fifteen mice that 
did not receive any kind of treatment were used as control. Three of the control mice were 
euthanized at week 4; All other mice were euthanized at week 8 as shown in the timeline 
graph (Figure 6-1). Blood was collected via a heart puncture and organs were harvested 
after being perfused with saline for further analysis. All animal use protocols for the study 
were approved by the Institutional Animal Care and Use Committee (IACUC) at Clemson 
University. 
 
Figure 6-1. Schematic representation of the study design. 
Ultrasound analysis of AAAs 
The ultrasound system, Fujifilm VisualSonics Vevo 2100 (Fujifilm VisualSonics, 
Toronto, ON, Canada), was used for monitoring percent dilation and to assess the 
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circumferential strain throughout the cardiac cycle and PWV of the aneurysm. The animals 
were placed in a supine position on the imaging table and were maintained under anesthesia 
by inhaling 2% to 3% isoflurane during imaging. Heart rate and body temperature of the 
mice were carefully monitored during the imaging process. Suprarenal aortic inner 
diameters were measured using the built-in ultrasound software on the basic-mode 
ultrasound images. The dilation was calculated using the equation given below, 
𝐷𝑖𝑙𝑎𝑡𝑖𝑜𝑛	(%) = (𝐷]) − 𝐷]*)/𝐷]) × 100 
where 𝐷]* represents the mean inner diameter of the suprarenal aorta before the surgery 
and 𝐷]) is the mean inner diameter after surgery at the time points mentioned above. 
Sagittal and transverse images for both healthy and aneurysmal aortas were 
obtained in motion mode. Systolic and diastolic diameters were measured and recorded at 
three different regions on each aneurysm or parent vessel using the built-in ultrasound 
software. The diastolic-to-systolic circumferential Green-LaGrange strains and the 
percentage change of the circumferential strains throughout the study were calculated 
assuming axial symmetry using the two equations given below, 
𝐶𝑆	(%) = (1/2)((𝐷]#$#/𝐷]%&')2 − 1) × 100    (1) 
𝐶𝑆	(%) = (𝐶𝑆) − 𝐶𝑆*)/𝐶𝑆) × 100    (2) 
where 𝐷]#$# represents the inner systolic aortic diameter, 𝐷]%&' represents the inner diastolic 
aortic diameter, 𝐶𝑆* represents the circumferential strain of the suprarenal aorta before the 
surgery and 𝐶𝑆) is the circumferential strain after surgery at the time points mentioned 
above. 
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PW Doppler mode was used to measure the blood flow at the beginning and the 
end of the suprarenal aortic lumen prior to each PWV acquisition. All PW Doppler 
measurements were performed at a PRF of 20 kHz and a 45° incidence angle. Throughout 
the acquisition, the ECG for each mouse was monitored and recorded. PWV at each time 
point and the change of PWV throughout the study were then calculated with the two 
equations below, 
𝑃𝑊𝑉 = 𝑑/(𝑡( − 𝑡+)     (1) 
𝑃𝑊𝑉	𝐶ℎ𝑎𝑛𝑔𝑒	(%) = (𝑃𝑊𝑉) − 𝑃𝑊𝑉*)/𝑃𝑊𝑉) × 100   (2) 
where d represents the distance between the beginning and end of the suprarenal aorta, 𝑡+ 
is the time when pressure wave arrives at the beginning point and 𝑡( is the time when 
pressure wave arrives at the endpoint referenced to the R wave of the ECG, and 𝑃𝑊𝑉) 
represents the PWV of the suprarenal aorta before the surgery and 𝑃𝑊𝑉* is the PWV after 
surgery at the time points mentioned above. 
Systemic interferon-gamma (IFN-γ) levels 
Blood was drawn via a heart stick with a 1 mL syringe. After allowing 30 min for 
clotting, the blood was centrifuged at 14,000 rpm for 10 min and the serum was collected. 
Mouse serum was examined for IFN-γ using a commercial mouse ELISA kit (Invitrogen, 
Carlsbad, CA) per manufactural protocol. 
Histological analysis of the aneurysms 
Frozen aortas were embedded in OCT compound (Sakura Finetek, Torrance, CA) 
after being washed in DI water. The blocks were allowed to stay in -80ºC for overnight and 
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then sectioned per standard procedures. Five-micrometer sections were mounted on 
positively charged glass slides. Slides were placed in 100% pre-cooled acetone (Fisher 
Science Education, Nazerath, PA) for 10 minutes to fix the sections. Subsequently, the 
slides were rinsed with tap water for 5 minutes to remove the OCT compound and stained 
with hematoxylin and eosin (H&E) for tissue morphology and VVG for elastic fibers. 
Some fresh samples were imaged directly after removing the OCT compound and imaged 
with a fluorescent microscope to visualize the DiR-NPs targeting within the tissue. 
In-situ zymography 
In-situ zymography was performed on 5µm cryosections to evaluate MMP activity 
in the suprarenal aortic tissue samples. All the cryosections were rinsed with tap water for 
5 minutes to remove the OCT. Each section was treated with 200µL of the mixture of 
0.2mg/mL DQ-Gelatin (Invitrogen, Eugene, OR) in developing buffer and then incubated 
at 37°C for two hours. After being washed in DI water for 5 minutes, all sections were 
stained with DAPI (Life Technologies, Carlsbad, CA) for 5 mins and an EVOSTM XL cell 
imaging system (Invitrogen, Bothell, WA) was used to capture images of the samples. 
Immunohistochemistry (IHC) for macrophages 
All the cryosections were rinsed with PBS 3 times for 5 minutes per time to remove 
the OCT compound. The sections were firstly treated with 3% hydrogen peroxide under 
room temperature for 10 minutes to block the endogenous peroxidase activity. Then, the 
unspecific binding sites on the sections were blocked with background buster (Innovex 
Biosciences, Richmond, CA) under room temperature for 30 minutes. The sections were 
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incubated with the primary antibodies (anti-CD68 and anti-CD80) at 4°C overnight. An 
avidin-biotin complex method (Vector, Burlingame, CA) was used to detect and amplify 
the target signal and the staining was completed using a DAB kit (Vector, Burlingame, 
CA). Slides were counterstained with hematoxylin. 
Flow cytometry 
The spleens and thymus of the mice from BLN-NPs, PGG-NPs, and control groups 
were collected, minced, and meshed on 70 μm filters. Immunofluorescence staining was 
performed as described in previous studies [201, 317]. Briefly, cells were incubated with 
Fc block solution (purified anti-mouse CD16/CD32, clone 2.4G2, BD Biosciences) for 15 
minutes at room temperature to prevent non-specific binding. For cell surface markers, 
cells were incubated with the fluorescently conjugated antibody with CD68, APC anti-
CD68 (clone FA-11) (BioLegend, San Diego, CA) in the dark for 30 minutes at 4ºC. For 
intracellular cytokine TGFβ-1 staining, cells were permeabilized with fix/permeabilization 
buffer (eBiosciences, San Diego, CA) for 15 minutes before antibody PE anti-TGFβ1 
(clone TW7-2089) (BioLegend, San Diego, CA) staining. After the extensive washing of 
cells in FACS buffer, the cytometric acquisition was performed using the Attune NxT flow 
cytometer (Thermo Fisher Scientific, Waltham, MA). Data analysis was performed using 
FlowJo (TreeStar, Ashland, OR) software. For gating, lymphocytes were identified using 
FSC and SSC gating, and signals were selected based on SSC-A/H and FSC-A/H 
characteristics. Then CD68+ or TGFb1+ cells were selected on the base of their expression 
level. Data are the representative of triplicate of repetition twice. 
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Quantitative polymerase chain reaction (qPCR) 
Suprarenal aortas were homogenized and lysed in TRIzolTM (Invitrogen, Carlsbad, 
CA) for mRNA extraction. mRNAs were isolated per manufacturer’s protocol. The quality 
of the mRNA extracted was confirmed with the A260/A280 ratio as measured by a BioTek 
Synergy 2 plate reader (BioTek, Winooski, VT). Primers were designed for obtaining 
cDNA copies of MMP-2, TIMP-1, TIMP-2, LOX, elastin (ELN), and housekeeping genes 
actin-beta (ACTB) and peptidylprolyl isomerase A (PPIA) (sequences are shown in Table 
6-1) and obtained from Integrated DNA TechnologiesTM (Coralville, IA). cDNA was 
obtained via reverse transcriptase (RT)-PCR using an OneStep RT-PCR kit (Qiagen, 
Valencia, CA) as per manufacturer’s protocol. The qPCR was performed in the following 
sequence using a Rotor gene qPCR machine (Qiagen, Valencia, CA): 15 secondes at 94ºC, 
30 seconds at 60ºC, and 30 seconds at 72ºC for 40 circles. Gene expression in each sample 
was normalized to the expression of the housekeeping genes and compared to the control  
group using the 2-(ΔΔT) cycle threshold (Ct) analysis as follow: 
∆∆Ct = (Ct,-./01	/030 − Ct	4050.0360	/030)7890.:;031-<
− (Ct,-./01	/030 − Ct	4050.0360	/030)=>31.>< 
Aortic biaxial mechanical testing and data analysis2 
The mechanical properties of aortic aneurysmal tissues and controls were tested at 
the University of South Carolina (UofSC) as described in Chapter 5. No more than 48 hours 
passed between animal sacrifice and mechanical testing. Aortas were mounted to a custom- 
 
2 Section prepared by John F. Eberth, PhD and Shahd Hasanain, BS 
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Table 6-1. Primers designed for qPCR 
MMP-2 
Mouse MMP2_FWD AACGGTCGGGAATACAGCAG 
Mouse MMP2_REV GTAAACAAGGCTTCATGGGGG 
TIMP-1 
Mouse TIMP1_FWD GGCATCTGGCATCCTCTTGT 
Mouse TIMP1_REV TTAGCATCCAGGTCCGAGTTG 
TIMP-2 
Mouse TIMP2_FWD TATCTACACGGCCCCCTCTT 
Mouse TIMP2_REV TCCCAGGGCACAATGAAGTC 
ELN 
Mouse ELN_FWD CCACCTCTTTGTGTTTCGCTG 
Mouse ELN_REV ACCCAAAGAGCACACCAACAAT 
LOX 
Mouse LOX_FWD ACGGCTTGTGTAACTGCAAAC 
Mouse LOX_REV TCTGGGAAAGCGCACAGAG 
designed biaxial testing rig. The details for this device and biaxial testing procedures can 
be found in Lane et al. 2020a and 2020b [291, 292]. Briefly, this test rig is equipped with 
a thin-beam loaded cell (LCL-113G; Omega Engineering), pressure transducer (PX409; 
Omega Engineering), RS-232 infuse/withdraw syringe pump (AL-1000; World Precision 
Instruments), motorized linear actuator (Z825B; Thorlabs), and K-Cube motor controller 
(KDC101; Thorlabs). All components had PC USB interface through a custom-written 
LabView code used to gather synchronous measurements while controlling pumps and 
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actuators. The testing chamber was filled with warm PBS solution to maintain hydration 
throughout testing and PBS was flushed through the vessel lumen and device tubing to 
remove bubbles. The unloaded outer diameter ( ) and length ( ) were recorded using 
digital calipers. The artery then underwent five preconditioning cycles consisting of 
pressurization from 10 to 160 mmHg and axial stretching to a deformed length ( ) at, and 
5% above and below, the pressurization force-invariant axial stretch ratio, deemed the in-
vivo axial stretch. 
For data acquisition, the artery was extended to the three axial stretch ratios 
described previously before undergoing pressurization cycles (0–120 mmHg) with 
simultaneous force and outer diameter measurements at 10 mmHg pressure increments. 
Data was recorded in triplicate and the average and standard deviations of these tests 
reported. Primary continuous data collection consisted of pressure ( ), deformed outer 
diameter at the peak bulge location ( ), axial force ( ), and axial stretch ratio ( ). Then 
vessels were pressure fixed by replacing luminal PBS with 4% paraformaldehyde solution 
and re-inflated to 100 mmHg in the axially extended state for 4 hours. In the deformed but 
fixed state, micro-Computed Tomography Imaging (Quantum GX Micro-CT Imaging 
System; PerkinElmer) was used to measure the deformed inner diameter. This step was 
necessary due to the lack of transparency of these calcified and heterogeneous tissues. 
Measurements consisted of an average of 4 locations along the circumference of the 
aneurysm bulge and were processed using Fiji-ImageJ.  
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Assuming axial symmetry and incompressibility, the inner diameter is calculated 
from, 
  (5) 
where  is the volume measured using a combination of micro-CT and biaxial testing. 
From the primary data collection described above, the mid-wall circumferential and 
axial stretch ratios are calculated from 
    (6) 
where  is the unloaded inner diameter. 
The mean circumferential and axial stresses are then calculated from  
   (7) 
and the lumen area compliance from 
 , (8) 
where  is the change from diastolic to systolic transmural pressures (80 to 120 
mmHg) and  the change in inner diameter at these pressures.  
In general, discrete data were analyzed at a common pressure and in vivo axial 
stretch ratio unless otherwise noted. 
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Statistical analysis 
The data are reported as the mean ± standard deviation. Data from the same group 
at different time points were analyzed by paired T-test. Data from different groups were 
analyzed by one-way ANOVA followed by Tukey’s HSD as a post-hoc test. 
6.3 Results 
AngII infusion induced mouse model and in-vivo targeting study 
After four weeks of AngII infusion, aneurysms with different sizes were found at 
the suprarenal region of the mice. According to the ultrasound diameter measurements on 
week four, some aortic dilations were less than 50%, which didn’t meet the diagnostic 
standard for AAAs (part of the data presented). To bestow the study more clinical 
significance, we focused on mice with dilation of more than 50% at the suprarenal aorta 
for further study.  
For studying the in-vivo targeting of the nanoparticle carrier, DiR-NPs were 
delivered systemically via tail vail and allowed to circulate for 24 hours. The aortas of the 
mice were explanted and imaged ex-vivo using the IVIS Lumina imaging system 
(PerkinElmer, Branford, CT) to visualize the DiR-NPs signal (Figure 6-2). According to 
the IVIS images (Figure 6-2 a2 and a3), the suprarenal region of the mice aortas where the 
aneurysms were found (Figure 6-2 a1) showed high fluorescent signal exclusively, 
indicating the accumulation of the DiR-NPs in the aneurysmal tissue. Further histological 
analysis showed that the DiR-NPs appeared at the sites where degraded elastin was 
displayed in the VVG staining (Figure 6-2 b and c). These results confirmed that our 
nanoparticle carrier could successfully reach and accumulate in the aneurysmal tissue by 
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targeting the degraded elastin in the ECM. These nanocarriers could be used for targeted 
drug delivery to stabilize the ECM and stop the progression of the aneurysm. 
 
Figure 6-2. DiR-NPs targeting in AngII mice model. a. Overall targeting in the aorta; b. 
VVG staining indicating sites of degraded elastin; c. Fluorescent imaging of the counterpart 
visualizing DiR-NPs distribution within the tissue.  
The influence of PGG treatment in aortic dilation percentage 
All the mice that were used in the treatment study showed similar percentages of 
dilation when the AngII infusion was finished. According to the average inner diameters 
of aneurysms at week four measured and calculated from in-vivo abdominal ultrasound, all 
three groups (n=5) had a more than 100% diametric increase during the AngII infusion. 
After four more weeks (2 injections) of treatment, only in the PGG-NPs group, it has been 
found that the size of the aneurysms became smaller. The dilation percentages for 
aneurysms in the BLN-NPs group and the control group kept increasing even without the  
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Figure 6-3. In-vivo ultrasound and percentage of dilation change in all three groups. a. 
Representative B-mode in-vivo ultrasound images of abdominal aortas before pump 
implantation, at 4 weeks when the infusion of the Ang II was finished, and 8 weeks when 
the treatment was finished; b. Gross view of the aortas from BLN-NPs (b1), PGG-NPs 
(b2), and control group (b3) at the endpoint.  
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AngII infusion (Figure 6-3a). The gross views of the explanted aortas also presented 
smaller outer aortic diameters of the suprarenal area in the PGG-NPs group comparing to 
the BLN-NPs and the control group (Figure 6-3b).  
Precisely, after the treatment, the PGG-NPs group showed a decrease (p=0.07) in 
aortic dilation percentage from 139.16±49.14% at week four to 97.75±49.77% at week 
eight. However, for the BLN-NPs group, the aortic diameter kept increasing to a significant 
level (p<0.01) from 104.10±34.14% at week four to 182.44±46.55% at week eight. And 
the aortic diameter significantly increased (p=0.03) from 109.38±27.13% at week four to 
188.11±84.92% at week eight for the control group. (Figure 6-4).  
 
Figure 6-4. Dilation percentage (> 50% at week 4) of BLN-NPs group, PGG-NPs group, 
and control group before the treatment at week 2 and 4, and during the treatment at week 
5, 6, 7 and 8, green arrows indicated the timepoints when the injection happened.  
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The same trend has also been observed in the suprarenal aortas with a dilation 
percentage smaller than 50% (Figure 6-5). By the end of the AngII infusion, these mice 
only presented moderate enlargement of the suprarenal aorta. After the treatment, the PGG-
NPs group still showed a significant decrease (p=0.02) in aortic dilation percentage from 
22.09±5.24% at week four to 7.82±8.26% at week eight. As for the control group, the aortic 
diameter kept increasing from 21.01±18.71% at week four to 43.95±17.94% at week eight.  
 
Figure 6-5. Dilation percentage (< 50% at week 4) of PGG-NPs group and control group 
before the treatment at week 2 and 4, and during the treatment at week 5, 6, 7, and 8. Green 
arrows indicated the timepoints when the injection happened. 
The influence of PGG treatment in CSs and PWVs  
All the mice used for the study had a decrease of the systolic diameter to diastolic 
diameter ratio at the end of the AngII infusion. During four weeks of the PGG-NPs 
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treatment, the mechanical behavior of the aortic walls during a cardiac cycle started 
returning to normal while in the BLN-NPs and the control group, the ratios kept decreasing  
 
Figure 6-6. Change in circumferential strains for PGG-NPs, BLN-NPs, and control groups. 
a. Representative M-mode in-vivo ultrasound images of abdominal aortas before pump 
implantation, at 4 weeks when the infusion of the Ang II was finished, and at 8 weeks when 
the treatment was finished, showing the mechanical behavior change in a cardiac cycle; b. 
(%) change of corresponding circumferential Green-LaGrange strains throughout the 
cardiac cycle at week 2 and 4, and during the treatment at week 5, 6, 7, and 8. Green arrows 
indicated the timepoints when the injection happened. 
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(Figure 6-6a). CSs were further calculated to evaluate the change in the distensibility of 
the aneurysmal aortic wall (Figure 6-6b). All aneurysmal aortas showed a reduction in the 
strain values after the formation of the aneurysms.  
By the end of the AngII infusion, the CSs of PGG-NPs, BLN-NPs, and control 
groups have decreased by 58.25±8.25%, 53.30±2.36%, and 56.85±4.73%, respectively. 
And after 4 weeks of NPs treatment, the aortas treated with PGG-NPs started to regain their 
distensibility, showing only a 24.50±10.34% CS decrease comparing to the healthy aortas. 
However, the CSs for both BLN-NPs treated group and control group decreased even more 
to 70.42±4.73% and 78.14±4.77% respectively at the endpoint of the treatment.  
PWVs were also calculated to evaluate the progression of the AAAs (Figure 6-7). 
Before the surgery, the PGG-NPs group, BLN-NPs group, and control group have PWVs 
of 2.28±0.27 mm/ms, 2.21±0.17 mm/ms, and 2.38±0.28 mm/ms respectively. All 
aneurysmal aortas showed a reduction in the PWV after the formation of the aneurysms. 
The PWVs for the PGG-NPs, BLN-NPs, and control group dropped to 1.35±0.33 mm/ms, 
1.56±0.11 mm/ms, and 1.49±0.19 mm/ms, respectively, after the AngII infusion. With four 
weeks of treatment, the PWV of the PGG-NPs group increased back to 2.43±0.13 mm/ms 
while the PWV was 0.97±0.12 mm/ms for BLN-NPs group and 1.09±0.32 mm/ms for the 
control group.  
The changes in CSs and the PWVs were also monitored for the suprarenal aortas 
that had a dilation percentage of less than 50% at different time points. Both of the 
parameters changed in the same pattern as bigger aneurysms reported above (Figure 6-8). 
The CSs on average dropped by 28.07% after the AngII infusion in the PGG treated group 
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Figure 6-7. Change in pulse wave velocities for PGG-NPs, BLN-NPs, and control group 
at week 2 and 4, and during the treatment at week 5, 6, 7, and 8. Green arrows indicated 
the timepoints when the injection happened. 
and by 8.32% in the control group. After four weeks of treatment, the average drop of CSs 
in the PGG treated group was only 6.89% comparing to 50.83% in the control group 
(Figure 6-8a). Moreover, the PWVs of the PGG group firstly decreased from 2.82±0.22 
mm/ms to 1.32±0.31 mm/ms as the AAAs progress, and then increased to 2.34±0.22 
mm/ms after PGG-NPs treatment. On the other hand, the PWVs of the control group firstly 
decreased from 2.12±0.23 mm/ms to 1.43±0.24 mm/ms as the AAAs progress, and then 
kept decreasing to 1.24±0.13 mm/ms without any treatment (Figure 6-8b). 
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Figure 6-8. Change in a. circumferential strains and b. pulse wave velocities for suprarenal 
aortas that have <50% dilation in PGG-NPs and control group at week 2 and 4, and during 
the treatment at week 5, 6, 7, and 8. Green arrows indicated the timepoints when the 
injection happened. 
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Histological analysis 
H&E and VVG staining of the suprarenal aortic sections from all three groups and 
aneurysms harvested at week 4 right after the AngII infusion provided information about 
the tissue morphology, cellular infiltration, and elastin degradation. The staining for the 
sections from the 4-week group exhibited the original status of the aneurysms before the  
 
Figure 6-9. Histological images of tissue sections with H&E and VVG staining for 4-week, 
control, BLN-NPs, and PGG-NPs group at 4X and 40X. 
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treatment. An increase in aortic diameter was observed after the aneurysm formation. 
Massive inflammatory cells infiltrated the adventitial and medial layer of the aortas and 
severe elastin degradation in the aortic medial was also remarked. Comparing to the 4-
week aneurysm and the sections from BLN-NPs and control group, the morphology of the 
tissues from PGG-NPs group were the closest to healthy with a relatively normal size and 
minimal infiltration of inflammatory cells (Figure 6-9a and 6-9b). Moreover, the VVG 
staining showed the most intact elastin laminae in the PGG-NPs group, while in the other 
three groups, there was severe degradation of elastin and formation of intraluminal plaques 
(Figure 6-9c and 6-9d). 
Assessment of systemic inflammation 
Serum IFN-γ levels were measured to evaluate the systemic inflammation. The 
control group had the highest amount of IFN-γ (49.94 ± 14.30 pg/ml) in the serum, 
followed by the BLN-NPs group (33.34 ±13.16 pg/ml). The PGG-NPs treated group has 
the lowest serum IFN- γ concentration (13.55 ± 8.09 pg/ml). The difference in IFN-γ 
concentration between the BLN-NPs and the control group was not significantly different 
at the 0.05 level. However, IFN-γ concentration in the PGG-NPs group was significantly 
lower than the control group (p<0.01) and BLN-NPs group (p=0.04) (Figure 6-10). 
Flow cytometry showed a significant decrease of CD68 positive cells in the spleens 
(p<0.058) and a modest decrease in the thymuses from PGG-NPs treated mice comparing 
to the control group (Figure 6-11a). Similarly, the TGFβ-1 level significantly decreased 
after the treatment with PGG-NPs compared with the control group (p<0.05) in spleens 
(Figure 6-11b). 
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Figure 6-10. Serum IFN- γ concentrations of control, BLN-NPs, and PGG-NPs group. 
 
Figure 6-11. Flow cytometry dot plots and scatter plots for CD68+ cells and TGFβ1+ 
expression in spleens and thymuses from the control group and PGG-NPs treated group. 
*p<0.05.  
Assessment of local inflammation 
IHC staining for CD68 and CD80 in suprarenal aortic sections from PGG-NPs, 
BLN-NPs, control, and 4-week group identified the infiltration of macrophages in the 
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aneurysmal tissue. The BLN-NPs, control and the 4-week group showed an intense pan-
macrophage (CD68) staining (Figure 6-12 a1-a3). The PGG-NPs group was stained 
positive for CD68, but the staining only appeared in limited areas in the tissue and was less 
intense compared to the other three groups (Figure 6-12 a4). The BLN-NPs group, control 
group, and the 4 weeks group also showed intense M1 macrophage (CD80) staining (Figure 
6-12 b1-b3) while the PGG-NPs group barely showed any staining (Figure 6-12 b4). 
 
Figure 6-12. IHC results for CD68 (a1-a4), staining for the macrophage infiltration, and 
CD80 (b1-b4), staining for the M1 macrophages, in the suprarenal aortic tissue from the 4-
week group, control group, BLN-NPs group, and PGG-NPs group. 
In-situ zymography of the suprarenal aortic sections from PGG-NPs, BLN-NPs, 
control, and 4-week group visualized the MMP activities. The PGG-NPs group showed 
significant suppression of signal from MMP activities (Figure 6-13d) comparing to 4-week, 
control, and the BLN-NPs group (Figure 6-13 a, b, and c). 
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Figure 6-13. In-situ zymography showing MMPs activity in aneurysms harvested from the 
a. 4-week group, b. control group, c. BLN-NPs group, and d. PGG-NPs group. 
qPCR analysis of the mRNA from the cells in the aneurysmal tissue showed that 
the BLN-NPs treatment did not seem to significantly affect all tested gene expressions. The 
MMP-2 expression in the PGG-NPs group was significantly lower compared to the control 
group (p=0.04) (1/5 of the control group expression) and modestly lower than the BLN-
NPs group (1/4 of the BLN-NPs group expression) (Figure 6-14 a). TIMP-1 and TIMP-2 
expression were both upregulated in the PGG-NPs group. PGG-NPs group showed a 2.2-
fold upregulation of TIMP-1 and a significantly higher expression of TIMP-2 (2.8-fold 
 151 
upregulation) comparing to the control group (p=0.07), and a 2-fold upregulation of TIMP-
1 and 1.6-fold upregulation of TIMP-2 comparing to BLN-NPs group (Figure 6-14 b, c). 
 
Figure 6-14. qPCR results of mRNA extracted from aneurysms harvested from the control 
group, BLN-NPs group, and PGG-NPs group for MMP-2, TIMP-1, and TIMP-2 
expression. **p<0.05, *p<0.1. 
The effect of PGG treatment on elastin related genes 
qPCR analysis of the mRNA of ELN and LOX from the cells in the aneurysmal 
tissue showed a slightly increased ELN expression by 1.8-fold and 1.5-fold higher LOX 
expression in the PGG treated group. The BLN-NPs treatment again did not seem to change 
both ELN and LOX gene expressions comparing to the control group (Figure 6-15). 
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Figure 6-15. qPCR analysis of ELN and LOX for the control group, BLN-NPs group, and 
PGG-NPs group.  
Biaxial mechanical testing 
A leftward shift in the pressure-diameter curves indicated decreased dilation in the 
PGG treated group across the entire pressure range with a more prominent inflection point 
normally observed in elastic arteries of small animals (Figure 6-16 a). Accordingly, both 
unloaded and physiologically loaded outer diameters significantly decreased with elastase 
PGG-NP treatment. The direct observation of the force vs. pressure relationship showed 
an increasing value of force for PGG-NP group compared to the control group (Fig. 6-16 
b). A significantly higher force was recorded for physiological pressures at these axial 
stretch ratios for the PGG-NPs group compared to the control group. A decrease in stiffness 
was observed in the circumferential direction in the PGG-NP group as indicated by the 
slope of the stretch-stress responses (Figure 6-16 c). A much lower circumferential stress 
in the control group was required to achieve the same circumferential as the PGG-NP 
treated group. Moreover, an increase in lumen area compliance was present in the PGG-
NPs groups compared to the control group (Figure 6-16 d). 
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Figure 6-16. Biaxial test results for PGG-NPs and control group. 
6.4 Discussion 
Targeted drug delivery to AAAs possesses certain inherent challenges like 
hemodynamic conditions in the aorta and the complexity of pathophysiological markers 
expressed in the tissue. Much of the remodeling happens in the ECM of the aneurysmal 
tissue thus making it vital to design a vehicle that can reach and be retained in the ECM to 
maximize its effect. Being one of the most common animal models of AAA, we chose to 
work with the AngII model to stimulate spontaneous AAA formation in mice [289]. The 
formation of AAAs in this model resembles human disease in aspects that include male 
a b 
c
 
d
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gender preponderance, the setting of mild hypertension, and the presence of hyperlipidemia 
[290]. Moreover, the formation of intraluminal thromboses (ILT), which has been 
commonly seen in this model as well as in human AAAs, would limit the access to the 
aortic wall from the lumen for targeting drug delivery. 
Owing to our group’s documented publications that elastin degradation presents as 
a hallmark signal in AAAs, a novel targeting technique has been developed [318]. We have 
loaded BSA nanoparticles with DiR dye in order to quench autofluorescence from ECM 
proteins to test the targeting ability of these nanocarriers to degrading elastin in-vivo [319]. 
Concurring with the data shown by Nosoudi et al. [169], and Karamched et al. [242], we 
demonstrate the targeted delivery of nanoparticles to the aneurysmal site. More 
importantly, our histological results showed that the DiR-NPs accumulated at the medial 
layer of the aorta where the elastin was degrading. It indicated that the targeting of the NPs 
was achieved actively under the guidance of the conjugated antibodies regardless of the 
ILT. This finding was supported by our previous study suggesting the NPs targeted through 
the vasa vasorum rather than from the aortic lumen [169]. 
The change of aneurysmal aortic diameter is one of the most intuitional parameters 
that could be used to decide the efficacy of a AAA pharmacotherapy. We measured the 
inner diameter of the aneurysms at different timepoints throughout the study as a part of 
the evaluation for the status of aneurysms. Not all mice presented a more than 1.5-fold 
aortic enlargement, a clinical criterion for diagnosing AAAs, by the end of the AngII 
infusion. Then, we looked at two important biomechanical properties of aorta i.e., CS and 
PWV to further assess the development of the aneurysms. CS decreased significantly in 
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AngII infused mice developing aneurysms. It indicated that the aneurysmal aortic walls 
responded less to blood pressure variation after the aneurysm formation. Our observations 
coincide with other documented results, for example, by Favreau et al. [303], Trachet et al. 
[320], and Phillips et al. [321]. 
In contrast to the findings of increased PWVs [322-324], we noticed a significant 
decrease after 28 days of Ang-II infusion. This follows our hypothesis that increased local 
aortic diameter at the site of the aneurysm increases the time taken by the pulse to travel 
along the aneurysm. Moreover, the decrease of PWVs as a result of larger aortic diameters 
overweighed the increase of PWVs caused by the increase of aortic wall stiffness. Nandlall 
et al. also reported a decrease in PWV after AAA formation in an ApoE/TIMP-1 -/- murine 
model [325]. 
After 4 weeks of treatment, we observed a significant decrease in the size of PGG-
NPs treated aneurysms. However, the aneurysm sizes in the BLN-NPs and untreated group 
kept increasing. The PGG-NPs treated aneurysms also restored part of their CSs and 
showed a significant increase in PWVs while the CSs and PWVs kept decreasing in the 
control groups. In coherence with the findings in a CaCl2 induced rat model [169], we 
believe that the targeted delivery of PGG could restore the mechanical properties of the 
aneurysmal tissue and regress the aneurysms. This has been further confirmed by the 
observations from biaxial mechanical tests. The results from the biaxial mechanical tests 
indicated that PGG-NP treatment AAAs had better elasticity compared to the control group 
and presented higher strength against pressurization. Overall, our research demonstrated 
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the potential for the PGG-NP treatment to help aneurysmal tissue to regain better 
mechanical properties and decrease the rupture risk of the AAAs.  
Then we looked into the mechanism of how PGG functioned both systemically and 
locally to halt and reverse the AAA progression. Inflammation in the aortic wall is a main 
trigger of AAA onset. Chronic inflammatory cell infiltration in the adventitial and medial 
aortic layers and the upregulation of the pro-inflammatory cytokine would result in the 
VSMCs apoptosis and ECM degradation, primarily elastic lamina degradation by 
proteolytic enzymes such as MMPs and cathepsins [35, 77, 78]. The progression of the 
local aortic inflammatory response requires the enhanced recruitment of inflammatory cells 
from the system [326]. Mellak et al. reported that the monocytes from the spleen could be 
mobilized by the presence of AngII and contribute to the development of AAA and the 
occurrence of rupture [327]. According to our flow cytometry results, a significant decrease 
in CD68 positive cells in the spleen was observed in PGG-NPs treated group compared 
with the control group. This indicated that PGG could reduce the available monocyte 
subsets in the system, thus, decrease the aortic macrophage accumulation and attenuate the 
inflammatory response in the local aneurysmal tissue. 
The formation of AAAs also usually results in an altered systemic level of cytokines 
such as IFN-γ and TGFβ1. The expression of IFN-γ has been reported to be consistently 
upregulated in the circulation and tissues of patients with AAA [328], and has been shown 
to induce productions of MMP-9 in macrophages and MMP-2 in SMCs to promote AAA 
progression [329]. IFN-γ producing CD8 positive T cells were found to promote the 
development of aneurysm by increasing MMP producing macrophages [330]. It has been 
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reported that the inhibition of IFN-γ in the elastase AAA mouse model could abrogate the 
formation of aneurysms [329, 330]. We observed a significantly higher level of IFN-γ in 
the serum of the BLN-NPs treated group and the control group compared to the PGG-NPs 
treated group, indicating the systemic IFN-γ suppressing role of PGG-NPs in the AngII 
mouse model. 
We further looked at how PGG treatment influenced the TGFβ1 level systemically. 
An overexpressed local level of TGFβ1 has been proved to be beneficial for stopping the 
progression of AAAs and stabilizing the already-formed aortic aneurysms [82, 331]. Here, 
interestingly, we found that the TGFβ1 cytokines level significantly decreased in the 
spleens. This could be evidence to support that the PGG-NPs reduced the systemic 
inflammatory responses in the AngII mouse model, but further studies are required to 
describe the role of the spleen TGF β1 level in the formation and progression of AAAs. 
Overall, our results suggested that PGG-NPs treatment could suppress the production of 
systemic inflammatory markers.  
At the aneurysmal site, PGG can be thought to have two functions, one is to 
stabilize the ECM by inhibiting MMPs locally and two, to increase elastin fiber deposition. 
It is known that MMP-2 is one of the key players in AAA’s pathophysiology. MMP-2 
expression levels have been known to increase in AAA conditions in humans [332]. 
Activated macrophages are responsible for producing MMP-2, whose levels are not 
counter-balanced by the activity of their inhibitors (TIMPs) [333]. TIMPs play a crucial 
role in reducing aortic aneurysm formation. Results from Eskandari et al. [334] and 
Ikonomidis et al. [335] stressed the importance of TIMP-1 in protecting ECM against 
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aneurysm formation. The role of TIMP-2 is, however, controversial in the pathology of 
AAAs. Although TIMP-2 inhibits some MMPs it can also act as an MMP-2 activator. So, 
it can both promote and attenuate aneurysm formation. Xiong et al.[336] have reported that 
the absence of TIMP-2 led to protection against aneurysm formation probably by 
hampering MMP-2 production. However, Aoki et al. showed the protective effect of TIMP-
2 in AAA formation by reducing the MMP-2 activity [337]. Putting all these facts aside, 
the imbalance of MMP and TIMP activity is primarily responsible for the degradation of 
collagen and elastin [85], which are the integral parts of the ECM.  
Parasaram et al.[338] have reported that PGG could inhibit MMP activity in-vitro 
and even under acellular conditions (PGG added to development buffer during zymography 
rather than in cell culture medium). They have also shown that TIMP-1 levels were 
increased in rat pulmonary fibroblasts treated with PGG in-vitro. In our study, we showed 
that PGG inhibited MMP activity in the aneurysmal tissue by performing in-situ 
zymography on the aneurysmal sections. PGG-NPs treated aortas showed diminished 
MMP activity compared to the control and BLN-NP group. Moreover, we observed that 
PGG-NPs treatment significantly reduced the MMP-2 expression while upregulated the 
TIMP expression in the aneurysmal tissue compared with the control group. PGG-NP 
treatment was suggested to help achieve a protease/anti-protease balance in the aneurysmal 
tissue.  
Sinha et al. [18] and Parasaram et al. [338] have further shown that PGG also helped 
in increasing elastin deposition in cell cultures, possibly by holding the tropoelastin 
molecules together. This helps LOX to finish crosslinking them before being “washed out”. 
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While the amount of tropoelastin produced by cells remained fairly similar in control and 
PGG treated cells, PGG treated cells have more elastic fibers laid down in the ECM. Our 
results of VVG staining indicated the replenishment of elastin fibers that were lost during 
the aneurysm development in the PGG-NP treated group. Restoration of elastin fibers at 
the aneurysmal site explained the changes observed in the biomechanical properties of 
aorta in this group. However, the expressions of ELN and LOX were not significantly 
enhanced in the PGG-NPs treated aneurysmal tissue. This could be a result of 1) the loaded 
PGG has been fully released from the nanocarrier after two weeks so the local genetic 
expressions returned to normal as shown in our previous cell culture study [338], and 2) 
the fact that most elastin fibers have already been repaired at the point of sample harvesting.  
By stabilizing the elastin fibers in the ECM, PGG-NP treatment further ameliorated 
the inflammation in the AAAs. Some products of ECM degradation, such as elastin 
fragments (EFs) or elastin degradation products (EDPs), at the site of injury are 
chemotactic to macrophages [339]. Thus, suppression of elastin degradation may have 
further led to a suppression of macrophage activity in the area and significant suppression 
of MMP activity in the PGG-NP group. We have shown using IHC that the levels of CD68 
stained macrophages decreased significantly with PGG treatment. Furthermore, CD80 
staining reveals a complete absence of pro-inflammatory (M1) macrophages at the 
aneurysmal site. With the obtained results, one can arrive at the conclusion that PGG works 
by both inhibiting MMPs and restoring elastin in the aorta, which stops the recruitment of 
macrophages, thereby restoring a “normal” microenvironment at the aneurysmal site. 
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6.5 Conclusion 
In this specific aim, we investigated the AAA treatment efficacy of PGG-NPs in 
the AngII infusion induced mice model. The PGG-NPs treated mice showed restoration of 
normalcy in the aorta with developed aneurysms in terms of aortic diameter, tissue 
morphology, elastin fibers in the ECM, inflammation scenario, and the mechanical 
properties. Targeted delivery of these PGG-NPs demonstrated a very promising therapeutic 
strategy for the reversal of already established AAAs. 
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7. CONCLUSION AND FUTURE RECOMMENDATIONS 
7.1 Conclusions 
AAA diagnosis and treatment have always been challenging owing to the 
complexity of the lesion location and AAA pathophysiology. Misdiagnosing of AAAs that 
tend to rupture can put the patients in a life-threatening situation. Even if the AAAs were 
successfully diagnosed with the current clinical diagnostic strategies, the mortality of the 
patients who received treatment remains high. In this research, we focused on targeting the 
degradation of elastin in the aneurysmal tissue, an essential protein that maintains the aortic 
elasticity and the degradation products of which mediates the local inflammation, in an 
attempt to develop a safe and efficient diagnostic tool as well as pharmacotherapy. 
The first part of this research aimed to develop a targeted imaging contrast agent 
using AuNPs to provide details about aortic mechanical properties that could help generate 
a more accurate diagnosis. In this part of the research, we synthesized negatively charged 
150nm AuNPs and modified their surfaces with antibodies that could target the degraded 
elastin. We have shown that these EL-AuNPs are not cytotoxic and also could be mostly 
clear out of the system within ten days. Moreover, we showed that optimized EL-AuNPs 
could enhance the CT imaging contrast of the tissue with elastin damage exclusively. And 
the contrast enhancements of signal in the CT-scans are positively correlated to the elastin 
damage level in the in-vitro arterial models. We further tested these EL-AuNPs in the AngII 
infusion induced mouse AAA model and showed targeting of the EL-AuNPs to the 
aneurysmal tissue in both in-vivo and ex-vivo CT scans. Correlations between the 
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accumulation of EL-AuNPs in the aneurysms and the mechanical properties (burst pressure 
and biaxial tests) have been built to render the EL-AuNPs potential to be used as a tool to 
assess the rupture risk of the AAAs. 
The second part of the research focused on studying the therapeutic effects of PGG 
loaded BSA nanoparticles on AAAs in the same AngII model. Two injections of PGG-NPs 
within four weeks have shown to be effective in reducing the inflammatory response both 
locally and systemically. By stopping the inflammation in the aneurysmal tissue, PGG-NPs 
helped preserve the ECM and thus slowed down the AAA progression. Besides the anti-
inflammatory effect, the treatment of PGG-NPs restored the elastin fibers in the aortic 
media, which improved the mechanical properties of the aneurysmal tissue and reduced 
their risks of rupture. Therefore, targeted delivery of PGG-NPs could be a promising 
pharmacotherapy for the AAA patients who are not recommended to undergo surgical 
interventions. 
7.2 Recommendation for future work 
• In this dissertation, we investigated the possibility of using EL-AuNPs as a 
targeted contrast agent to provide information about the micro defects in the 
aneurysmal tissue. We chose bursting tests and biaxial tests to assess the 
mechanical properties of the AAAs in order to find their correlation with 
the EL-AuNPs accumulated int the tissue. However, very limited 
parameters were tested in this study, and the accumulation of EL-AuNPs 
was correlated to each one of them independently. Considering the 
complication of the actual in-vivo environment, it is desired to develop a 
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scoring system that combines all the mechanical data into one total score, 
which will later be correlated to the EL-AuNPs. It will increase the overall 
accuracy of using EL-AuNPs accumulation to represent the AAA rupture 
potential.  
• In our ex-vivo study, we observed the accumulation of EL-AuNPs in the 
weak spot within the aneurysmal sac. The areas that showed the highest 
signal intensity in the AAAs were found to rupture the first in the bursting 
tests. This indicated that we could use the EL-AuNPs to visualize the 
potential rupture sites in the AAAs. However, it was very challenging to 
apply this idea to the in-vivo study due to the limited quality of the CT 
imaging and the large amount of connective tissue around the AAAs. It 
would be essential to increase the imaging quality and visualize the weak 
spot of the AAAs in the in-vivo CT scans. The detailed EL-AuNPs maps 
that show the weak spot in the aneurysmal wall could be beneficial in 
assisting the clinical AAA repairing.  
• It would be of interest to optimize the AuNP dose used in visualizing the 
AAAs in-vivo. In this dissertation, we only used one dose, 10mg/kg animal 
weight for both in-vivo and ex-vivo imaging studies. In the cell culture 
studies, we have shown very low toxicity of AuNPs at a dose that equaled 
to 100mg/kg animal dose in animal studies. An increased dose may increase 
the sensitivity of detecting the micro defects in the AAAs while remaining 
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non-toxic to the animals that receive the injection. Also, the optimization of 
the AuNPs dose can increase the CT imaging quality and accuracy. 
• AuNPs could also be used as an imaging contrast agent for other elastin 
damage related diseases such as thoracic aortic aneurysms and chronic 
obstructive pulmonary disease. We have already shown in this research that 
the EL-AuNPs can achieve targeting in the aorta and can be distributed to 
the lungs. 
• In this research, many aspects of how PGG-NPs helped stop and reverse the 
AAA progression has been studied. We revealed the anti-inflammatory and 
ECM regenerating role of the PGG-NPs. It would be interesting to study 
how PGG interacts with the aneurysmal tissue on the molecular level. It 
would provide us more insights into the AAA pathophysiology. This could 
also help us to optimize the dose of PGG-NPs injected to achieve the best 
treatment efficacy. 
• Our in-vivo data showed that the treatment of PGG could restore the local 
elastin in the aneurysmal tissue. However, it didn’t resolve the ILT that was 
commonly observed in this animal model as well as in the human AAAs. It 
would be useful to develop a combined treatment using PGG and drugs that 
could either resolve or stabilize the ILTs. On the one hand, the anti-
inflammatory effect of PGG could help to slow down the formation of ILTs; 
on the other hand, the complementary drugs could resolve or stabilize the 
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existed ILT and prevent the formation of deadly embolus. It would help 
restore the normal functionality of the aneurysmal abdominal aorta. 
• In this dissertation, we developed a diagnostic tool that could be used to 
assess AAA rupture potential as well as pharmacotherapy that has shown 
effectiveness in curing AAAs. It would be interesting to combine the use of 
AuNPs and PGG-NPs into one NP system to achieve theranostic purposes. 
By loading the BSA nanocarriers with both AuNPs and PGG, this novel 
nanoparticle system can not only be used as a contrast agent for visualizing 
the AAAs but also locally release PGG in a controlled manner that cures 
the disease. 
• All the in-vivo studies we have performed in this study were performed in 
an AngII infusion induced mouse model. The targeting of NPs would be 
challenging in large animals. The dose of injection, the biodistribution and 
toxicity after injection can be totally different in larger animals as well as 
human. In order to translate all our findings into clinical use, it is important 
to perform further studies in larger animal models such as elastase induced 
porcine model.  
• Here, in this research, the antibodies were designed to target the elastin 
degradation in rodents. In order to successfully target the AAAs in human 
for clinical use, the antibodies used for modifying the NPs should be 
customized to target the human elastin fragments. And the conjugation 
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conditions should be further optimized for the new antibodies to achieve 
better imaging or treating efficacy. 
• We have developed a nanocarrier that could be used to deliver drugs locally 
to the AAAs. We could use this nanocarrier to load other drugs that have 
shown to reduce the inflammatory response in the cell culture studies or in 
animal studies but failed in clinical trials when they were delivered 
systemically, such as doxycycline, statins and coumaperine derivatives.  
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